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 Abstract 
 
Malaria caused by Plasmodium falciparum is still a major health problem in many tropical 
countries infecting 500 million people leading to 1 to 2 millions of deaths annually. An 
effective vaccine is not available but is a major goal to reach as a measure for disease control. 
The blood stages responsible for the pathology exhibit great antigenic variation and diversity 
in surface antigens, an immune evasion strategy of the parasite, which hampers the rapid 
acquisition of protective immunity. Antigenic variation is used for parasite proteins expressed 
at the surface of infected erythrocytes while antigenic diversity manifests at the surface of 
merozoites, the invasive form of blood stages. Despite their extensive polymorphism, 
merozoite surface antigens are among the most promising vaccine candidates since high 
antibody titres against these proteins are associated with protection from clinical disease and 
specific antibodies to different merozoite antigens can inhibit parasite growth in vitro.  
One antigen displayed on merozoites is the merozoite surface protein 2 (MSP2). MSP2 is 
GPI-anchored and an abundant component of the merozoite surface coat. Its structure shows a 
central polymorphic part containing extensive tandem amino acid repeats. These repeat 
regions are flanked by semi-conserved non-repetitive domains defining two allelic families 
(3D7-like and FC27-like). The repeat sequences and their organisation differ considerably 
between the two families. The N- and C-terminal parts of MSP2 are conserved among all 
alleles. 
The 3D7 allele of MSP2 was one of three components in the blood stage subunit vaccine 
Combination B recently tested in an area of Papua New Guinea endemic for Plasmodium 
falciparum malaria. The Combination B trial showed promising results in reducing parasite 
densities and genotyping of blood samples revealed that MSP2 was a major active 
component. The vaccine exerted a selective effect on infecting parasite strains favouring those 
carrying an MSP2 of the FC27-type, not represented by the vaccine. 
In this thesis we showed that the antibody response against the MSP2 component of 
Combination B was exclusively directed against the repetitive and semi-conserved central 
domains. Together with the observed selective effect on infecting parasite genotypes in the 
vaccinees, this has implications for future MSP2-based vaccines. It strongly suggests the 
inclusion of representatives of both allelic families. 
We also analyzed the sequences of 3D7-like MSP2 alleles found during the Combinaton B 
trial and compared the sequences of alleles found in vaccinees with those found in placebo 
recipients. Phylogenetic analysis showed no clustering of alleles found in breakthrough 
 infections in vaccinees. This suggests that vaccine-induced antibodies against the family-
specific non-repetitive part were protective. 
In the search for an improved MSP2-based vaccine we designed and evaluated two long 
synthetic peptides representing the two allelic families. These peptides contain the family-
specific part and the C-terminal conserved part. We show that both peptides are well 
recognized by immune sera and that recognition matches the one of recombinant proteins 
corresponding to the family-specific parts. The peptides elicited high antibody titres in mice 
and monoclonal antibodies raised were shown to react with parasite-derived MSP2 in 
immunofluorescence assays. We also show that antibodies purified on our peptides react with 
the merozoite surface and that they have the potential to inhibit parasite growth in cooperation 
with human monocytes. The results obtained from our evaluation studies encourage the 
further development of long synthetic peptides as vaccine candidates. 
We also asked the question of the functional role of the different domains of MSP2. We 
hypothezised that the immunodominant repeat region has merely an immunological role in 
distracting the antibody response to non-protective epitopes and that it is dispensable for in 
vitro growth. Therefore we made transgenic parasites attempting to replace the endogenous 
msp2 gene with a gene showing an internal deletion of the repeat region. Our plasmid 
constructs targeted the msp2 locus, however, a gene replacement was not achieved. This 
indicates that the repeat region has an essential function in addition to its proposed importance 
in immune evasion. 
We also addressed the question of the functional role of the conserved domains of MSP2. 
MSP2 is a GPI-anchored protein and therefore the mechanisms used for its transport to the 
cell surface are not known. We hypothesised that putative transport signals are likely to lie 
within the conserved domains. We generated a series of transgenic parasites expressing 
fluorescent reporter proteins flanked with different portions of terminal MSP2 sequences. We 
found that a fluorescent reporter flanked by the conserved MSP2 domains was transported to 
the surface of merozoites while the same reporter only flanked by the MSP2 signal peptide 
and the GPI anchor signal remained in the ER. This suggests that trafficking signals necessary 
for targeting of MSP2 to the plasma membrane are located in either of the conserved domains. 
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 1. Literature review 
 
1.1 Introduction 
 
Malaria is the most important human parasitosis and is caused by protozoan parasites of the 
genus Plasmodium. Four species can cause human disease: Plasmodium falciparum, 
Plasmodium vivax, Plasmodium malariae, and Plasmodium ovale. Plasmodium falciparum is 
responsible for the majority of severe disease and death (Greenwood et al., 1991). 
Today approximately 40% of the world's population, mostly those living in the world's 
poorest countries, is at risk of malaria. Each year, 300-500 million people become infected 
with this deadly pathogen and 1 to 2 million will die (WHO, 2004). Clinical manifestations of 
severe malaria include cerebral malaria, severe anaemia, hypoglycaemia, renal failure, non-
cardiac pulmonary oedema and respiratory failure (Marsh et al., 1995; Warrell et al., 1990) 
Once in the blood, the processes associated with the multiplication of the parasite in red blood 
cells are responsible for most of the clinical symptoms of malaria and its associated morbitity 
and mortality. The synchronicity of rupture of infected red blood cells and the concomitant 
release of large numbers of merozoites leads to the well known malarial fever. The infected 
red blood cell undergoes dramatic structural and morphological changes during development 
of the parasite. These changes play a major role in the development of the severe 
complications accompanied by falciparum malaria. 
No vaccine is available and resistance to most antimalarial drugs occurs in many parts of the 
world. Research focuses mainly on P. falciparum because of its clinical importance. An in 
vitro culturing system is available (Trager and Jensen, 1978) and the genome has been 
sequenced for the culture strain 3D7 (www.plasmodb.org). 
 
 
1.2 Life cycle 
 
P. falciparum is an obligate parasite that cycles between the human host and a mosquito 
vector. The cycle begins when haploid sporozoites are injected into the human host by an 
infected female mosquito of the genus Anopheles (several species) during a blood meal.  
Once in the bloodstream, sporozoites pass the liver, where they penetrate endothelial and 
Kuppfer cells before invading a hepatocyte, the final host cell, thereby forming a 
parasitophorous vacuole (PV). Within the hepatocyte, the parasite grows and replicates by 
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 asexual division into a so-called liver schizont carrying thousands of merozoites that are 
released in the bloodstream after schizont and hepatocyte rupture and are ready to invade 
erythrocytes to start the intraerythrocytic cycle. After invasion, which does also implicate the 
formation of a parasitophorous vacuole, the parasite grows, feeding mainly on haemoglobin, 
and develops into a trophozoite and finally an erythrocytic schizont. The schizont and the host 
cell rupture 48 hours after invasion, releasing 16 to 32 merozoites to start the next 
intraerythrocytic cycle. Some of the intraerythrocytic parasites develop into sexual blood 
stages (gametocytes). These gametocytes must be taken up by an anopheline mosquito during 
another blood meal. Once in the mosquito gut, gametocyes develop into gametes and sexual 
reproduction takes place whereby 8 flagellated microgametes are released from a male 
gametocyte fertilizing the female macrogamete to form a diploid zygote. The zygote develops 
into an ookinete capable of penetrating the gut wall and maturing to an oocyst in about 10 
days. The oocyst finally ruptures to release a large number of haploid sporozoites into the 
haemolymph. The sporozoites migrate to the salivary gland from where they are injected into 
the human host during the next blood meal to complete the cycle.  
 
 
1.2.1 The asexual blood stages 
 
The asexual blood stages of the parasites are fully responsible for the symptoms and the 
pathology of malaria. Three aspects are particularly noteworthy: i) The rapid exponential 
growth of the parasites and the synchronicity of schizont and red blood cell rupture accounts 
for the intermittent malarial fever. ii) The parasite modifies the surface of the infected red 
blood cell by insertion of a number of parasite-derived proteins into the plasma membrane of 
the host cell. One of these proteins, P. falciparum erythrocyte membrane protein 1 (PfEMP1), 
present in knob-like structures, mediates binding of infected red blood cells (iRBCs) to the 
host microvasculature via endothelial markers like ICAM-1 and CD36. PfEMP1 is a protein 
family encoded by around 60 highly variable var genes per genome of which only one is 
expressed at a certain time. Sequential expression of different var genes leads to antigenic 
variation, a way to evade the hosts immune system. iii) Schizont rupture releases around 24 
merozoites into the bloodstream. The merozoites are the only stage of the asexual blood 
stages that are directly exposed to the host’s immune system. Therefore, the parasite has to 
find a way to resist elimination by the host’s immune response. It does so by expressing a 
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 large panel of surface antigens with stretches of high sequence diversity to mislead the host’s 
immune system.  
 
 
1.2.2 Merozoite invasion of human erythrocytes 
 
After asexual division in the hepatocyte, up to 30’000 merozoites are released in the blood 
stream that have the capability of invading red blood cells. P. falciparum merozoites are small 
oval shaped cells with a diameter of 1-1.5µm and a length of 1.5-2µm. (Aikawa, 1971; 
Aikawa et al., 1978; Bannister et al., 1975). The conical apical end of the merozoite consists 
of three proteinaceaous rings, known as the polar rings, attached to subpellicular 
microtubules. The rhoptries and micronemes that localise to the apical end of the merozoite 
build the so-called apicomplex. The apicomplex and the dense granules, which are distributed 
throughout the merozoite, are organelles implicated in erythrocyte invasion (Levine et al., 
1980). The merozoite also has a thick bristly coat, composed of a number of glycoproteins, 
the merozoite surface proteins, implicated in the initial interaction with the erythrocyte. 
 
The whole process of merozoite invasion is believed to occur in about 10-60 seconds (Dvorak 
et al., 1975; Mitchell and Bannister, 1988) and free merozoites thought to be non-viable after 
a short period of time (Johnson et al., 1980). It is also believed that a merozoite will die unless 
the first attempt to invade an erythrocyte was successful. Since the host erythrocyte is non-
endocytic, merozoite invasion is an entirely active process. After the initial reversible 
interaction with the erythrocyte, the merozoite reorients to bring its apical end in direct 
contact with the erythrocyte plasma membrane. After apical reorientation a closer, irreversible 
membrane-membrane interaction, the ‘tight junction’, is formed. When the tight junction 
moves towards the posterior end of the merozoite, the parasitophorous vacuole is formed and 
the contents of the rhoptries are released. In the final stage, the tight junction pinches off and 
the erythrocyte plasma membrane is released to leave the parasite within the host cell, 
surrounded by a parasitophorous vacuole. 
 
P. falciparum merozoites can invade human erythrocytes using several different pathways, 
using different receptors on the host erythrocyte. These pathways have been defined using 
enzyme-treated (neuraminidase, trypsin) and mutant erythrocytes and determining their 
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 susceptibility to merozoite invasion (Dolan et al., 1990; Hadley et al., 1987; Mitchell et al., 
1986; Perkins and Holt, 1988).  
 
 
1.3 The merozoite surface coat 
 
The initial reversible contact of merozoite and erythrocyte seems to involve the merozoite 
surface coat filaments that consist of 40 nm fibrils and 18-22 nm fibrils in P. falciparum and 
P.knowlesi (Bannister et al., 1986b). The interaction occurs over distances between 15-40 nm 
and is thus larger than those of the tight junction (4nm) that forms later during the invasion 
process (Aikawa et al., 1978; Bannister et al., 1986a). This reversible adhesion is 
accompanied by deformations of the erythrocyte plasma membrane that wraps partially 
around the merozoite and is thought to be important for the apical reorientation, the next step 
in invasion (Bannister et al. 1986b). 
 
The molecules probably involved in this reversible adhesion are the merozoite surface 
proteins (MSPs) that are thought to make up the merozoite surface coat, as the GPI-anchored 
proteins MSP1 (Holder and Freeman, 1982; Holder and Freeman, 1984b), MSP2 (Smythe et 
al., 1988; Miettinen-Baumann et al., 1988; Clark et al., 1989), MSP4 (Marshall et al., 1997), 
MSP5 (Marshall et al., 1998), and MSP8 (Black et al., 2001). The alanin-rich heptad repeat-
containing MSP3 (McColl et al., 1994; Oeuvray et al., 1994), MSP6, and MSP7 do not show 
a GPI-anchor signal nor a transmembrane domain, but have a very distinct, acidic C-terminus 
and a leucine zipper domain. MSP6 and MSP7 form a complex with MSP1 (Heidrich et al., 
1983; McBride and Heidrich, 1987; Stafford et al., 1996; Trucco et al., 2001). Recently, 
MSP10, and MSP11 have been added to the list of proteins associated with the merozoite 
surface (Black et al., 2003; Pearce et al., 2005). MSP10 contains EGF-like domains, which 
relates it to MSP1, MSP4, and MSP5, while MSP11 is a paralogue of MSP3/MSP6. 
 
In addition to the MSPs, some other proteins appear to be associated with the merozoite 
surface. The Apical membrane antigen-1 (AMA-1) is a micronemal transmembrane protein 
secreted at the apical end and distributed over the merozoite surface during merozoite release 
(Narum and Thomas, 1994). Acidic basic repeat antigen (ABRA) (Stahl et al., 1986) and the 
S-antigen (Coppel et al., 1983) are peripheral membrane proteins. ABRA has been shown to 
interact with Band 3 on the erythrocyte surface (Kushwaha et al., 2002). 
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 Disruption of many merozoite antigens has been attempted in oder to elucidate their 
functional importance. Only for one merozoite surface protein a successful integration into the 
chromosomal locus resulting in a truncation of the protein has been reported to date (Mills et 
al., 2002). The truncated version of MSP3 nor ABRA is trafficked to the surface of the 
merozoite in these parasites and growth is reduced in vitro. 3’ replacements, resulting in 
complementation of the sequence with that from other strains or species have been reported 
for MSP1, MSP2, MSP3, and AMA1 (reviewed in Cowman et al., 2000). The difficulty to 
disrupt individual genes coding merozoite surface antigens suggests that there is very limited 
functional redundancy among merozoite surface porteins. Every member appears to have a 
specific function that is even essential in vitro. 
 
 
1.3.1 Merozoite Surface Protein 2 (MSP2) 
 
MSP2 has first been identified as a 45 to 51 kDa GPI-anchored protein that localises to the 
merozoite surface (Clark et al., 1989; Miettinen-Baumann et al., 1988; Smythe et al., 1988) 
MSP2 is encoded by a single exon on chromosome 2, and analysis of MSP2 sequences from 
different isolates shows that it is a polymorphic antigen consisting of  highly conserved N- 
and C-terminal regions flanking a variable central region (Anders and Smythe, 1989). The 
variable region contains a central repeat region, which is flanked by non-repetitive semi-
conserved regions. These non-repetitive variable regions have been used to define two allelic 
families, the 3D7/IC-1 family and the FC27/K1 family (Thomas et al., 1990; Fenton et al., 
1991; Felger et al., 1997). The function of MSP2 remains unknown and several attempts of 
disrupting the msp2 gene to elucidate the role of MSP2 were not successful (Cowman et al., 
2000; Paul Sanders, personal communication).  
 
Interestingly, despite of the obvious essentiality of MSP2 for P. falciparum, no homologs or 
paralogs have been found in any other human malaria parasite species. The only homolog 
found to date is in the chimpanzee parasite Plasmodium reichenowi, which is evolutionary 
very closely related to P. falciparum. The P.reichenowi MSP2 basically shares the conserved 
parts of its P. falciparum homolog with only 3 and 9 amino acid substitutions found in the N- 
and C-terminal regions, respectively (Dubbeld et al., 1998). The repeat region of the only 
sequenced P.reichenowi allele is of the P. falciparum 3D7 type. In contrast to P. falciparum 
3D7-type repeats, Threonine is found as a major component of the repeat but the poly-
13
 Threonin tract always present downstream of P. falciparum 3D7-type repeats is missing from 
the P.reichenowi MSP2. The non-repetitive central part is a mosaic of the two P. falciparum 
allelic families and sequences unique to P.reichenowi. 
Several studies reported that antibodies against the two allelic forms of MSP2 are associated 
with decreased malaria morbidity (Al-Yaman et al., 1994; Al-Yaman et al., 1995; Taylor et 
al., 1998). 
Two mouse monoclonal antibodies directed against an epitope in the repeat region of the 
Papua New Guinean isolate FC27 inhibit parasite growth in vitro. The epitope comprises the 
linear amino acid sequence Ser-Asn-Thr-Ser. These antibodies, designated 8G10/48 and 
9E3/48 are the only inhibitory MSP2 antibodies described to date (Epping et al., 1988). 
Monoclonal antibody 8G10/48 has been shown to only marginally inhibit growth of strain 
Indochina I (IC-I), a parasite carrying a 3D7-type MSP2 (Saul et al., 1989). Other monoclonal 
antibodies reactive to the family-specific part of MSP2 (8F6/49, Ramasamy 1987) or rabbit 
sera raised against full-length MSP2 did not inhibit parasite growth in vitro (Robin Anders, 
personal communication). In another study, affinity-purified rabbit sera raised against an 
octapeptide from the conserved N-terminal region showed inhibitory activity (Lougovskoi et 
al., 2000). Inhibition experiments were also performed with immune sera from Papua New 
Guinean adults shown to react with MSP2 in enzyme-linked immuno sorbent assays (ELISA). 
Using a transgenic parasite line expressing an FC27-type MSP2 allele on a 3D7 background 
and the parental 3D7 strain, differences in growth inhibition of these two lines were only 
found for some individual sera (Wickham, 2002). The differential parasite growth inhibition 
due to MSP2 antibodies is minor compared to that attributable to MSP1-19 antibodies as seen 
in a similar assay using a transgenic P. falciparum line expressing a P.chabaudi MSP1-19 
(O’Donnell et al., 2001a). 
In addition to the growth inhibitory MSP2 antibodies, two MSP2 peptides (20mers from the 
N-terminal conserved region and the 3D7-family-specific non-repetitive part) were shown to 
inhibit parasite growth directly by binding to red blood cells (Ocampo et al., 2000). 
 
 
1.4. Immunity to malaria 
 
Sterile immunity to malaria cannot be obtained by natural exposure. However, protective 
immunity, associated with the absence of clinical symptoms, can be acquired gradually 
through continuous exposure to infection over several years, depending on the degree of 
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 malaria endemicity (Baird, 1998). The acquisition of immunity is a two-step process. The first 
step is the development of resistance to the neurological complications induced by P. 
falciparum and is typically acquired by the age of 3 to 5 years. The second step is the 
development of true anti-parasite immunity allowing the control of high parasite loads. This 
seems to be acquired only after adolescence. The age at which optimal protection is reached is 
inversely correlated with the intensity of parasite transmission (reviewed in Baird, 1995). 
Most of malaria-related morbidity and mortality in endemic regions is found in children 
below the age of five years, suggesting that malaria antigens inducing protective immune 
responses are poorly immunogenic.  
Malaria antigens are very polymorphic (varying between strains) or variable (changing over 
time within strains). Both, antigenic diversity and antigenic variation are used by the malaria 
parasite as immune evasion strategies. Polymorphic antigens are presented at the surface of 
extracellular stages (merozoites and sporozoites) while antigenic variation is used by 
intraerythrocytic stages for antigens presented at the surface of the infected red blood cell. 
Due to these two phenomena, an accumulation of a large and diverse immunological memory 
is required to reach a state of protective immunity to many different variants. 
 
 
1.4.1 Antibody-mediated immunity 
 
It is well established that antibodies play a crucial role in immunity to malaria. Passive 
transfer of gamma-globulin (IgG) fractions of human immune sera to naïve individuals 
dramatically reduces parasite densities and clinical symptoms (Cohen et al., 1961; Edozien et 
al., 1962; Cohen and Butcher, 1970). Both, East Africans and Thais could be treated with 
West African immune sera, suggesting that protective epitopes are not strain-specific 
(McGregor et al., 1963; Sabchareon et al., 1991). Infants are found to be largely protected 
against malaria in the first months of life. This protection is thought to involve, together with 
other protective factors, maternal antibodies transferred through the placenta and ranges from 
3 to 6 months depending on the intensity of transmission (Snow et al., 1998). 
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 1.4.1.1 Importance of IgG subclasses 
 
Analysis of antibodies conferring protection in passive transfer experiments showed that 
specific IgG subclasses are important for the transfer of immunity. According to the structural 
diffenences in their heavy chains, human IgG can be grouped into four subclasses, IgG1 to 
IgG4. The major differences lie in sequence length and number of disulfide bonds in the hinge 
region, resulting in differential rotational flexibilities of the antigen-binding fragments. The 
structural differences influence the biological properties of the IgG subclasses, especially the 
effector functions mediated by the constant region of the Fc. Probably the most important 
effector function of IgG immunoglobulins is the fixation of complement. IgG3 is the strongest 
complement-fixing subclass, followed by IgG1. IgG2 has a weak potential of complement 
fixation and IgG4, which does not fix complement, is considered to be protective against the 
biological effects of complement-fixing antibodies. Another important function of human IgG 
is to bind to cell surface Fc-receptors. Once it is fixed to the surface of certain cell types, the 
IgG antibody can complex antigen and facilitate clearance of antigens or immune-complexes 
by phagocytosis. Three classes of human IgG Fc receptors (FcR) on leukocytes can be found: 
the FcR-I, FcR-II, and low-affinity receptor (FcR-Io). FcR-I is only expressed on monocytes, 
FcR-II on monocytes, neutrophils, eosinophils, platelets, and B cells; and FcR-Io on 
neutrophils, eosinophils, macrophages, and killer T cells. IgG1 and IgG3 strongly bind to all 
three Fc-receptors while IgG2 and IgG4 bind only weakly or not. Due to their FcR-binding 
capacities, IgG1 and IgG3 are termed cytophilic subclasses.  
The IgG subclasses also differ in their half lives (21–23 days for IgG1, IgG2, and IgG4; 7-8 
days for IgG3) and their average serum concentration. IgG1 is by far the most abundant 
subclass in healthy individuals followed by IgG2, IgG3, and IgG4. All subclasses have been 
reported to be transferred through the placenta. 
The switch from IgM to IgG subclasses occurs by rearrangement of the heavy-chain genes 
under the influence of cytokine signals. Antigens can influence heavy-chain switching 
because they can induce different cytokine secretion patterns. The antibody subclass profile to 
a certain antigen does not only depend on the nature of the antigen, but also on the time that 
passed since the exposure. IgG1 and IgG3 levels are comparable early after exposure to a 
protein antigen. Later, switching from IgG3 to IgG1 will occur, leading to a great 
predominance of IgG1 over IgG3. 
 
Several studies found that antibodies to Plasmodium falciparum antigens are predominantly 
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 of the cytophilic subclasses (IgG1 and IgG3) in immune adults. In contrast, in non-protected 
individuals, i.e. children and adults with a primary malaria attack, anti-parasite antibodies are 
found to be mainly of non-cytophilic sublasses (IgG2 and IgM) (Bouharoun-Tayoun et al., 
1992a, 1992b). Another study suggests that IgG2 antibodies are associated with protection 
from P. falciparum (Aucan et al., 2000), which may be contradictory to the importance of 
cytophilic subclasses. However, Aucan and co-workers found that 70% of the study subjects 
possessed the H131 allele of the Fc-RIIa, which is known to bind IgG2. High specific IgG4 
levels (to conserved regions of MSP2 and ring-infected erythrocyte membrane protein 
(RESA)) are associated with enhanced risk of infection (Aucan et al., 2000). This suggests 
that the non-cytophilic IgG4 blocks cytotoxic effector functions against the parasite by 
competing with cytophilic subclasses for antigen recognition. 
Parasite-specific IgG3 levels as well as IgG3/IgG4 ratios increase with age. It was further 
found that IgG effective in passive transfer experiments did not inhibit growth of the 
particular infecting strain on its own in vitro (Bouharoun-Tayoun et al., 1990). An inhibitory 
effect mediated by these antibodies in vitro was only seen in cooperation with monocytes 
(Khusmith and Druilhe, 1983b; Bouharoun-Tayoun et al., 1990).  
 
 
1.4.1.2 Effector functions of antibodies against the malaria parasite 
 
Taken together, the above mentioned data strongly suggest a crucial role for Fc-receptor-
mediated effector functions in immunity to malaria. The inhibitory activity of immune sera 
was 22-fold increased in the presence of normal human monocytes (Khusmith and Druilhe, 
1983b; Bouharoun-Tayoun et al., 1990), indicating that direct inhibition of merozoite invasion 
by binding to essential invasion molecules is not a major function of parasite-specific 
antibodies in vivo. Nevertheless, in vitro inhibition studies have shown that antibodies to 
merozoite surface proteins and other merozoite stage antigens directly inhibit parasite growth 
(Epping et al., 1988; Ahlborg et al., 1993; O’Donnell et al., 2001; Moreno et al., 2001; Müller 
et al., 2003). Immune sera have been found to inhibit merozoite dispersal in vitro and it has 
been proposed that this protective mechanism reflects the immune status of the donor (Green 
et al., 1981). The specifities of the antibodies present in such immune clusters of merozoites 
could be assigned to only 8 different antigens (Lyon et al., 1989). Among these antigens 
MSP1 and MSP2 were present (Lyon et al., 1997; Thomas et al., 1990). 
Opsonization and phagocytosis of parasitized erythrocytes (Celada et al., 1982; Celada et al., 
17
 1983) and merozoites (Khusmith and Druilhe, 1983a; Groux and Gysin, 1990) by normal 
monocytes and polymorphonuclear leukocytes has been demonstrated in vitro. Also, the 
FcRIIa polymorphisms (-Arg/Arg131 and –His/His131) were investigated and it was found 
that phagocytosis by FcRIIa-His/His131 was highest with immune sera predominantly 
containing IgG3, while phagocytosis by FcRIIa-Arg/Arg131 was highest with sera containing 
IgG1 (Tebo et al., 2002). In addition to phagocytosis, an antibody-dependent cellular 
inhibition (ADCI) mechanism has been proposed that involves soluble factors released from 
monocytes. An in vitro assay has been established, identifying tumor necrosis factor (TNFα) 
as a crucial, but not the sole factor mediating the effect. It is hypothezised that at the time of 
schizont rupture, the contact between some components of the merozoite surface and 
cytophilic antibodies bound to monocytes via Fc-receptors triggers the release of soluble 
factors. In the in vitro assay, these appear to block the division of surrounding 
intraerythrocytic parasites (Bouharoun-Tayoun et al., 1990; 1992; 1995). Other studies also 
indicated that soluble mediators are important for parasite killing (Butcher and Clark, 1990; 
Naotunne et al., 1991). A major role in antibody-dependent cellular inhibition has been 
assigned to IgG3. IgG fractions containing IgG1, IgG2, and IgG4 but no IgG3 gave negative 
inhibitions in ADCI assays, while the complete IgG fraction or IgG3 alone showed positive 
inhibition (Tebo et al., 2001). Specific antibodies to multiple plasmodial antigens have been 
shown to be associated with protection and to mediate an ADCI effect. The best-studied 
antigens with regard to their role in ADCI are MSP3 (Oeuvray et al., 1994a; Oeuvray et al., 
1994b; Singh et al., 2004) and GLURP (Theisen et al., 2000; Theisen et al., 2001; Theisen et 
al., 2004) 
 
 
1.4.1.3 The humoral immune response to MSP2 
 
Antibody responses to MSP2 have been investigated in multiple studies. Aquisition of 
specific MSP2 antibodies was shown to be age-dependent. Prevalence and titres of MSP2 
antibodies are found to be high in semi-immune individuals. This indicates that repeated 
exposure to infection is required to induce antibody responses. Most semi-immune individuals 
are positive for antibodies to 3D7- and FC27-type MSP2 but some, and especially children, 
react only with one form of MSP2, indicating that the major response is directed against the 
central variable domains,  and not the conserved termini (Al-Yaman et al., 1994). As shown in 
the same study, the presence of antibodies specific for MSP2 was associated with fewer fever 
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 episodes and anaemia. In another, prospective longitudinal study of malaria morbidity the role 
of the humoral response to MSP2 and other antigens in protection was assessed. When age 
and post exposure was controlled for, only antibodies to full-length 3D7-MSP2, 3D7-MSP2 
with a deleted repeat region, and RESA predicted a reduction of incidence rate of malaria, but 
not SPf66 nor the FC27 form of MSP2 (Al-Yaman et al., 1995). The reason for the FC27 
form of MSP2 not predicting protection may be explained in this case by the low prevalence 
of parasites with FC27-type MSP2 in the study area (Felger et al., 1994). The qualitative 
difference observed in the response to FC27 and 3D7 MSP2 indicates that the protective 
effect is likely to be related to epitopes in the variable, and not the conserved regions (Al-
Yaman et al., 1995).  
Several studies have looked at the distribution of IgG subclasses in MSP2-specific antibodies. 
In sera from adults from The Gambia, antibodies to both MSP2 families were predominantly 
of the cytophilic and complement-fixing IgG3 subclass (Taylor et al., 1995). In a further study 
it was found that the presence of IgG3 antibodies to 3D7-type MSP2 was negatively 
associated with the risk of clinical malaria while IgG1 antibodies to the FC27-type were 
associated with increased risk of clinical malaria (Taylor et al., 1998). Individuals showing 
IgG3 reactivity to both MSP2 families had the most significantly reduced risk (Metzger et al., 
2003). Compared to antibody responses to total schizont lysate the proportion of IgG3 is 
considerably higher for MSP2-specific antibodies (Rzepczyk et al., 1997; Ferrante and 
Rzepczyk, 1997). 
 
The conserved N-and C-terminal regions of MSP2 appear to be poorly antigenic (Thomas et 
al., 1990; Taylor et al., 1995; Saul et al., 1992) indicating that they are not exposed to the 
immune system. Nevertheless, these conserved parts remain interesting in terms of inclusion 
in a subunit vaccine since their immunogenicity has been shown on different occasions in 
mice (Saul et al., 1992; Lougovskoi et al., 2000; Lawrence et al., 2000)  
 
T-cell responses to MSP2 have also been studied and compared between the two allelic forms. 
T-cell epitopes in both, the N- and C-terminal conserved parts have been identified in mice 
(Rzepczyk et al., 1992). From this it was concluded that conserved sequences, when used in a 
vaccine, may induce MSP2-specific memory Th cells that could be boosted by subsequent 
exposures to all parasite strains. 
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 1.4.3 Malaria vaccines 
 
In 1973 human protection from malaria by vaccination was first reported. The vaccine 
consisted of attenuated sporozoites delivered by hundreds of X-irradiated mosquitoes on 
several occasions (Clyde et al., 1973). The protection was also against a heterologous strain 
but not durable (< 16 weeks after the last immunization with irradiated sporozoites). This 
study showed that a malaria vaccine should be feasible and that a sterile immunity can be 
induced by vaccination with pre-erythrocytic stages. In contrast, sterile immunity can hardly 
be obtained by natural exposure to infection. A whole parasite vaccine is not practical because 
of difficulties to produce large amounts of irradiated sporozoites. Therefore in the last 30 
years, research mainly concentrated on the identification of protective antigens to be used in 
subunit vaccines against the pre-erythrocytic and blood stages. Vaccines against pre-
erythrocytic stages (sporozoites and liver stages) aim at producing sterile immunity or at 
dramatically reducing parasite numbers reaching the blood stage to attenuate disease. The 
latter effect would also provide the opportunity for natural immunity to develop.  
Vaccines against the blood stages are clearly thought as anti-disease vaccines by reducing the 
multiplication of the parasite in the blood, the target being free merozoites or intra-
erythrocytic stages. An alternative blood stage vaccine strategy is to target malaria toxins to 
reduce severe disease and death (Schofield et al., 2002). The target population for anti-blood 
stage vaccines are infants, young children, and pregnant women in endemic areas. 
Gametocytes present in the blood stream exhibit a target for a transmission-blocking vaccine. 
Such a vaccine aims at reducing the rate of infected mosquitoes in the population and thus 
would not give direct protection against disease to the vaccinees. 
 
 
1.4.3.1 Prerequisites of a malaria vaccine 
 
An effective malaria vaccine must initiate and expand immune responses of the appropriate 
type and specificity. Depending on the life cycle stage that is targeted, the desirable responses 
vary considerably. Extracellular invasive stages (sporozoites and merozoites) may be 
neutralized by antibodies blocking them or eliminating them from the circulation. To achieve 
this,  CD4+ T-helper cells must also be generated because they are required for activation and 
maturation of B-cells. The elicited antibodies must be sufficiently strong and of a subclass 
allowing important effector functions (e.g. phagocytosis and complement fixation). 
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 Targeting hepatocytic stages requires a strong T-cell response. Such a response is probably 
difficult to achieve since the liver is thought to be a relatively immunosuppressive site. 
Epithelial cells of the liver sinusoid have been shown to induce T-cell tolerance through 
presentation of local antigens (Knolle et al., 2000). Furthermore it has been found that P. 
falciparum-infected red blood cells can induce apoptosis of parasite-specific T-cells (Xu et 
al., 2002). 
Common to malaria vaccines directed against different life cycle stages is that a long lasting 
effect is desirable. This is probably most difficult to achieve since natural immunity has been 
shown to be short-lived (Cavanagh et al., 1998; Giha et al., 1999), which was suggested to 
involve defects in memory B-cell populations specific for some malarial antigens (Dorfman et 
al., 2005). Another crucial prerequisite of a subunit vaccine is that it provides strain-
transcending protection. This clearly favors conserved and semi-conserved antigens or 
epitopes over polymorphic ones, however, conserved domains of malarial antigens are 
generally poorly immunogenic. 
 
 
1.4.3.2 Vaccine candidates 
 
According to WHO there are currently 21 pre-erythrocytic stage vaccines, 38 blood stage 
vaccines, 7 combination (multi stage) vaccines, and 3 transmission-blocking vaccines in the 
pre-clinical developmental phase. (www.who.int/vaccine_research/documents/en/malaria 
_table.pdf). 
 
 
1.4.3.3 Erythrocytic stage vaccine candidates 
 
A number of vaccine candidates derived from asexual blood stage antigens have been 
extensively studied in the past decade. These are MSP1, MSP2, apical membrane antigen 1 
(AMA1), rhoptry-associated protein 1 (RAP1), RAP2, ring-infected erythrocyte surface 
antigen (RESA), erythrocyte-binding antigen 175 kDa (EBA175), and glutamate-rich repeat 
antigen (GLURP) (reviewed in Anders and Saul, 2000). 
 
The only pure blood stage vaccine, for which a phase IIb trial (efficacy trial in volunteers in a 
disease endemic country) has been completed, is Combination B (Genton et al., 2002). The 
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 antigens included in Combination B are recombinant proteins corresponding to the N-terminal 
fragment of MSP1, the full-length MSP2 from strain 3D7, and RESA. The vaccine was  
formulated in Montanide 720 and injected in Papua New Guinean children aged 5 to 9 years. 
Combination B showed an efficacy of 62% in reducing parasite density. Vaccinees had a 
lower prevalence of infection with parasites carrying a 3D7-type MSP2 allele (the one 
represented by the vaccine), favouring parasites carrying an MSP2 allele of the FC27 type. 
This suggests that the vaccine effect was at least partially due to the MSP2 component. This 
was the first occurrence of a selecting effect by a malaria vaccine on the parasite population in 
the field. 
There was no difference in the number of clinical episodes between vaccine and placebo 
recipients. The vaccine induced a statistically significant antibody response to all three 
antigens, irrespective of pre-treatment with sulfadoxine-pyrimethamine (SP) (Genton et al., 
2003). For MSP2, the pre-vaccination antibodies were considerably higher than post 
vaccination levels in naïve Australian adults (phase I trial, Saul et al., 1999). Nevertheless, the 
antibody levels increased substantially post-vaccination. In contrast, MSP1 and RESA 
antibodies failed to increase to higher levels than that seen in naïve adult volunteers post-
vaccination. 
In Papua New Guinean adults the antibody titres to the 3 antigens were about one order of 
magnitude higher than in vaccinated children (Genton et al., 2003). Vaccination following 
drug treatment (SP) did not increase antibody levels in these adults. Antibody levels even 
dropped substantially for MSP2 and RESA after vaccination. This suggests that antibodies to 
MSP2 and RESA are short-lived. 
Cellular responses to Combination B were assessed by production of IFN-γ, TNF-α, IL-4, and 
IL-10). The vaccine induced a significant IFN-γ response to MSP1 only. 
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The 3D7 form of the merozoite surface protein 2 (MSP2) of Plasmodium falciparum was one of three subunits
of the malaria vaccine Combination B that were tested in a phase I/IIb double-blind randomized placebo-
controlled trial, which was undertaken with 120 Papua New Guinean children of 5 to 9 years of age. Because
only one variant of the highly polymorphic MSP2 was used for vaccination, we examined whether the elicited
response was directed against conserved or strain-specific epitopes. Postvaccination (week 12) titers of anti-
body against recombinantly expressed individual domains of MSP2 were measured by enzyme-linked immu-
nosorbent assay and compared to baseline values. We found that vaccination with the 3D7 form of MSP2
induced a significant strain-specific humoral response directed against the repetitive and semiconserved
family-specific part. The conserved N- and C-terminal domains were not immunogenic. Titers of antibody
against the alternate FC27 family-specific domain showed a tendency to increase in vaccinated children, but
there was no increase in antibodies against FC27-type 32-mer repeats. These results indicate that vaccination
with one MSP2 variant mainly induced a strain-specific response, which can explain the selective effect of
vaccination with combination B on the genotypes of breakthrough parasites. These findings support the
inclusion of both family-specific domains (3D7 and FC27) in an improved vaccine formulation.
The antigenic diversity of Plasmodium falciparum represents
a significant challenge for the development of a malaria vac-
cine. The merozoite surface protein 2 (MSP2) has been con-
sidered a candidate antigen despite being highly polymorphic.
The different msp2 alleles, which differ in number and se-
quence of intragenic repeats, can be grouped into two allelic
families, FC27 and 3D7, according to the central dimorphic
domain (18).
The 3D7 allelic type of MSP2 formed one of three subunits
of the malaria vaccine Combination B, which is one of the few
malaria vaccines tested in a field trial so far. This subunit
vaccine, consisting of the three recombinant proteins MSP1
(190LCS.T3), MSP2, and ring-infected erythrocyte surface an-
tigen, was assessed in a randomized, placebo-controlled, dou-
ble-blind phase I/IIb trial (natural challenge) using 120 Papua
New Guinean (PNG) children of 5 to 9 years of age (12).
Montanide ISA720 was used as an adjuvant. The placebo doses
consisted of adjuvant alone. Vaccination reduced parasite den-
sities (the primary outcome) by 62%. It remains unclear which
of the three vaccine components is responsible for this protec-
tion, but molecular monitoring provided evidence that this
effect was at least partly due to the efficacy of the MSP2
component (6). The parasites in all blood samples collected
during the trial in fortnightly intervals over 18 weeks were
genotyped at the msp2 locus. When the effect of vaccination on
parasite prevalence was assessed, the prevalence of parasites
with a 3D7-type msp2 genotype was found to be significantly
reduced, while the vaccine made no difference in the preva-
lence of parasites with an FC27-type msp2 genotype (12). Also,
the vaccine effects on preventing new infections were signifi-
cantly different for the two allelic families. Genotyping blood
samples, collected from these 120 children over a period of 1
year following the trial during morbid episodes, revealed that
vaccination led to an increase in incidence of morbid episodes
with FC27-type MSP2 alleles. This was the first report of a
selective effect exerted by vaccination with a polymorphic ma-
laria vaccine (6, 12). The demonstration of a specific effect of
the vaccine against the development of infections of the 3D7
type indicated that the activity of Combination B is due, at
least in part, to the MSP2 component, which seems to protect
children against homologous parasites.
This finding of vaccine-induced selection targeted at MSP2
prompted us to analyze the anti-MSP2 humoral immune re-
sponse elicited by vaccination. By analyzing in great detail the
effect of Combination B on (i) msp2 genotypes detected in trial
participants and (ii) the strain-specific anti-MSP2 response, we
hope to elucidate the effects observed in this field trial in PNG
and gather important information for a future MSP2-based
vaccine or for other polymorphic vaccines in general.
Of particular interest was the immunogenicity of the con-
served N- and C-terminal domains, which could potentially
confer immunity across all strains, in contrast to a strain-spe-
cific response indicated by antibodies against the intragenic
repeats of the 3D7 allele. Immunogenicity of the 3D7 family-
specific region could protect against all infecting parasites with
an MSP2 of this family. We also investigated whether re-
sponses against different regions of the family-specific domain
of the alternative FC27 allelic family were elicited. To quantify
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immune responses against the conserved, variable, or repeti-
tive domains of MSP2, the corresponding fragments of the
gene were cloned and expressed in Escherichia coli.
In the PNG trial, antibody responses were elicited against all
three antigens included in the vaccine (11). A significant in-
crease in the anti-MSP2 antibody level was observed in re-
sponse to vaccination. The serological analysis was performed
using the full-length 3D7 type of MSP2 antigen, which was
included in the Combination B vaccine. These tests did not
permit delineation of the response with respect to the different
domains of MSP2.
In anticipation of further vaccine trials of MSP2, there is a
need to analyze what effects could have been responsible for
the protection observed in the recent trial and why these effects
did not protect completely. We were particularly interested in
exploring whether vaccination induced an immunological re-
sponse against the conserved parts of the molecules or specif-
ically against the 3D7 family-specific domain. In light of the
limited natural recognition of the conserved domains of MSP2
(14), performing such analyses with samples from immunized
children becomes crucial for deciding the composition of the
next generation of an MSP2 vaccine. We also investigated
whether antimalarial pretreatment led to increased immuno-
genicity of the vaccine, as has been proposed previously (3, 10).
MATERIALS AND METHODS
Study area and study design. The study was conducted in four villages of the
Wosera District of the East Sepik Province of PNG. The study area shows
intense and perennial malaria transmission. Entomological inoculation rates
were estimated to be 35 infectious bites per year for P. falciparum. One hundred
twenty children from ages 5 to 9 years were enrolled in the double-blind, block-
randomized (within age groups), four-arm, placebo-controlled trial to assess
safety, immunogenicity, and pilot efficacy of the Combination B vaccine. Since it
has been debated whether preexisting infections should be cleared before im-
munization, half the children were pretreated with sulfadoxine pyrimethamine
(SP) (Fansidar; Hoffmann LaRoche, Basel, Switzerland) at baseline (week 1).
Injections were given twice, at weeks 0 and 4.
Blood samples were collected at baseline and every 2 weeks from weeks 4 to
18. The primary outcomes of the trial were the rate of adverse events and the
geometric mean P. falciparum parasite density (assessed for all positive samples
from weeks 8 to 18).
Ethical clearance was obtained from the PNG Medical Research Advisory
Committee. Detailed study procedures were described previously (11).
Cloning of recombinant msp2 constructs. The different MSP2 domains were
PCR amplified and cloned in the pQE30 expression vector (QIAGEN, Valencia,
Calif.), providing an N-terminal His6 tag. The primers and msp2 alleles used as
a template for amplification are given in Table 1. A recombinant FC27 family-
specific domain was generated by ligating two PCR products representing the
region upstream of the 32-mer repeats and the region downstream of the 12-mer,
respectively. The restriction sites necessary for ligating the two PCR fragments
gave rise to three additional residues, arginine, asparagine, and serine, which are
not found at this position in wild-type MSP2 variants. Cloning of N- and C-
terminal constant domains was described previously (8). All constructs cloned in
E. coli were confirmed by DNA sequencing on an ABI Prism 310 genetic analyzer
(Perkin-Elmer). Accession numbers are given in Table 1.
Antigen preparation. Five recombinant antigens corresponding to different
MSP2 domains were expressed as His6-tagged proteins in E. coli strain M15
(QIAGEN) and purified under denaturing conditions (8 M urea) by use of a
Ni-nitrilotriacetic acid column in accordance with the manufacturer’s protocol
(QIAGEN). The reactivities of the antigens were assessed by immunoblot anal-
ysis using a serum pool of 20 semi-immune adults from PNG. The concentrations
of purified antigens were determined with a bicinchoninic acid protein assay
(Pierce). The recombinant proteins correspond to the conserved N-terminal
part, the conserved C-terminal part, the 3D7 family-specific part, the FC27
family-specific part, and an FC27-type 32-amino-acid sequence repeated four
times. We failed to recombinantly express the 4-mer repeat glycine-glycine-
serine-alanine (GGSA) of the 3D7 strain. Therefore, a synthetic peptide (mo-
lecular size, 1,379 Da) corresponding to (GGSA)5 was used. This peptide was
kindly provided by Giampietro Corradin, Lausanne, Switzerland.
Determination of antibody titers. Titers of antibody against the above-men-
tioned antigens were determined by a standard enzyme-linked immunosorbent
assay (ELISA). Immulon 2HB plates (Thermo Labsystems, Franklin, Mass.)
were coated overnight with 50 l of antigen at a concentration of 2 g/ml
(recombinant proteins) or 10 g/ml (synthetic peptide). Plates were blocked for
1 h at room temperature in phosphate-buffered saline containing 5% nonfat milk
powder. Antibody reactions were carried out in phosphate-buffered saline con-
taining 0.5% milk powder and 0.05% Tween 20. Serum samples were serially
diluted threefold starting from a 1:50 dilution. A pool of serum from 20 adults
from PNG was used as an internal standard at a dilution specific for each antigen
to give an optical density of about 1. Dilutions of the serum pool were 1:10,000
for the 3D7 family-specific domain and for the FC27-type repeat, 1:1,200 for the
FC27 family-specific domain, and 1:100 for the two conserved domains and for
the 3D7-type repeat.
The plates were incubated for 2 h at room temperature. Plate washing was
TABLE 1. Sequences and accession numbers of MSP2 constructs
Antigen Primer sequence (restriction site)a Accession no.(allele) Recombinant protein sequence
3D7 family-specific
domain
5-cgggatcccgTGGTAATGGTGCT-3 (BamHI) M60188 (FCR3) MRGS-HHHHHH-GSR-(FCR3 aab 109–214)-
GYPGSTCSQA
5-ggggtaccccAGATTGTAATTCG-3 (KpnI)
FC27 family-specific
domain
5 part 5-cgggatcccgTAAGAGTGTAGGTG-
CAAATGCTCCAAAAggaattcc-3 (BamHI/
EcoRI)
M59766 (K1) MRGS-HHHHHH-GSRKSVGANAPK-GIP-(FC27
fsp)-APQEP
5-ggaattcc (EcoRI)
Fused to 3 part 5-gggattccAGAAAGTTCAAGTT-3 (EcoRI) MS9766 (K1) QTAENENPA-GYPGSTCSQA
5-ggggtaccccAGCAGGATTTTCA-3 (KpnI)
FC27-type repeat
(32aa)4
5-cgggatcccgTGCTCCAAAAGCT-3 (BamHI) AY532388 (lfa
45)
MRGS-HHHHHH-GSR-APK-(32-aa repeat)4-
ADTP-GYPGSTCSQA
5-ggggtaccccAGGGGTATCAGCA-3 (KpnI)
a Lowercase nucleotides indicate mismatches with respect to the msp2 nucleotide sequence; underlined nucleotides indicate restriction sites used for cloning.
b aa, amino acid.
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performed with an ELISA washer with water containing 0.05% Tween 20. Horse-
radish peroxidase-labeled goat anti-human immunoglobulin G (IgG) (Kirkeg-
aard & Perry Laboratories, Inc., Gaithersburg, Md.) was used as a secondary
antibody at a 1:4,000 dilution and incubated for 2 h at room temperature. After
extensive washing, ABTS [2,2-azinobis(3-ethylbenzthiazolinesulfonic acid)] per-
oxidase substrate (Kirkegaard & Perry) was added. The reaction was stopped
after 30 min with 1% sodium dodecyl sulfate, and the optical densities of the
plates were read at 405 nm. Antibody titers were determined from the last
dilution giving an optical density above 0.1 after standardization and background
subtraction (same serum dilution on the uncoated plate).
PCR-restriction fragment length polymorphism genotyping. IsoCode STIX
PCR template preparation dipsticks (Schleicher & Schuell, Inc., Keene, N.H.)
were used for transport and storage of blood pellets after removal of serum from
all blood samples collected during the study. Isolation of P. falciparum DNA and
msp2 genotyping were performed as previously described (7). Genotyping of
FC27-type alleles was done by a HinfI restriction digestion. To identify each
3D7-type allele unequivocally, additional DdeI and ScrFI digestions were done.
Statistical analysis. For each child, the ratio of the titer at week 12 to that at
baseline (week 1) was computed. Two sample t tests were used to test the
statistical significance of the difference in this ratio between the placebo and
vaccine groups. To evaluate whether the diversity of infecting parasites modified
the level of antibody, Spearman correlations were computed between the mean
multiplicity of infection (MOI) from weeks 4 to 12 and the specific antibody titers
at week 12. To ascertain whether any specific antibody appeared to be protective,
the correlations were computed between the mean MOI from weeks 14 to 18 and
the antibody titers at week 12.
RESULTS
The different MSP2 domains used for ELISA are depicted
schematically in Fig. 1. We failed to express the 3D7 repeats in
E. coli; therefore, a synthetic peptide was used.
Effect of vaccination. The responses against the MSP2 com-
ponent of the Combination B vaccine were compared among
the four study groups, i.e., those receiving either (i) vaccine
with no SP, (ii) placebo with no SP, (iii) vaccine with SP, or (iv)
placebo with SP. Serum samples analyzed were derived from
the baseline survey of the vaccine trial at week 1 and from
the parasitological survey at week 12 after vaccination. We
chose sera collected at week 12 because titers of IgG against
the full-length MSP2 vaccine molecule were found to peak in
vaccinated children at this time (11). Figure 2 gives the average
titers to all six antigens for the four treatment groups. To test
for vaccine effects, the ratio of the antibody titers of the two
time points was determined for each child. Table 2 shows the
effect of vaccination on this ratio. A significant increase in
anti-MSP2 antibody titers in vaccinated children was found for
the 3D7-specific antigens. The increase was 4.9-fold (95% con-
fidence interval, 2.72 to 8.83) for the 3D7 family-specific do-
main and 3.1-fold (95% confidence interval, 1.97 to 4.86) for
the 3D7 repeats (P  0.0001). The Combination B vaccine did
not significantly increase the titers of antibody against the
FC27 32-mer repeats or the conserved N- or C-terminal do-
mains. In contrast, titers of antibody against the FC27 family-
specific domain decreased in the placebo group but remained
almost constant in the vaccine group, leading to an overall
positive effect of vaccination (Fig. 2). Thus, this latter result
must be viewed with care.
Effect of SP treatment prior to vaccination. Half of the
children (30 vaccine treated and 30 placebo treated) were
pretreated with SP in the week prior to the first immunization.
To identify whether this pretreatment modified the antibody
response, we carried out a comparison of the responses in the
SP-treated and untreated groups. We found no significant ef-
fect of SP treatment on the ratio of week 12 titer to baseline
titer for any of the antigens corresponding to the vaccine mol-
ecule, nor were the responses against the N- and C-terminal
constant domains or to the FC27 32-mer repeat affected by
prevaccine treatment. The only effect of SP treatment was
observed for the FC27 family-specific domain. Children who
did receive SP showed reduced titers of antibody against this
FC27 domain (Table 2).
We also tested for a possible interaction between antimalar-
ial treatment and vaccine effect. SP treatment did not signifi-
cantly modify the effect of vaccination on any of the titers.
Effect of present or new infections. In order to assess
whether P. falciparum infections present during the trial period
influenced the serological outcomes independently of the ef-
fect of vaccination, we calculated Spearman correlations be-
tween antibody titers and the mean MOIs determined by PCR-
restriction fragment length polymorphism. This was done
separately for the MOIs of FC27- and 3D7-type parasites. The
MOI was chosen as the end point because it reflects the expo-
sure during that period. The initial analyses considered only
children who were not treated with SP (59 children in the
placebo and vaccine groups), since SP-treated children re-
mained largely uninfected. Among the untreated children,
there were no significant relationships between the mean MOI
from weeks 4 to 12 of either the 3D7 or the FC27 type of
parasites and any antibody at week 12, suggesting that stimu-
lation by recent infections had little effect on the antibody
levels. In particular, titers of antibody against the 3D7 family-
specific domain of MSP2, which were significantly increased by
vaccination, showed no significant correlation to the MOI of
3D7-type parasites nor to the MOI of FC27-type parasites
(correlation coefficients were 0.15 [P  0.3] and 0.09 [P 
0.5], respectively).
When the SP-treated group was analyzed, no relationship
was detected between the MOI and the levels of antibody
against any of the antigens tested. However, when we deter-
mined the prospective effect of antibody levels measured at
FIG. 1. Schematic diagram of recombinant and synthetic MSP2
antigens used for ELISA. The constructs are aligned with full-length
MSP2 alleles representing the two allelic families of MSP2. The 3D7
vaccine molecule included in Combination B is also shown.
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week 12 in all non-SP-treated children, irrespective of whether
they had received placebo or vaccine, we found positive asso-
ciations between antibodies against nonvaccine epitopes
(FC27) and the mean MOI from weeks 14 to 18 (Table 3). This
finding suggests that these antibodies reflect the long-term
history of exposure of the host. There was little or no relation-
ship between titers of antibody against vaccine epitopes (3D7)
and post-week 12 MOIs, probably because the levels of these
antibodies were modified by vaccination so that they no longer
represented long-term exposure. This analysis included non-
SP-treated children only in order to exclude the effects of this
long-acting antimalarial drug on MOI.
DISCUSSION
The aim of including the conserved N- and C-terminal do-
mains of MSP2 in a multicomponent vaccine was to elicit a
FIG. 2. IgG responses of different treatment groups to recombinant and synthetic MSP2 constructs. Geometric means of titers are shown for
each treatment group to all tested antigens: conserved N terminus, conserved C terminus, 3D7 family-specific domain, 3D7 4-mer repeat, FC27
family-specific domain, and FC27 32-mer repeat. White columns represent titers at baseline; gray columns represent titers at week 12 postvac-
cination with combination B. Standard errors are indicated. The numbers of tested sera at baseline and week 12, respectively, for the different
groups were as follows: placebo, 56 and 57; vaccine, 56 and 58; placebo with no SP, 29 and 29; vaccine with no SP, 29 and 30; placebo with SP,
27 and 28; and vaccine with SP, 27 and 28.
TABLE 2. Effect of vaccine and of SP pretreatmenta
Antigen
Vaccine SP pretreatment
 95% CI t P t 95% CI
b t P
Conserved N
terminus
0.84 0.561.27 1.24 0.2 NS
Conserved C
terminus
1.23 0.871.76 1.17 0.2 NS
3D7 family
specific
4.90 2.728.83 5.12 0.0001 NS
3D7 repeat 3.10 1.974.86 4.88 0.0001 NS
FC27 family
specific
1.57 1.042.37 2.11 0.037 0.59 0.39–0.89 2.49 0.01
FC27 repeat 1.42 0.902.23 1.5 0.14 NS
a v  xv,12xp,1/xv,1xp,12, where xv,1 is the geometric mean titer in the
vaccine group at baseline, xp,1 is the geometric mean titer in the placebo group
at baseline, xv,12 is the geometric mean week 12 titer in the vaccine group, xp,12
is the geometric mean week 12 titer in the placebo group, and , is the corre-
sponding ratio testing the effect of SP treatment rather than of vaccination. A
value of 1 for  or t corresponds to no effect.
b CI, confidence interval; NS, not significant.
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strain-transcending immune response. We found that vaccina-
tion with Combination B did not induce an antibody response
to either of the conserved termini of MSP2. This finding is
consistent with generally low titers of naturally occurring an-
tibodies to the conserved parts of MSP2 (14, 15, 20, 22, 24).
Also, our recombinant constructs of the N- and C-terminal
constant domains had been tested previously in immunoblots
with a panel of sera of malaria-exposed adults and had shown
only limited reactivities (8).
This finding contrasts with previous results from immuniza-
tions of mice suggesting that the conserved parts are immuno-
genic. Both a recombinant fusion of the conserved N and C
termini (14) and short synthetic peptides representing parts of
the conserved MSP2 regions (13) were immunogenic in mice.
Humoral responses were elicited against the immunogens, but
both studies reported very little reactivity with the full-length
MSP2 protein.
Despite not being immunogenic in response to vaccination
with Combination B, the conserved domains of MSP2 were
recognized to be highly prevalent but generally to exist at low
titers in all study groups. Our findings suggest that the con-
served domains are antigenic to some extent in naïve individ-
uals. However, vaccination or continuous natural exposure
does not boost the response, indicating some tolerogenic prop-
erties of these parts of the molecule. This finding is also sup-
ported by our observation (unpublished) that titers of antibod-
ies to conserved regions are generally found to be higher in
young children than in semi-immune adults.
The repetitive domain of MSP2 is allele specific, and repeat
sequences differ considerably between individual 3D7-type al-
leles. At week 12 postvaccination, we found significantly in-
creased titers of IgG against the central repeat region in vac-
cinees. But it remains unclear how much the observed
antirepeat response has contributed to protection against other
3D7-type parasite infections via cross-protective epitopes. The
repeat unit GGSA of the 3D7 vaccine molecule occurs only
rarely in the study area (unpublished observation). This finding
is reflected by low baseline titers of anti-GGSA antibodies as
opposed to high titers of antibodies to the FC27-type repeat
(mean titers of 107 and 2,479, respectively). It might be pos-
sible that we failed to measure the entire anti-GGSA response
in our ELISA because we used a short synthetic peptide
[(GGSA)5] which may present the repeat in a conformation
different from that in the full-length vaccine molecule. How-
ever, using this synthetic peptide for measuring the anti-GGSA
response seems adequate in view of the high titers (	12,000)
found in some sera after vaccination.
The anti-3D7 responses were impressive, with a 4.9-fold
increase in titers of antibody against the family-specific domain
in vaccinated children irrespective of SP treatment. This result
is consistent with the previously described 2.5-fold increase in
antibody titers against the entire 3D7 vaccine molecule (11).
The result is also in line with a significant reduction in the
prevalence of 3D7-type infections in the non-SP-treated vac-
cinated children (12).
The immunogenicity result supports the inclusion of the 3D7
family-specific domain in further vaccine formulations. Our
finding suggests, but does not prove, that vaccine-induced anti-
3D7 antibodies specifically protect against infections with par-
asites of the same allelic family, consistent with findings of
cross-reactivity within the allelic family (8, 9). Whether the
specific anti-3D7 response accounted for the vaccine-induced
reduction in parasite densities remains open.
In trials of malaria vaccines (1, 2), insecticide-treated mos-
quito nets (for examples, see references 16 and 19), and drugs
(21), participants are often pretreated with antimalarials in
order to clear parasitemia and to allow determination of time
to infection. Such treatment also has been advocated because
of the immunosuppression during immunization caused by
acute malaria infections and asymptomatic malaria para-
sitemia (3, 23). But pretreatment does reduce the statistical
power to determine the primary end point for efficacy (e.g.,
parasite density as in the Combination B trial) and molecular
measurements by preventing infections for much of the fol-
low-up period. The benefits of pretreating vaccine trial partic-
ipants have also been questioned on the grounds of effects on
immune responses (4), adverse events, or resistance of para-
sites (5, 17). Our results from the PNG trial of Combination B
showed no interaction between SP treatment and vaccine effect
on anti-MSP2 antibody titers but dramatically reduced the
statistical power of the trial to detect the parasitological effects
of the vaccine.
SP treatment had a small but significant effect in reducing
titers of antibody against the FC27 family-specific domain, the
antigen not represented by the MSP2 variant included in the
Combination B vaccine, presumably due to the reduction in
exposure caused by the clearance of FC27-type parasites at
baseline.
Genotyping all blood samples gave important information
on whether the immune response to the MSP2 vaccine was
modified by the presence of parasites, which is a topic of
considerable interest in malaria vaccine trial design. There was
no indication that exposure of the children studied to naturally
presented malaria antigen primed them for additional boosting
by the 3D7 vaccine component because antibody titers were
unaffected by SP treatment. Also, multiplicity of 3D7-type in-
fections did not affect titers of anti-3D7 antibody titers. Our
finding is in agreement with a previous indication that a par-
ticular infecting MSP2 variant was not associated with the
boosting of a strain-specific antibody response in semi-immune
adults from Vietnam (24).
During the 1-year follow-up period after the trial of Com-
bination B, an increase in morbidity associated with FC27-type
alleles was observed, suggesting that the vaccine caused a se-
TABLE 3. Correlations between MOI (weeks 14 to 18) and
antibody titer at week 12 irrespective of vaccinationa
Antigen
3D7 family FC27 family
Spearman’s 
 P value Spearman’s 
 P value
Conserved N terminus 0.41 0.001 0.27 0.04
Conserved C terminus 0.19 0.14 0.27 0.04
3D7 family specific 0.11 0.4 0.11 0.4
3D7 repeat 0.14 0.3 0.09 0.5
FC27 family specific 0.38 0.003 0.35 0.007
FC27 repeat 0.26 0.05 0.49 0.001
a Results shown are for only the 59 non-SP-treated children with complete
data. Calculation of MOI included samples with no infections. Mean MOI of
3D7-type infections, 0.24 (standard deviation, 0.40); mean MOI of FC27-type
infections, 0.24 (standard deviation, 0.46).
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lective effect favoring the allelic family not represented in the
vaccine (12). Here we showed that the vaccine had only a small
effect on specific anti-FC27 antibody titers, consistent with
evidence that there is a limited degree of cross-reactivity be-
tween the two allelic families (8). However, by reducing the
stimulus caused by 3D7-type infections, the vaccine may have
reduced immune stimulation against other malaria epitopes
and hence made the hosts more vulnerable to FC27 infections.
Our results strongly encourage inclusion of both variants of the
central dimorphic region in a future MSP2 vaccine.
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 ABSTRACT 
Extensive genetic polymorphism is generally found in Plasmodium falciparum surface 
antigens. This poses a considerable obstacle to the development of a malaria 
vaccine. In order to assess possible effects of a polymorphic vaccine, we have 
analyzed the genetic diversity of parasites collected in the course of a phase 2b field 
trial of the blood stage vaccine Combination B in Papua New Guinea. The full length 
3D7 allele of the merozoite surface protein 2 (MSP2) was included in Combination B 
as one of three subunits. Vaccinees had a lower prevalence of parasites carrying a 
3D7-type allele (corresponding to that in the vaccine) and selection appeared to 
favour the alternative FC27-type alleles resulting in a higher incidence of morbid 
episodes associated with FC27-type parasites. We sequenced MSP2 alleles 
detected in study participants after vaccination to identify breakthrough genotypes. 
Extensive genetic diversity of MSP2 was observed in both the repetitive and family-
specific domains, but alleles occurring in vaccine recipients were no different from 
those found in placebo recipients. A phylogenetic analysis showed no clustering of 
3D7-type breakthrough infections from vaccine recipients. The repeat unit present in 
the vaccine molecule occurred in a number of alleles from the trial area and was also 
observed in vaccinated individuals. Thus the anti-repeat immune response did not 
lead to elimination of parasites carrying the same repeat unit. We conclude that the 
conserved epitopes in the family-specific domain were the most important 
determinants of the vaccine effect against new 3D7-type infections and that the 
hypervariable domains were not subject to selective effects of the vaccine. 
 
Keywords: Plasmodium falciparum, malaria vaccine, breakthrough infection, 
merozoite surface protein 2, genetic diversity, phylogenetic analysis 
 
 
INTRODUCTION 
 
Plasmodium falciparum surface proteins, and in particular those coating the invasive 
merozoite stage, are considered prime candidates for vaccine development. 
Merozoite surface proteins are accessible to the immune system between the rupture 
of a schizont-infected erythrocyte and reinvasion.  Antigens located on the merozoite 
surface are generally well recognized by the immune system, but unfortunately these 
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 antigens also exhibit extensive polymorphism. Antigenic diversity is thought to help 
the parasite in escaping human immune defences (Anders, 1986).  
 
Extensive genetic polymorphism poses considerable obstacles to vaccine design. If 
only a single allele of a polymorphic antigen is used as a malaria vaccine, the 
protection achieved might be directed only against the same or similar variants. The 
merozoite surface protein 2 (MSP2) of P. falciparum, which constitutes a major 
component of the surface coat of the merozoite, is an example of a highly 
polymorphic antigen that has been used for vaccination. The recombinant, full length         
MSP2 molecule was one component of the Combination B subunit vaccine along 
with MSP1 (190LCS.T3), and the Ring-infected Erythrocyte Surface Antigen (RESA). 
In 1998 Combination B was tested in a randomised, 4-armed placebo-controlled, 
double-blind Phase I/IIb trial (natural challenge) in 120 Papua New Guinean children 
aged 5-9 years. Vaccinated children were found to have reduced parasite densities, 
with an efficacy of 62% (Genton et al.,  2002).  
 
A single allele of the highly polymorphic MSP2, deriving from the 3D7 strain, was 
included in the Combination B vaccine. The major portion of MSP2 is polymorphic, 
only the N- and C-terminal domains are conserved. A dimorphic region flanking a 
repetitive domain identifies the two allelic families of MSP2, the 3D7-type and FC27-
type alleles. The units of tandem repeats vary considerably in length and sequence 
between different msp2 alleles. Difference in repeat copy number causes extensive 
length polymorphism which forms the basis of various msp2 genotyping schemes.  
 
Genotyping all blood samples collected during the trial at fortnightly intervals over 18 
weeks revealed that the vaccine efficacy exhibited specificity for infections belonging 
to the 3D7 allelic family. Genotyping of blood samples from morbid episodes, 
collected from these 120 children over a period of one year following the trial, 
revealed that vaccination favoured FC27-type alleles, thus increasing morbidity in 
vaccinated children. These were the first reports of a selective effect exerted by 
vaccination with a polymorphic malaria vaccine (Genton et al., 2002; Felger et al., 
2003). 
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 Combination B, as most other malaria vaccines currently in development, was not 
expected to provide sterilizing immunity. Such imperfect vaccines may select for 
specific breakthrough parasites, comprising variants not cleared by vaccine-induced 
immunity. While genotyping of all samples from the vaccine trial had shown that the 
3D7 vaccine differentially affected the alleles of the FC27 and 3D7 family (Genton et 
al., 2002), the vaccine effect on individual 3D7-type MSP2 alleles from subsequent 
infections has not yet been examined. To monitor the impact of the imperfect MSP2 
vaccine subunit of Combination B on the subsequent genetic diversity of MSP2, we 
have now sequenced msp2 alleles from both breakthrough and placebo group 
infections. Phylogenetic sequence analysis was applied to identify characteristics of 
genotypes resistant to vaccine effects. Such analysis has been postulated to be of 
great relevance, since partially effective vaccines could potentially select for more 
virulent pathogens (Gandon et al., 2001).  
 
 
MATERIALS AND METHODS 
 
Study population. 120 children aged 5 – 9 years from the Wosera area of Papua New 
Guinea were recruited for a phase I/IIb field trial of Combination B, starting in 
February 1998. The study was designed as a 4-armed placebo controlled trial with 
one half of the children being pretreated with SP at baseline. Venous or finger prick 
blood samples were collected at baseline and during 8 consecutive cross-sectional 
surveys as described by Genton et al. (2002). During a one-year morbidity follow-up 
finger prick blood samples were taken from all children reporting with a history of 
fever in the last three days.  
 
Sample collection. From the 120 children enrolled in the trial, 1079 blood samples 
were collected at baseline and during the 18 weeks follow-up period. Isocode stix dip 
sticks (Schleicher and Schuell) were used for transport and storage of blood pellets 
after removal of serum. All samples were analyzed by PCR, and 257 of these were 
found to be positive for P. falciparum. In addition, 449 blood samples were collected 
from those 120 children during the one-year morbidity follow-up (296 samples from 
self-reported case detection at the health center and 153 samples from community-
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 based case detection through weekly visits by village reporters). From these 449 
morbidity follow-up samples, 202 were positive for P. falciparum by PCR.  
 
Genotyping. Isolation of P. falciparum DNA and msp2 genotyping was performed as 
previously described (Felger et al., 1994; Felger and Beck, 2002). The variable 
central part of the P. falciparum msp2 gene was amplified by PCR. Subsequent 
restriction digests produced a genotype-specific RFLP pattern for each different 
parasite clone in a blood sample. PCR-RFLP genotyping distinguished 39 msp2 
alleles in 257 parasite-positive blood samples of the trial. During the following year of 
morbidity follow-up, 3 additional msp2 alleles were detected in morbid episodes. This 
amounts to 42 msp2 alleles (8 of the FC27 family, 34 of the 3D7 family) present in 
the study area. 
 
Sequencing. During the entire study we sequenced 32/34 different 3D7-type msp2 
alleles identified by PCR-RFLP. Alleles from single infections were chosen for 
analysis. The nested msp2 PCR product was directly sequenced using both PCR 
primers and internal sequencing primers. The sequencing reaction was performed 
with Big Dye sequencing reagents (Applied Biosystems) according to the supplier’s 
instructions and loaded to an ABI PRISM 310 genetic analyzer. The ABI Sequence 
Navigator program was used for sequence analysis. Sequences were submitted to 
Genbank under the accession numbers: U07001, AY534507, U07009, U16840, 
U16842, DQ162622, DQ168572, DQ166534, DQ185319, AJ318755, AJ318753, 
AJ318752, AJ318754, DQ166535, DQ174442, DQ166536, DQ158904, DQ185320, 
DQ168571, DQ166545, DQ166537, DQ166538, DQ166546, DQ166539, DQ166540, 
DQ166541, DQ166542, DQ166543, DQ166544, DQ171731, DQ171732, M73810. 
 
Phylogenetic analysis. For sequence alignment the ClustalX program (ftp://ftp-
igbmc.u-strasbg.fr/pub/ClustalX/) was used. Phylogenetic analysis was performed 
with PHYLIP (Phylogeny Inference Package) version 3.6.a3 (Felsenstein, 2002). 
Distance and parsimony methods were chosen to calculate the fractions of sites that 
differ between MSP2 alleles. Trees were constructed by the Neighbor Joining as well 
as by the parsimony algorithm using 1000 bootstrap replicates. Phylogenetic trees 
were viewed by the TreeView program version 1.5.2. (Page, 1996). 
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 Definition. A breakthrough infection was defined as a new infection which occurred 
from week 8 onwards in children immunized with Combination B, and which has not 
been present in the blood sample of the same individual at baseline and at weeks 4 
and 6. Immunizations were carried out at baseline and at week 4.  
 
 
RESULTS 
 
Genetic diversity of 3D7-type msp2 alleles 
DNA sequence data was generated for 32 out of a total of 34 3D7-type alleles 
identified by PCR-RFLP genotyping in the course of the entire study. Seven alleles 
were detected in baseline samples only, or persisted from baseline onwards but did 
not occur in new infections in either of the trial groups. 25 alleles were detected in the 
80 3D7-type new infections detected in all trial groups after week 8. Among these 80 
new infections, 37 occurred in children immunized with Combination B and thus were 
considered breakthrough infections. These 37 breakthrough infections corresponded 
to 19 different alleles; only 6 alleles were absent from breakthrough infections. This 
finding suggests that most alleles were able to resist the effects of vaccination. The 
fact that 6 alleles of a total of 34 different 3D7-type MSP2 alleles detected in this 
study were absent from breakthrough infections might reflect chance effects in 
transmission. In the small number of 37 breakthrough infections, it would be unlikely 
that all 34 3D7-type MSP2 alleles would occur. 
 
An answer to the question whether this involves any selective effect as a 
consequence of vaccination, can best be given by measuring the sequence similarity 
between breakthrough alleles and the 3D7 vaccine molecule. 
 
 
MSP2 Gene trees 
Phylogenetic analysis of genes with intragenic repeats is difficult. Sequence 
alignment of 3D7-type msp2 alleles was problematic because repeat units of the 
various alleles differed in sequence and lengths and were often scrambled. The 
repeat region includes tandem and scrambled repeats and is defined on nucleotide 
sequence level by regular spacing of thymidines, giving rise to solely (XXT) codons 
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 (Felger et al., 1997). This previous observation was confirmed by all new msp2 
alleles sequenced in this study. Figure 1 shows an alignment of the polymorphic 
domains of 32 3D7-type MSP2 alleles detected in the trial area. For comparison, the 
3D7 vaccine molecule is added to the alignment, despite the fact that this variant was 
not present in the study area. The repeats are followed by a non-repetitive but 
polymorphic region of variable length, which reveals several clusters of similar 
sequences. Downstream of this variable region all 3D7-type msp2 alleles contain a 
poly-threonine (T) stretch, also varying in lengths, which represents on the nucleotide 
sequence level in fact another tandem repeat. Further downstream of the poly-
threonine stretch follows the so-called family-specific domain of 90 residues that in 
parts is well conserved with the exception of a region of microheterogeneity (starting 
at position 14 after poly-T). This region of microheterogeneity revealed 10 SNPs 
within a stretch of 25 residues, and synthetic peptides representing a part of this 
region bound to human red blood cells and inhibited parasite invasion of erythrocytes 
(Ocampo et al., 2000). Just upstream of the repeats, a second small region of 
microheterogeneity within the family-specific domain is located, spanning six residues 
of which only the serine at position 3 is conserved. 
 
In order to quantify the sequence similarity between each allele and the 3D7 vaccine 
molecule, we performed a distance analysis and applied the Neighbour Joining 
algorithm. First the analysis was performed with the entire polymorphic region 
between the N- and C-terminal constant domains. The resulting MSP2 gene tree is 
shown in Figure 2a. The vaccine molecule 3D7 (accession number M28891) was 
chosen as outgroup when drawing the tree. We found that breakthrough infections 
were not clustered in any branch of the tree, and that alleles not found in 
breakthrough infections were distributed over all clusters. The same analysis was 
performed with alignments from which increasing portions of the variable regions had 
been removed. Figure 2b shows the MSP2 gene tree obtained after the (XXT)n 
repeat region had been removed. Both trees were consistent in their key finding, that 
breakthrough infections found in vaccinated individuals showed no greater distance 
to the vaccine molecule than alleles from the placebo group. In addition to the 
distance method for constructing a gene tree, we also applied the maximum 
parsimony algorithm. Trees obtained were similar with the major clusters maintained 
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 (data not shown). Breakthrough alleles were again evenly spread over all clusters of 
the tree. 
 
Because the region of microheterogeneity located downstream of the poly-T stretch 
and spanning 25 residues was implied in competitive invasion inhibition (Ocampo et 
al., 2000), we also analyzed this region in greater detail. For Figure 2c this region of 
25 residues was aligned together with a stretch of 6 residues preceding the tandem 
repeats and also displaying sequence heterogeneity. The gene tree showed that 
breakthrough infections were not clustered and did not reveal less similarity to the 
3D7 vaccine molecule than sequences found in the placebo group. Thus, vaccination 
obviously did not select for alternative variants. However, the considerable number of 
variants detected in our samples suggests that this region is nevertheless under 
selection. 
 
Repeats of breakthrough infections 
The intragenic repeats of 3D7-type alleles are mainly responsible for length 
polymorphism.  Some alleles share the same repeat units, but vary in copy number 
of repeats (Felger et al., 1997). We were interested in how far the 3D7 repeats, which 
had been found to be immunogenic in the Combination B vaccine trial (Flück et al., 
2004), might have cross-protected vaccinated children against becoming infected 
with an allele carrying the same repeat unit. We found that, while the 3D7 allele 
representing the vaccine molecule 3D7, was not present in the study area, its 4-mer 
repeat Glycine-Glycine-Serine-Alanine (GGSA) was present in three alleles from the 
trial area. One allele harbouring a GGSA repeat (accession number DQ166535) was 
detected in two vaccinated children. The same 4-mer motif was also represented in 
another, larger repeat unit present in four additional alleles (DQ174442, DQ171732, 
DQ166539, DQ166543), three of which were found in vaccinees.  
 
Sequence fidelity and persistence in time of msp2 alleles in the study area 
At the site of the vaccine trial, in the Wosera area in PNG, msp2 diversity has been 
studied six years prior to the trial by using the same genotyping technique. In this 
previous cross-sectional survey in 1992, 38 different msp2 alleles of both families 
were detected in two villages (Felger et al., 1994). When we compared the nucleotide 
sequence and frequencies of RFLP-genotypes, we found that the most frequent 
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 genotypes in 1992 were still frequent six years later, and that some alleles had been 
maintained without a single point mutation.  Alleles of low allelic frequency seem to 
fluctuate and were mostly new.  
 
Because PCR-RFLP detects length polymorphism and mutations at restriction sites, 
it does not reveal all sequence diversity present. In order to establish sequence 
fidelity within a RFLP genotype, we chose the most frequent alleles, KF1916, for a 
detailed sequencing analysis. Seven nested msp2 PCR products, all classified as 
KF1916 genotype by PCR-RFLP, were directly sequenced. These KF1916 
sequences were aligned together with the original KF1916 sequence from Genbank 
(accession number M73810) that derived from a PNG isolate adapted to culture in 
the 1980s (Marshall et al., 1992). Three KF1916 sequences from the 1992 survey 
were also added to the alignment. Figure 3 shows that KF1916 is well conserved, 
mutations did not accumulate over time, and SNPs were found at an average 
frequency of one per clone sequenced. The repetitive domain and most part of the 
family-specific domain were totally conserved whereas SNPs were only detected in 
the two regions of microheterogeneity. From these data we concluded that PCR-
RFLP genotypes are stable over time.  
 
In summary, our results showed a high amount of sequence heterogeneity at the trial 
site. Allelic diversity in msp2 was not restricted to the actual repetitive domain alone. 
High diversity was also found in a considerable part of the dimorphic or family-
specific domain. Strictly conserved within all 3D7-type MSP2 alleles was a stretch of 
53 residues upstream of the C-terminal constant domain. Specifying the boundaries 
of strictly conserved dimorphic domains has implications for design of other MSP2 
vaccine molecules. We showed that in the Combination B vaccine trial, the diverse 
domains seem to have not contributed to vaccine efficacy, because breakthrough 
infections in vaccinated individuals were independent of similarity with the 3D7 
vaccine molecule. This suggests that the well conserved epitopes in the family-
specific domain must have been the important determinants of the vaccine effect 
against 3D7-type infections. 
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 DISCUSSION 
 
Antigenic diversity in P. falciparum represents a significant challenge for the 
development of a malaria vaccine. As polymorphism is prevalent in most P. 
falciparum antigens, it is unrealistic to expect complete parasite clearance in 
vaccinated individuals. Not even natural immunity prevents infection entirely, and 
sterilizing immunity is never achieved in individuals from endemic areas. Most current 
efforts in malaria vaccine development consider partially effective vaccines and 
combination of multiple subunits consisting of several candidate antigens or of 
several variants of a polymorphic vaccine molecule is the currently favoured strategy 
(Mahanty et al., 2003).  
 
Little evidence from field data is available on selective effects in malaria vaccine 
trials. Despite the extensive polymorphism of MSP2, the MSP2 allele of the 3D7 
strain was included as a subunit in the Combination B malaria vaccine. Thus, it is 
likely that escape mutants emerge in the population by filling ecological niches 
emptied by variants eliminated by vaccine-induced immunity. Our previously 
published genotyping results from the Combination B trial had shown selection acting 
on the level of allelic families (Genton et al., 2002). Now we have investigated 
whether a vaccine effect is evident also on the level of individual alleles. The impact 
of the imperfect 3D7-MSP2 vaccine on breakthrough infections occurring in 
vaccinated children was assessed by sequence analysis of all msp2 alleles detected 
during the trial. 
 
Msp2 repeat units as smoke screen epitopes 
The function of intragenic tandem repeats in plasmodial surface antigens remains 
obscure. It has been speculated that the arrays of repeats represent “smoke screen” 
epitopes, which divert the immune system from protective responses by directing the 
response to irrelevant repetitive epitopes (Anders, 1986, Kemp et al., 1987). It has 
been proposed that repeats are immunodominant, but even so induce only non-
neutralizing antibodies by crosslinking hapten-specific surface immunoglobulin on B 
cells thus providing a thymus-independent activation with no memory elicited 
(Schofield, 1991). It is generally assumed that levels of anti-repeat antibodies are not 
correlated with protection, but this has not yet been shown conclusively for MSP2. 
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 Our data cannot provide much evidence to either support or reject this hypothesis, 
mainly because the (Gly-Gly-Ser-Ala)5 repeat of the vaccine molecule was found only 
rarely in alleles in the study area. Nevertheless we inspected the anti-(Gly-Gly-Ser-
Ala)5 response at week 12 post vaccination in the few vaccinated individuals infected 
with a parasite displaying the (Gly-Gly-Ser-Ala) motif, either as tandem repeat or as 
part of a larger repeat unit. From those individuals antibody titres were available in 
the serological data base of Flück et al. (2004). Antibody titres were either not raised 
at week 12 compared to baseline values, or only a minor increase was observed 
(data not shown). Thus, it remains unclear whether infection by these genotypes 
could have been prevented if an anti-(Gly-Gly-Ser-Ala)5 response had  been induced 
in these vaccinated children.  
 
Variable non-repetitive domain 
After deleting the repeat regions from all sequences of the alignment of 3D7-type 
MSP2 alleles, a region of about 50 residues of the dimorphic domain proved totally 
conserved. This region is located adjacent to the C-terminal conserved region. 
Further upstream, flanking the repeats, highly polymorphic non-repetitive blocks are 
found characterized by an accumulation of point mutations. We have tested 
particularly whether these regions of microheterogeneity were subject to selection in 
vaccinated individuals. We found that sequence similarity of this SNP-rich region to 
the vaccine molecule did not affect a genotype’s presence or absence in the 
immunized group. Therefore it has to be assumed that responses elicited against 
these regions were not protective. It follows that the 50-residues-long totally 
conserved dimorphic region might have been responsible for the selective effect 
acting on the level of the allelic family.   
 
We assume that the regions of microheterogeneity were immunogenic, because 
several studies have mapped immunogenicity to these regions. Immunization with a 
short peptide including a part of the C-terminal region of microheterogeneity (peptide 
40 in Jones et al., 1992) elicited IFA-positive antibodies.  Lawrence and co-workers 
(2000) have mapped linear antibody epitopes within MSP2 after vaccinating a human 
volunteer with the 3D7 variant of MSP2, corresponding to the 3D7 component of 
Combination B. The same analysis was performed after immunizing mice with the 
same molecule. Both experiments showed in parallel that the regions of local 
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 microheterogeneity were found to be the major targets of antibody response in the 
family-specific domain of MSP2. This hypervariable region downstream of the poly-
threonine stretch revealed 10 sites of non-synonymous mutations clustered in a 
stretch of 25 amino acids (underlined in Figure 3). It is exactly this block that seems 
to play an important role in merozoite invasion of human red blood cells. Ocampo et 
al. (2000) have identified an MSP2 peptide with high specific binding to human 
erythrocytes, which is identical with this block. The peptide also inhibited in vitro 
parasite invasion by up to 95%. It remains unclear how a possible function in 
invasion can be reconciled with the hypervariability we have documented in our small 
sample size. 
 
Conserved regions within the family-specific domain 
The Combination B vaccine was effective in reducing parasite densities, yet the effect 
was incomplete. Despite vaccination, some 3D7-type infections could establish 
themselves in immunized children but the vaccine effect may have lead to faster 
elimination and thus to the reduced prevalence of 3D7-type parasites observed in the 
trial (Genton et al., 2002). In search of new improved vaccine formulations, the 
question arises which domain of MSP2 could have caused the selective effect? The 
3D7 family-specific domain contains 50 residues of invariant sequence. This is a 
likely candidate to account for selection observed on the level of the allelic family. We 
have previously shown that antibody levels against the recombinant 3D7 family-
specific domain and against the 3D7 repeats were significantly higher in vaccinated 
children (Flück et al., 2004). However, our phylogenetic analysis does not allow us to 
pinpoint the active component of the 3D7 subunit vaccine; it can only indicate 
whether a polymorphic region is selected and thus subject to protective antibodies.  
 
As with naturally induced immune responses, responses elicited by vaccination are 
directed against many different epitopes, only a fraction of which might lead to 
protection. We assume that an antibody response against both the repeats and 
regions of microheterogeneity was elicited, but did not protect the vaccinated children 
against new infections. This does, however, not exclude activity of these antibodies 
against high parasite densities.  
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 This analysis does not take into account the pre-existing acquired immunity to 3D7 
genotypes nor the possibility that an ongoing 3D7-type infection inhibits a newly 
occurring infection of the same allelic family via within-host competition (e.g. for 
resources). The extent of competitive interactions in multiple clone infections is only 
recently being studied (de Roode et al., 2004). It is unclear whether such conditions 
can be ignored in the analysis of selectivity. 
 
Conclusion 
The vaccine trial has shown that the 3D7-MSP2 component had some efficacy, 
though this was imperfect and numerous breakthrough infections occurred. When 
analyzing the breakthrough genotypes, we found no evidence that responses against 
the Gly-Gly-Ser-Ala repeats and hypervariable stretches might have protected 
against new infection by similar variants. We conclude that a response against the 
conserved stretches within the family-specific dimorphic domain is more likely to 
account for the MSP2 family-specific selective effect seen in the Combination B trial.  
 
The occurrence of replacement by FC27-type infections in vaccinees in the 
Combination B trial, leading to increased morbidity, confirms that selective effects of 
imperfect polymorphic malaria vaccines are of real concern.  As more results from 
other and bigger trials of polymorphic vaccines become available, it will become clear 
whether such selective effects are a general side effect of vaccine interventions. 
There is a clear need to include several variants in a single vaccine formulation. 
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 Figure legends 
 
Figure 1: Sequence alignment of the 3D7-MSP2 vaccine molecule and 32 3D7-type 
MSP2 alleles that were detected in children participating in the Combination B 
vaccine trial in PNG. Names of sequences correspond to Genbank accession 
numbers. Stretches of sequence microheterogeneity are bold. 
 
Figure 2: Phylogenetic analysis of 3D7-type msp2 alleles detected in children from 
the Combination B trial. Sequences occurring in breakthrough infections (new 
infections after week 8 post vaccination) of vaccinated children are underlined. The 
phylogenetic tree was built using the Neighbor Joining method with 1000 bootstrap 
replicates. The tree was drawn with the vaccine molecule 3D7 as outgroup. The 
scale bar indicates sequence distance. a) msp2 gene tree obtained from an 
alignment of the entire variable region including repeats. b) msp2 gene tree based on 
3D7-type msp2 sequences from which the repeats had been deleted. c) msp2 gene 
tree based on regions of microheterogeneity flanking the repetitive domain.  
 
Figure 3: Sequence fidelity of the PCR-RFLP genotype KF1916 of MSP2 over a 
period of 20 years. Isolates were collected in Papua New Guinea in 1992 and 1998 
and compared to the KF1916 sequence submitted to Genbank that derived from an 
isolate collected in the 1980s. The polymorphic central part of msp2 corresponding to 
the nested PCR product is shown. Underlined residues correspond to the two regions 
of microheterogeneity where SNPs are frequent. 
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KF1916 M73810 S I R R S M A E S K P P T G T G A S G S A G S G A G A S G  
1992 (n=3)    - - - - - - S(2/3)- - - - - - - - - - - - - - - - - - - - 
1998 (n=7)    - - - - - - E(1/6)- S(3/6)- - - - - - - - - - - - - - - - 
 
KF1916_M73810 S A G S G D G A V A S A R N G A N P G A D A E G S S S T P  
1992 (n=3)    - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
1998 (n=7)    - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
 
KF1916_M73810 A T T T T T T T T T T T T T T N D A E A S T S T S S E N P  
1992 (n=3)    - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
1998 (n=7)    - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
 
KF1916_M73810 N H N N A E T N P K G K G E V Q K S N Q A N K E T Q N N S  
1992 (n=3)    - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
1998 (n=7)    - - - - - - - - - - - N(1/6)- - - P(1/6)- - - - - - - - - 
 
KF1916_M73810 N V Q Q D S Q T K S N V P P T Q D A D T K S P T A Q P E Q  
1992 (n=3)    - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
1998 (n=7)    - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
 
KF1916_M73810 A E N S A P T A E Q T E S P E L Q S A P E N 
1992 (n=3)    - - - - - - - - - - - - - - - - - - - - - - 
1998 (n=7)    - - - - - - - - - - - - - - - - - - - - - - 
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Abstract 
 
Merozoite surface protein 2 (MSP2) is a promising candidate for a vaccine against 
Plasmodium falciparum bloodstages. A recombinant 3D7 form of MSP2 was a subunit of 
Combination B, a bloodstage vaccine tested in the field in Papua New Guinea. A selective 
effect in favour of the allelic family not represented by the vaccine argued for a MSP2 
vaccine consisting of both dimorphic variants. An alternative approach to recombinant 
manufacture of vaccines is the production of long synthetic peptides. Long peptides exceeding 
a length of well over 100 amino acids can now be routinely synthesized. Synthetic production 
of vaccine antigens cuts the often time-consuming steps of protein expression and purification 
short. This considerably reduces the time for a candidate to reach the phase of clinical trials. 
Here we present the evaluation of two long synthetic peptides representing both allelic 
families of MSP2 as potential vaccine candidates. The peptides were well recognized by 
human immune sera from different locations and different age groups. The peptides share 
major antigenic properties with native MSP2. Immunization of mice with these peptides 
yielded high titre antibody responses and monoclonal antibodies recognized parasite-derived 
MSP2. Antibodies affinity-purified from human immune sera on our peptides inhibited 
parasite growth in vitro in cooperation with human monocytes. Our results justify to take 
these candidate peptides on into further vaccine development. The results obtained encourage 
the development of synthetic peptides as malaria vaccine candidates. 
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 Introduction 
 
Plasmodium falciparum, the causative agent of the most severe form of malaria infects 500 
million people per year and kills at least one million. One of the most cost-effective 
intervention would be a vaccine, which to date is not available (Mahanty et al., 2003). The 
reasons for this are mainly the complex life cycle of the parasite, its antigenic variation and 
diversity, the wide variety of immune responses it induces, and the incomplete knowledge of 
protective immunity. Individuals living in malaria endemic regions develop a clinical 
immunity associated with high antibody titers against major surface molecules of the 
merozoite stage, however, immunity is never sterile. Passive transfer studies have shown that 
immunoglobulins from semi-immune individuals can confer clinical immunity to individuals 
exposed to geographically diverse parasite strains (McGregor et al., 1963; Sabchareon et al., 
1991). Vaccines against the blood stages of the parasite could accelerate the acquisition of 
natural immunity. They do not aim at preventing infection, but at protecting from morbidity 
and mortality. An advantage of this type of vaccine is constant boosting of the immune 
response by naturally occuring infections. 
 
The polymorphic merozoite surface portein 2 (MSP2) is considered a vaccine candidate 
because several studies have shown that high antibody titres to MSP2 are associated with 
protection against P. falciparum malaria (Al-Yaman et al., 1994, Al-Yaman et al., 1995; 
Aucan et al., 2000; Metzger et al., 2003). MSP2-specific antibodies in immune individuals are 
found to be predominantly of the cytophilic IgG3 subclass (Taylor et al., 1995; Taylor et al., 
1998; Metzger et al., 2003). The major part of MSP2 is polymorphic. A central amino acid 
repeat region is flanked by a dimorphic region that defines the two allelic families 3D7 and 
FC27. The function of MSP2 remains unclear but appears to be essential, because targeted 
gene disruption failed (Cowman et al., 2000). The location of MSP2 on the merozoite surface 
suggests a role in invasion, and monoclonal antibodies to MSP2 inhibited the invasion of 
merozoites into erythrocytes (Epping et al. 1988; Ramasamy, 1990). Natural antibody 
reponses have been shown to be directed mainly against the dimorphic and polymorphic 
regions but not against the highly conserved termini (Thomas et al., 1990; Lawrence et al., 
2000a; Metzger et al., 2003; Weisman et al., 2001). Peptides corresponding to polymorphic 
and conserved parts of the molecule were immunogenic in mice (Jones et al., 1991; Saul et 
al., 1992; Lougovskoi et al., 2000). 
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 Combination B was the only subunit vaccine against P. falciparum blood stages so far that 
showed a promising efficacy against parasite density (62%) when tested in a phase I-IIb field 
trial in Papua New Guinean children (Genton et al., 2002; Genton et al., 2003). The MSP2 
component consisted of a recombinant version of the full-length protein of strain 3D7. The 
activity of this subunit against parasite density was suggested by a selective effect of the 
vaccine in favour of parasite strains carrying an MSP2 allele belonging to the allelic family 
not represented by the vaccine (Genton et al., 2002). The finding of a selective effect strongly 
indicated inclusion of both allelic families in an improved MSP2 vaccine. 
 
The 3D7 MSP2 component of Combination B had been produced as recombinant protein in 
Escherichia coli (Genton et al., 2000). The limitations of recombinant expression of vaccine 
molecules are folding and purification of the antigens. Since the function of MSP2 is not 
known, it is difficult to prove that the protein expressed in E. coli or other expression systems 
is correctly folded. Demonstration of cross-antigenicity to native protein is a means to 
evaluate correct conformation of a recombinant antigen. 
 
Production of correctly folded recombinant antigen is a major problem in vaccine 
development. It could be tackled using a eukaryotic secretory expression system. However,  
this would lead to N- and O-linked glycosylation of the recombinant antigen, a feature that is 
very limited in P. falciparum. (Kimura et al., 1996; Gowda et al, 1997; Gowda and Davidson, 
1999). In particular, no N- or O-linked glycosylation has been found for MSP2 (Berhe et al., 
2000) despite the presence of potential glycosylation sites. When producing MSP2 for a 
malaria vaccine, it is not desirable to introduce inappropriate modifications by the expression 
system, which could compromise the efficacy of the humoral response. Problems of 
purification and undesired glycosylation can be overcome by producing the antigens 
synthetically. Also, recombinantly expressed antigens often contain unrelated amino acids 
resulting from affinity tags, linkers, or protease cleavage sites that can alter the antigenic 
properties of the molecule. Thus, the use of synthetic peptides as vaccines has some 
advantages over recombinant antigen production. 
 
The absence of a suitable animal model and lacking knowledge of surrogate markers for 
protective immune reponses in humans constitute major limitations to vaccine development. 
Due to this lack, other approaches to assess the potential of vaccine candidates need to be 
taken to carry malaria vaccines from the bench to the clinic. Before a vaccine is tested in a 
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 human trial, the candidate antigen is evaluated by immunogenicity studies in rodents, 
immuno-epidemiological studies, and in vitro assays. These tests provide justification for 
further development of candidate vaccines. While there is no agreed developmental pathway 
for vaccine candidates, several empirically found assessment tools are available. (1) The 
vaccine potential of antigens can be assessed by immuno-epidemiological data, e.g. by a 
prospective study design, where protection is defined by absence of a malaria episode during 
the time following blood sampling. (2) Immunoassays with monoclonal antibodies are used to 
establish the antigenicity of the candidate molecule. In particular, it is important to show that 
antibodies raised against the vaccine candidate react with parasite-derived protein, i.e. in an 
indirect immunofluorescence assay. (3) Two in vitro assays are available. First, a direct 
growth inhibition assay can be used to assess the potential of specific antibodies to inhibit 
parasite growth (Epping et al., 1988; Egan et al., 1999; O’Donnell et al., 2001; Mueller et al., 
2003). Such inhibitory antibodies are thought to interfere with the invasion process. 
Antibodies of any isotype purified from human sera or mouse monoclonal antibodies can be 
used likewise. Second, the inhibitory potential of an antibody in cooperation with human 
monocytes can be determined. Human monocytes have been shown to act with merozoite-
specific cytophilic antibodies in a cooperative manner against intraerythrocytic P. falciparum 
stages via a mechanism termed antibody-dependent cellular inhibition (ADCI) that involves 
secretion of TNF-α and other factors. (Bouharoun-Tayoun et al, 1990; Oeuvray et al., 1994a, 
Oeuvray et al., 1994b; Bouharoun-Tayoun et al., 1995; Theisen et al., 2000; Singh et al., 
2004).  
 
All these approaches to measuring protection fall short of a definite proof of concept, since 
they are no absolute correlates of protection. This remains to be shown in efficacy field trials. 
We have applied the experimental tests 1-3 for the evaluation of a new MSP2 vaccine 
candidate consisting of two long synthetic peptides representing both allelic families. 
 
 
Material and Methods 
 
Synthetic peptides 
All of the peptides used in this study were synthesized at the Institute of Biochemistry, 
Lausanne, using solid-phase Fmoc chemistry (Applied Biosystem 431A, Foster City, 
California). Briefly, peptides were prepared on a p-alkoxybenzylalcohol resin (Wang resin). 
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 After cleavage from the resin, the crude peptide was purified by RP-HPLC (C18 preparative 
column; H2O 0.1% TFA/ acetonitrile 0.1% TFA from 90/10 to 20/80 in 70 minutes with a 
flow rate of 10 mL/min). The purity (>80%) was determined by analytical C18 HPLC and 
mass spectroscopy (MALDI-TOF, Applied Biosystem, Foster City, California). Lyophilised 
peptides were dissolved in phosphate buffered saline (PBS) at a concentration of 1 mg/ml. All 
peptide sequences are shown in figure 1. 
 
Human Sera 
Sample set I: Sera had been collected in the framework of the The Malaria Vaccine 
Epidemiology and Evaluation Project of Papua New Guinea (Alpers et al., 1992) in the 
Wosera area of the Maprik District in the East Sepik Province, Papua New Guinea (PNG), an 
area which is highly endemic for malaria. 214 adults from 2 villages (Kunjingini 1 and 2) had 
been recruited, consisting of 125 females and 89 males, aged 12 to 72 years (mean age 35.5 
years). Sera of twenty of these subjects were pooled and used as positive control in enzyme 
linked immunosorbent assays (ELISAs). 
 
Sample set II: Sera had been collected during an antigenicity study conducted in Burkina Faso 
(Meraldi et al., 2004). 37 adult volunteers from three different villages situated 50 km from 
Ouagadougou were bled in March and/or December 2000. 
 
Sample set III: Sera had been collected for a study conducted to determine the effect of 
insecticide-treated bednets on prevalence and multiplicity of P. falciparum infections in 
infants in the village of Kiberege, Kilombero District, southern Tanzania (Fraser-Hurt et al., 
1999). The area is holoendemic for malaria with approximately 300 infectious bites per year 
with perennial transmission and little seasonal changes of parasite prevalence and density 
(Smith et al. 1993). Two finger-prick blood samples were collected seven months apart from 
30 children initially aged 5 to 15 months who used insecticide-treated nets (ITNs), and from 
30 children of the same age group not using ITNs. 
 
Immunization of mice with long synthetic MSP2 peptides MR141 (3D7 MSP2) and 
MR144 (FC27 MSP2) 
Groups of five mice each were immunized three times subcutaneously with 20 µg of peptide 
(MR141 (3D7 MSP2) or MR144 (FC27 MSP2), respectively in 50 µl adjunvant. Group 1: 
BALB/c mice, 20 µg peptide MR141 + montanide ISA 720; Group 2: CB6F1 mice, 20 µg 
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 peptide MR141 + montanide ISA 720; Group 3: BALB/c mice, 20 µg peptide MR141 + 
incomplete Freund’s adjuvant (IFA); Group 4: CB6F1 mice, 20 µg peptide MR144A + 
montanide ISA 720. 
 
Production of monoclonal antibodies (mAbs) 
Mice giving the highest titres against the immunogen were chosen for production of 
monoclonal antibodies (mAbs). Mice were injected a fourth time intraperitoneally with 1 µg 
of the peptide in 100 µl PBS. Three days after the fourth immunization, spleens were sterilely 
removed and fused with the mouse myeloma cell line X63.Ag8.653. Culture supernatants of 
growing hybrids were screened for antibodies by ELISA and indirect immunofluorescence 
assays (IFA). Positive hybrids, based on ELISA and IFA were cloned by limiting dilution. 
Hybridoma clones secreting the monoclonal antibodies of interest were grown in serum-free 
OPTIMEM medium. 
 
Enzyme linked immunosorbent assays (ELISAs) 
Recognition of the synthetic peptides by human sera and monoclonal antibodies was assessed 
by ELISA. The optimal coating concentration of the peptides was determined by a 
checkerboard titration with positive and negative control sera. The optimal concentration was 
1 µg/ml for MR141 and MR144A, and 5µg/ml for MR140. 
Immulon® 2HB plates (Thermo Labsystems) were coated overnight with 50 µl of peptide at 
the appropriate concentration. Plates were blocked for one hour at room temperature in 
phosphate buffered saline (PBS) containing 5% non fat milk powder. Antibody reactions were 
carried out in PBS containing 0.5% milk powder and 0.05 % Tween 20. Human sera were 
diluted 1:400 for assays on MR140 and 1:1000 for assays on MR141, and MR144A (sample 
sets I and III) or serially diluted 1:3 (sample set II). Supernatants from hybridoma cultures 
were also serially diluted 1:3. A serum pool of 20 semi-immune adults from PNG was used as 
internal standard. Pooled sera from 40 non-exposed European children aged 5-15 months 
were used to determine the cutoff value of our ELISAs. The plates were incubated for two 
hours at room temperature. Plate washing was performed in an ELISA washer with water 
containing 0.05% Tween 20. Secondary antibodies were incubated for two hours at room 
temperature. Goat anti-human IgG-γ specific HRP-conjugated antibody from Kirkegaard and 
Perry Laboratories (KPL) was used at a dilution of 1:2000 and Goat anti-mouse IgG 
(heavy+light chain) HRP-conjugated antibody from Biorad was used at a 1:5000 dilution. 
After extensive washing, ABTS peroxidase substrate (KPL) was added. The reaction was 
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 stopped after 30 minutes with 1% sodium dodecyl sulfate and the plates were read at 405 nm. 
For IgG subclass-specific ELISAs alkaline phosphatase (AP)-labelled anti-human IgG1, 
IgG3, and IgG4 antibodies (Southern Biotech) were used at a dilution of 1:1000 and an AP-
labelled anti-human IgG2 antibody (Zymed) was used at a dilution of 1:500.  
 
Affinity purification of antibodies from human sera and hybridoma supernatants 
5 mg of each peptide (MR141, MR144) were coupled to CNBr-activated sepharose with a 
final column volume of 1ml. The column was equilibrated with 50 ml of phosphate buffered 
saline (PBS) pH 7.3. Approximately 80ml of human sera were pooled, centrifuged for 10 
minutes at 6000 g, decanted, and diluted 1:5 in PBS and filtered through a 0.22 µm bottle top 
filter before loading to the sepharose column. Binding was performed at 0.5 ml/min at 4°C. 
The column was washed with 100 ml PBS and antibodies eluted with 0.1M glycine, 0.15M 
NaCl, pH 3.4 to 2.9 at 0.8 ml/min at room temperature. 2 ml fractions were collected and 
neutralised immediately after elution with 100 µl of 1 M Tris-HCl, pH 8.5. Fractions 
containing antibody were pooled and dialysed twice against 2 litres of PBS. Purified 
antibodies were concentrated using Centricon YM-10 centrifugal filter units (Millipore, 
Billerica, MA, USA). Antibodies were sterile filtered through a 0.22 µm syringe filter, 
aliquoted and stored at -80°C. Concentration of purified antibodies was determined with a 
bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL, USA) using a bovine serum 
albumin (BSA) standard. 
 
Hybridoma supernatants were sterile filtered through a 0.22 µm bottle top filter and purified 
on a HiTrap Protein G column (Amersham Biosciences) according to manufacturer’s 
protocol. Eluted fractions were processed as described above. The titre of purified antibodies 
against the corresponding peptide was determined by a standard ELISA as described above. 
 
Plasmodium falciparum in vitro cultures 
Plasmodium falciparum strains 3D7, K1, and FC27 were grown in human O+ red blood cells 
(Blutspendezentrum SRK beider Basel, Basel, Switzerland) at 5% hematocrit in RPMI 1640 
supplemented with Albumax (GibcoBRL) to a final concentration of 0.5% and gassed with 
5% CO2 and 0.5% O2 in N2 at 37 °C as described previously (Trager and Jensen, 1976). 
Parasite cultures were synchronised by two sorbitol treatments 10 hours apart (Lambros and 
Vanderberg, 1979). 
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 Immunofluorescence assays (IFAs) 
IFAs were performed on Plasmodium falciparum cultures containing at least 5% schizonts. 
Blood smears from strains 3D7 or FC27 were fixed with acetone/methanol (1:1). Slides were 
blocked for 30 minutes with 3% BSA in PBS. Primary antibody reactions were carried out for 
1 hour at room temperature in 3% BSA/PBS. Secondary antibodies were applied after 5 
washes with PBS and incubated for 1 hour at room temperature in 3% BSA/PBS. Cy3-
conjugated goat anti-human IgG (H+L) (Jackson Immunoresearch) and Cy3-conjugated goat 
anti-mouse IgG(γ) (Jackson Immunoresearch) were used at a dilution of 1:500. Slides were 
washed 5 times with PBS and mounted with Vectashield mounting medium H-100 (Vector 
Laboratories, Burlingame, CA, USA) containing DAPI at a concentration of 1µg/ml. 
Fluorescense images were captured using a Leitz Dialux 20 fluorescence microscope and a 
Leica DC 200 digital camera (Leica Microsystems AG, Germany). Images were processed 
using Adobe PhotoshopCS. 
 
In vitro growth inhibition assays 
Assays were done as described by Mueller et al. (2003). Parasite cultures were synchronized 
with 5% sorbitol 3 days and 1 day before the assay. The cultures were diluted with fresh 
erythrocytes to a parasitaemia of 0.5%. The final hematocrit in the test was 0.5%. Antibody 
solutions or control PBS (up to 50% of total culture volume) were pipetted into 96-well flat 
bottom microtitre plates and parasite cultures were added (final volume 100 µl). Each test was 
set up in sextuplicate. The assay plates were put in air tight boxes which were gassed with 4% 
CO2, 3% O2 and 93% N2 and incubated at 37°C. 96 hours later, plates were centrifuged at 180 
g for 5 minutes, the supernatants pipetted off and parasite cultures incubated with 15 µg/ml 
hydroethidine (Polysciences Inc., Warrington, PA.) in PBS for 30 minutes at room 
temperature. The red blood cells were washed twice with PBS, resuspended in a final volume 
of 200 µl PBS and analysed in a FACSscan flow cytometer (Becton Dickinson, San Jose, CA) 
with CellQuest 3.2.1fl software. The hydroethidine emission was detected in the FL2 channel 
by logarithmic amplification, and the erythrocytes were gated on the basis of their forward 
and side scatters. 30,000 cells were analysed per sample. Percent inhibition was calculated 
from the geometric mean parasitemias of sextuplicate test and control wells as 100 x [(control 
- test)/control]. Statistical significance was calculated by a two-sided t test. 
 
 
72
 Antibody-dependent cellular inhibition (ADCI) assays 
White blood cells were separated from erythrocytes on a Ficoll gradient. 107 white blood cells 
were incubated in a petri dish for 1 – 2 hours at 37°C. Non-adherent cells were washed away. 
The adherent monocytes were harvested using a cell-lifter and washed before use. 0+ 
erythrocytes were used for all assays at 2 % hematocrit and 1% parasitemia. The assays were 
set up in 96-well tissue culture plates. Assays were performed with monocytes alone, the test 
antibody alone, and the antibody together with monocytes. Antibodies were serially diluted in 
RPMI. Approximately 105 monocytes were used per well. The cultures were incubated at 
37°C with CO2 and harvested 22 hours and 42 hours later. The cultures were washed and 
fixed on 8-well slides with glutaraldehyde. They were stained with acridin orange and 
fluorescence microscopy was performed. 25 random fields were counted per well, each field 
representing 200 cells (total 40 000 cells). The growth inhibition was calculated with the 
formula: % inhibition = (% parasitemia in parasite control - % parasitemia test)/ % 
parasitemia in parasite control. 
 
 
Results 
 
Design of long synthetic MSP2 peptides. Two long synthetic MSP2 peptides were 
synthesized and evaluated. Due to the selective effect seen in the Combination B trial (Genton 
et al., 2002), where only one allelic MSP2 family had been represented by the vaccine, we 
designed two synthetic peptides representing both allelic families. Despite the presence of 
immunodominant epitopes within the polymorphic repeat regions, we excluded repeats from 
our candidate peptides because antibodies against repetitive sequences are likely to be non-
protective. It was proposed that such sequences present in malarial antigens, similarly to 
bacterial carbohydrates, induce T-cell-independent B-cell activation by crosslinking of 
surface immunoglobulin (Schofield, 1991). A T-cell-independent response is considered to be 
inferior to a T-cell-dependent response, because it lacks affinity maturation and formation of 
T- and B-cell memory. Furthermore, if repeats are immunodominant, they could suppress 
induction of antibody responses to neighbouring regions on the same antigen. After excluding 
the repetitive region, the dimorphic non-repetitive domain and the cnserved domains were 
considered. 
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 The Combination B vaccine elicited considerable levels of antibodies specific to the 
dimorphic part of the 3D7 vaccine molecule (Flück et al., 2004). These dimorphic domains 
are likely to contain protective epitopes and therefore constituted the major part of our 
synthetic peptides. The C-terminal conserved domain has been found to be only weakly 
antigenic in naturally exposed humans and Combination B did not induce a significant 
antibody response to it (Flück et al., 2004). This suggested that this conserved domain has 
anergic properties. However, the C-terminal conserved domain was still included in both 
peptides because it contains the only two cysteines of MSP2. Cysteines might be important 
determinants of protein structure. The peptide sequences are shown in figure 1. Peptide 
MR141 (3D7-MSP2) includes 88 amino acids of the non-repetitive semi-conserved part of the 
3D7 molecule and 40 amino acids of the C-terminal conserved part. Peptide MR144 (FC27-
MSP2) is its counterpart representing the other allelic family (67 amino acids of the non-
repetitive dimorphic part)  plus the 40 amino acids of the C-terminal conserved part. Two 
versions of the FC27-MSP2 were synthesized, MR144 and MR144A. MR144 includes one 
copy of the 12 amino acid repeat preceding the non-repetitive part and being present in 1 to 7 
copies in the majority of alleles sequenced to date. A shorter version of this peptide, 
MR144A, was made for antigenicity studies. The latter peptide does not include the 12 amino 
acid repeat. An additional peptide covering the 40 amino acids of the C-terminal conserved 
part (MR140) was also synthesized. The two C-terminal cysteine residues were reduced in all 
peptides. 
 
Antigenicity of long synthetic MSP2 peptides. The antigenicity of the synthetic peptides 
was evaluated by IgG ELISA using three sets of human sera from different age groups and 
different malaria endemic areas. The peptides MR141 and MR144A included the family-
specific part of 3D7 or FC27 MSP2. The prevalence of antibody against both peptides was 
high. 96% of the tested adult sera from Papua New Guinea (n=80) recognized the 3D7 peptide 
MR141. 93% recognized the FC27 peptide MR144A, and 43% recognized peptide MR140 
that represents the conserved C-terminus. The median OD value was 0.84 for the peptide 
representing the 3D7 family (quartiles: 0.31; 1.83). The median OD value for the FC27 
peptide was 0.42 (quartiles: 0.09; 0.49) and 0.16 (0.11; 0.27) for MR140. Dilution of Sera was 
1:1000 for assays on peptides MR140 and MR144A and 1:400 for assays on MR140. 
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 High antibody titres to peptides MR141 (3D7-MSP2) and MR144A (FC27-MSP2) were also 
found in adults from Burkina Faso (n=47). The geometric mean antibody titre was 17788 to 
peptide MR141 (quartiles: 5400; 437400) and 1345 to MR144A (quartiles: 600; 48600). 
 
Recognition of the peptides by sera of 6 to 14 months old Tanzanian children was also 
assessed. The ELISA results were compared to those previously obtained from the same sera 
but using recombinant proteins (Irion et al., 2002). These antigens were expressed in E. coli 
and  corresponded to the two MSP2 family-specific domains (3D7 and FC27) or to a fusion of 
the conserved N- and C-terminus. The prevalence of sera with IgG reactivity to the synthetic 
peptides agreed well with the positivity obtained for the recombinant proteins (Table 1). This 
indicates similar antigenic properties of the synthetic peptides and the recombinant proteins. 
Compared to the results obtained in adults, positivity against the dimorphic parts was higher 
in adults than in young children, but positivity against the conserved C-terminal part was 
higher in children, which is a surprising finding. 
 
Immunogenicity of peptides representing the two allelic MSP2 families. We immunized 
mice with MR141 (3D7-MSP2) and MR144 (FC27-MSP2) to determine immunogenicity of 
the peptides. CB6F1 mice injected 3 times with 20 µg of peptide with Montanide consistently 
gave antibody titres of 4x105. The C-terminal conserved part of MSP2 contained in peptides 
MR141 and MR144 also proved to be immunogenic giving titres ranging from 5x104 to 
4x105. This is consistent with the findings of previous studies also showing that peptides and 
recombinant antigens corresponding to the C-terminal conserved part of MSP2 were 
immunogenic in mice (Saul et al., 1992; Lougovskoi et al., 2000; Lawrence et al., 2000b). 
 
Monoclonal antibodies raised against synthetic peptide MR141 recognize parasite-
derived MSP2. Monoclonal antibodies were raised against peptide MR141 (3D7-MSP2). 24 
hybridoma cultures were positive against the peptide used for immunization (MR141). 5 of 
the 24 positive culture supernatants were also positive against peptide MR140, suggesting that 
they recognize an epitope in the conserved C-terminal part of MSP2. 11 of 24 of the ELISA-
positive cultures produced antibody that reacted with the merozoite surface of 3D7 parasites 
in indirect immunofluorescence assays (IFA). Four surface-reactive cultures were chosen for 
cloning. IgG subclasses IgG1, IgG2a, and IgG2b were found among the hybridoma clones. 
Figure 3C shows an immunofluorescence image with monoclonal antibody from a clone 
recognizing an epitope in the 3D7 family-specific domain. Figure 3D shows 
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 immunofluorescence reactivity of antibody from another clone, recognizing an epitope in the 
C-terminal conserved domain. Both monoclonal antibodies gave a pattern characteristic for 
surface staining in mature schizonts (Smythe et al., 1988). The production of hybridomas 
from mice immunized with MR144 failed twice for unknown reasons. 
 
Synthetic peptide MR140 was recognized by a monoclonal antibody that had been raised 
against a recombinant fusion of the two conserved terminal regions (Irion, 2000). This 
corroborates the statement that structural differences between the recombinant protein and the 
synthetic peptide are limited and do not lead to differential recognition by antibodies. 
 
Naturally occuring human antibodies purified on synthetic MSP2 peptides recognize 
parasite-derived MSP2 at the merozoite surface and are mainly of the IgG3 subclass. 
Sera from Papua New Guinean adults that gave high OD values (>1) in ELISA to MR141 
(3D7-MSP2) or MR144A (FC27-MSP2) were pooled for affinity purification of antibodies on 
the corresponding peptides. The affinity purification yielded 2 mg of anti-MR141 and 0.8 mg 
of anti-MR144 antibody. The antibodies purified on peptide MR141 represented ~1/700 of 
total IgG and corresponded to a serum concentration of 21 µg/ml. The antibody purified on 
peptide MR144 represented ~1/800 of total IgG and a serum concentration of 18 µg/ml. The 
reactivity and specificity of purified antibodies was confirmed by ELISA. A weak cross-
reactivity to the peptides representing the alternative allelic forms of MSP2 was found. This 
reactivity can be attributed to the conserved C-terminal part common to both peptides (Fig. 1), 
as it has been shown before that antibodies to the dimorphic part of one MSP2 family do not 
cross-react to a greater extent with the other MSP2 family (Lawrence et al., 2000a; Felger et 
al., 2003). 
 
Affinity-purified antibodies were used in immunofluorescence assays. The antibody staining 
obtained was typical for a merozoite surface protein (Fig. 3A, B). Thus, naturally occuring 
antibodies reactive to our synthetic peptides also recognize native parasite-derived MSP2. 
This indicates that the antigenic properties of our peptides are comparable to those of native 
MSP2.  
 
IgG subclasses of the purified human MSP2 antibodies were determined and cytophilic IgG3 
was found to be the dominant subclass in antibody preparations (Fig. 4). Such a high 
proportion of IgG3 antibodies is unusual for protein antigens but has been reported for MSP2-
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 specific antibodies in immune sera in several studies (Taylor et al., 1995; Rzepczyk et al., 
1997; Ferrante and Rzepczyk, 1997). Furthermore, in vitro IgG responses to MSP2 were also 
studied and found to be entirely restricted to IgG3 (Garraud et al., 2002).  
 
In vitro assays for the assessment of the inhibitory potential of peptide-purified MSP2 
antibodies. Antibodies to falciparum antigens are predominantly of the cytophilic and 
complement-fixing subclasses IgG1 and IgG3 in immune adults and of non-cytophilic 
subclasses (IgM, IgG2) in children (Bouharoun-Tayoun and Druilhe, 1992). We tested the 
inhibitory potential of the affinity-purified IgG antibodies in a direct growth inhibition assay 
and in cooperation with human monocytes in an antibody-dependent cellular inhibition 
(ADCI) assay. In the direct growth inhibition assay the antibodies did not inhibit parasite 
growth on their own at concentrations of 160 µg/ml (data not shown). This was not surprising 
since only a few MSP2-specific monoclonal antibodies to epitopes in the repeat region were 
shown to inhibit parasite growth at concentrations similar to those we used (Epping et al., 
1988; Ramasamy et al., 1990) while other monoclonals (Ramasamy et al., 1987) and rabbit 
sera against recombinant full-length MSP2 and homopolymeric peptides (Ramasamy et al., 
1999a; Ramasamy et al., 1999b) did not show an inhibitory effect. 
 
Since our affinity-purified human antibodies were predominantly of the cytophilic subclass 
IgG3, we tested their inhibitory potential in an ADCI assay. In cooperation with monocytes, 
the antibody purified on peptide MR141 (3D7-MSP2) gave 72% inhibition of parasite growth 
at a concentration of 32 µg/ml and 61% inhibition at a concentration of 16  µg/ml in a 22 hour 
assay. The control (no antibody) with only monocytes gave an inhibition of 20% at 22 hours. 
Microscopic examination of cultures showed that inhibition by monocytes alone was mainly 
caused by phagocytosis of erythrocytes infected with late stage parasites. Inhibition mediated 
by antibodies plus monocytes was mainly due to an attack of the intraerythrocytic stages, as 
plenty of parasites with a condensed morphology were seen. These data were obtained from a 
single experiment and are thus to be regarded as preliminary. To confirm the inhibitory 
activity of those antibodies, the assays have to be repeated. Also, antibodies purified on 
peptide MR144 will be assessed for ADCI activity. 
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 Discussion 
 
The results from the Combination B trial in Papua New Guinea justified further development 
of MSP2 as a component to be included in a subunit blood stage malaria vaccine. Selection 
induced by the Combination B was acting in favour of MSP2 genotypes not represented by 
the 3D7-MSP2 vaccine molecule. This identified MSP2 as a major active component in this 
vaccine (Genton et al., 2002) and further suggested to include the family-specific domain of 
both allelic families in an improved MSP2 vaccine. In search of an optimized MSP2 vaccine 
we produced and evaluated two long synthetic peptides representing both allelic families of 
MSP2. 
 
The MSP2 peptides presented here comprise the non-repetitive semi-conserved family-
specific domain plus the C-terminal domain that is highly conserved in all MSP2 alleles. Our 
antigenicity studies on immune sera from different malaria endemic areas and different age 
groups showed a high prevalence of antibody recognizing both long synthetic peptides. 
Furthermore, prevalences of antibodies to recombinant proteins corresponding to the family-
specific parts and the conserved parts were in accordance with results obtained with our 
peptides. This finding indicates similar structural and immunological properties of 
recombinantly produced and synthetic MSP2 antigens. In addition, we showed that antibodies 
from human immune sera purified on our candidate peptides react with native MSP2 on the 
surface of merozoites, showing cross-antigenicity with native MSP2. Taken together, these 
data provide evidence for our synthetic peptides to share major epitopes with parasite-derived 
MSP2. Presence of high titre antibodies to MSP2 was shown previously to be associated with 
protection against P. falciparum malaria (Al-Yaman et al., 1994; Al-Yaman et al., 1995; 
Aucan et al., 2000). Association with protection remains to be shown for our peptides. 
 
Circular dichroism spectra of 3D7 MSP2 showed that MSP2 is an intrinsically unstructured 
protein, random coil being the dominant conformation (Adda et al., 2004). The lack of a 
folded structure implies that it barely contains conformational epitopes. Thus, a peptide 
approach to an MSP2-based vaccine is promising. 
 
Both the family-specific and the C-terminal conserved regions present on the peptides MR141 
and MR144A elicited high titre IgG responses in CB6F1 mice when administered with 
montanide ISA 720. It was reported previously that the C-terminal conserved part of MSP2 is 
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 immunogenic in mice (Saul et al., 1992; Lougovskoi et al., 2000; Lawrence et al., 2000). This 
contrasts with the findings in naturally exposed humans where no high titre responses to this 
part are found, suggesting anergic properties of this part of the molecule (Thomas et al., 1990; 
Stower et al., 1997; Lawrence et al., 2000a). Also, vaccination with Combination B did not 
induce a response to the conserved regions of MSP2 (Flück et al., 2004). In general, 
conserved domains from Plasmodium falciparum antigens are thought to be poorly antigenic 
(Früh et al., 1991; Dodoo et al., 1999). Replacing some amino acids was shown to improve 
immunogenicity of conserved domains without affecting cross-reactivity with the parasite-
derived molecule (Torres et al., 2003; Espejo et al., 2004).  
 
We were able to generate monoclonal antibodies directed to both the 3D7 family-specific and 
the C-terminal conserved part in peptide MR141. These monoclonal antibodies were also 
reactive to the merozoite surface, confirming that antibodies were elicited that were cross-
reactive to the peptide and to native MSP2. 
 
An important criterion for the decision to carry on further development of a molecule as a 
vaccine is proof of efficacy in vitro. It needs to be shown that antibodies to the candidate can 
inhibit parasite growth in an in vitro assay. We tested both, affinity-purified antibodies from 
human immune sera and mouse monoclonal antibodies in direct growth inhibition assays. We 
did not get significant growth inhibition with either antibody preparation. Antibodies to 
merozoite surface antigens can act against parasite growth in different ways. In addition to 
directly blocking invasion into erythrocytes they can agglutinate merozoites (Lyon et al., 
1989; Lyon et al., 1997; Thomas et al., 1990) or induce monocytes to release soluble immune 
mediators killing parasites (Bouharoun-Tayoun et al., 1995). It has been reported that the 
inhibitory activity of immune sera was 22-fold increased in the presence of normal human 
monocytes (Khusmith and Druilhe, 1983; Bouharoun-Tayoun et al., 1990). This suggested 
that direct inhibition of merozoite invasion by binding to essential invasion molecules is not a 
major function of parasite-specific antibodies in vivo. Cytophilic subclasses, especially IgG3 
have been implicated in an antibody-dependent cellular inhibition (ADCI) involving 
merozoite-specific antibodies and the FC-gamma II receptor on blood monocytes 
(Bouharoun-Tayoun et al., 1990; Bouharoun-Tayoun et al., 1992; Bouharoun-Tayoun et al., 
1995). Subclass typing of antibodies purified on peptides MR141 and MR144 showed that 
IgG3 was the predominant subclass. This unusual subclass distribution in MSP2-specific 
antibodies is in line with previous reports (Taylor et al., 1995; Taylor et al., 1998; Rzepczyk 
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 et al., 1997; Ferrante and Rzepczyk, 1997). In a preliminary experiment antibodies purified on 
peptide MR141 showed ADCI activity reducing parasite growth by 41% at a concentration of 
16  µg/ml. This concentration compares well to the concentration of MR141-specific antibody 
in the serum pool we used for affinity purification. 
 
In summary, our results encourage the use of long synthetic peptides in subunit malaria 
vaccines. synthetic production of a vaccine seems to be justified, in particular, for MSP2, due 
to its lack of cysteines in all but the C-terminal domain and its predicted highly flexible 
random-coil conformation,. The peptides presented here have proven to be valuable 
candidates to be taken one step further in the pathway of vaccine development. 
 
The strategy of using long synthetic peptides as subunits of malaria vaccines as described here 
for MSP2, can be taken further. Availability of the P. falciparum genome allows the 
identification of novel vaccine molecules through bioinformatic analysis. In particular, 
unstructured domains could exhibit the same antigenic properties as in the native protein. By 
chemical peptide synthesis it is now possible to produce a large number of such unstructured 
domains within a very short time. They can then be screened for their recognition by human 
immune sera and promising candidates can be further tested. 
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   3D7   MKVIKTLSIINFFIF VTFNIKNESKYSNTF INNAYNMSIRRSMAE SKPSTGAGGTAGGSA GGSAGGSAGGSAGGS AGSGDGNGADAEGSS     90 
MR141 --------------- --------------- --------------- --------------- --------------- ---------------      0 
FC27  MKVIKTLSIINFFIF VTFNIKNESKYSNTF INNAYNMSIRRSMAN EGSNTNSVGANAPN- -------ADTIASGS QRSTNSASTSTTNNG     82 
MR144 --------------- --------------- --------------- --------------- --------------- ---------------      0 
MR140 --------------- --------------- --------------- --------------- --------------- --------------- 
  3D7   STPATTTTTKTTTTT TTTNDAEASTSTSSE NPNHKNAETNPKGKG EVQEPNQANKETQNN SNVQQDSQTKSNVPP TQDADTKSPTAQPEQ    180 
MR141 --------------- -----AEASTSTSSE NPNHKNAETNPKGKG EVQEPNQANKETQNN SNVQQDSQTKSNVPP TQDADTKSPTAQPEQ     70 
FC27  ESQTTTPTAADTIAS GSQRSTNSASTSTTN NGESQTTTPTAADTP TATESISPSPPITTT ESSSSGNAPNKTDGK GEESEKQNELNESTE    172 
MR144 --------------- --------------- -----------ADTP TATESISPSPPITTT ESSSSGNAPNKTDGK GEESEKQNELNESTE     49 
MR140 --------------- --------------- --------------- --------------- --------------- --------------- 
                                                          *       *                                                     
3D7   AENSAPTAEQTESPE LQSAPENKGTGQHGH MHGSRNNHPQNTSDS QKECTDGNKENCGAA TSLLNNSSNIASINK FVVLISATLVLSFAI    270 
MR141 AENSAPTAEQTESPE LQSAPENKGTGQHGH MHGSRNNHPQNTSDS QKECTDGNKENCG-- --------------- ---------------    128 
FC27  EGPKAPQEPQTAENE NPAAPENKGTGQHGH MHGSRNNHPQNTSDS QKECTDGNKENCGAA TSLLSNSSNIASINK FVVLISATLVLSFAI    262 
MR144 EGPKAPQEPQTAENE NPAAPENKGTGQHGH MHGSRNNHPQNTSDS QKECTDGNKENCG-- --------------- ---------------    107       
MR140 --------------- ---APENKGTGQHGH MHGSRNNHPQNTSDS QKECTDGNKENCG 
  3D7   FI    272 
MR141 --    128 
FC27  FI    264 
MR144 --    107 
MR140 --     40 
  Fig. 1 A
m
ino acid sequence alignm
ent of full-length M
SP2 alleles and long synthetic peptides. Peptides M
R
141 (3D
7 fam
ily-specific dom
ain + 
conserved C
-term
inal part) and M
R
144 (FC
27 12m
er repeat-fam
ily-specific dom
ain + conserved C
-term
inal part) w
ere used for affinity-purification 
of antibody from
 hum
an im
m
une sera. Peptide M
R
141 w
as also used to im
m
unise m
ice for production of m
onoclonal antibodies. Peptide M
R
144A
 
is a shorter version of M
R
144 starting from
 (SSSG
N
...). N
on-repetitive fam
ily-specific parts are shaded in light gray, conserved sequences are 
shaded 
in 
dark 
gray. 
The 
bold 
and 
underlined 
asparagine 
residue 
(N
) 
represents 
the 
putative 
cleavage 
site 
for 
the 
addition 
of 
the 
glycosylphosphatidylinositol (G
PI) anchor. The tw
o cysteine residues in the C
-term
inus (m
arked w
ith asterisks) w
ere reduced in the peptides used 
for affinity purification.  
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Fig. 2 Recognition of long synthetic MSP2 peptides by PNG human immune sera. 
Enzyme-linked immuno sorbent assays (ELISA) with adult sera from a region in Papua New 
Guinea where malaria is highly endemic on synthetic MSP2 peptides. 96% of the tested sera 
recognized peptide MR141 (3D7-cons), 93% recognized peptide MR144A (FC27-cons), and 
43% recognized peptide MR140 (cons). The median OD value was 0.84 for the 3D7-cons 
peptide with 50% of the values lying between OD 0.31 and 1.83. The median OD value for 
FC27-cons was 0.42 (50% percentile from 0.09 to 0.49) and 0.16 (0.11 to 0.27) for the C-
terminal conserved peptide (cons).  
 
 
 
 
 
 
 
MR141 MR144A MR140 
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Fig. 3. Immunofluorescence microscopy analysis of P. falciparum parasites with MSP2-
peptide specific antibodies. Acetone / methanol-fixed P. falciparum schizonts and 
merozoites were reacted with MSP2-specific antibodies. (A) human antibody affinity-purified 
on peptide MR141 (3D7cons) on 3D7 parasites. (B) human antibody affinity-purified on 
peptide MR144 (FC27cons) on K1 parasites. (C) Mouse monoclonal antibody raised against 
peptide MR141 with an epitope mapped to the 3D7-specific region (C) and to the C-terminal 
conserved region (D) on 3D7 parasites. Left hand panels show parasite nuclei stained with 
DAPI, central panels show the MSP2 antibody labelling followed by a Cy3-conjugated anti-
human IgG-specific (A, B) or anti-mouse IgG-specific antibody (C, D), respectively. The 
right hand panels are a merge of the blue and red fluorescence channels. 
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Fig. 4. IgG3 is the dominant subclass of MSP2-specific antibodies affinity-purified from 
human immune sera. Standard ELISA on human MSP2 antibody affinity-purified on 
synthetic peptides MR141 (black columns; antibody dilution 1:450) and MR144 (white 
columns; antibody dilution 1:150). Microtitre plates were coated with 1 µg/ml of peptide and 
reacted with affinity-purified human antibodies followed by subclass-specific anti-human 
antibodies. OD values are given for each IgG subclass. Values represent mean values of one 
experiment run in duplicates. 
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Abstract 
 
Merozoite surface protein 2 (MSP2) is a polymorphic component of the merozoite surface 
coat of Plasmodium falciparum. Its polymorphism is restricted to the central part of the 
molecule while the two terminal domains are highly conserved. The function of MSP2 is yet 
unknown. We hypothesized that the polymorphic repeat region is only of immunological 
importance and is dispensable for in vitro growth. To investigate the importance of the repeat 
domain and the central dimorphic domain in vitro we conducted gene replacements at the 
msp2 locus. The endogenous 3D7 msp2 gene was to be replaced by the FC27 allele lacking  
the polymorphic repeat region or a fusion of the two conserved termini. We were able to 
target the msp2 locus with plasmid constructs containing the partially deleted msp2 genes. 
Plasmids recombined via a single cross-over. However, double cross-over recombination that 
would have led to a replacement of the msp2 gene was not obtained. This indicates that the 
polymorphic and dimorphic parts of the molecule are essential for in vitro growth.  
 
 
Introduction 
 
Merozoite surface protein 2 (MSP2) is the second most abundant antigen on the surface of 
Plasmodium falciparum merozoites. It is a 45 to 51 kDa protein anchored to the plasma 
membrane via a glycosylphospatidylinositol (GPI) anchor. Its surface localisation has been 
proven by immuno-electron microscopy (Epping et al., 1988). MSP2 is highly polymorphic. 
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 The polymorphism is restricted to the central part of the molecule, with semi-conserved 
dimorphic domains that flank a highly polymorphic repeat region. According to their 
dimorphic domains, msp2 alleles are grouped into the 3D7 or FC27 family. Common to all 
alleles from both families are the highly conserved N- and C-terminal regions. The conserved 
N-terminal domain spans 43 amino acids including a classical signal peptide at the N-
terminus. The C-terminal domain includes 74 amino acids and shows a putative cleavage site 
for addition of the lipid anchor 34 residues upstream of the stop codon. 
 
The protein’s function is unknown. It is thought to be involved, like other MSPs, in the 
primary attachment of the merozoite to the erythrocyte. However, MSP2 has never been 
shown to bind to red blood cells although two MSP2 peptides showed high specific binding, 
which also inhibited parasite growth in vitro (Ocampo et al., 2000). Its sequence does not 
predict any stable secondary structures and is thought to be intrinsically unstructured (Adda et 
al., 2004). Another possibility is that MSP2 functions as a scaffold protein underlying other 
components of the merozoite coat. MSP2 has been shown to have the propensity to 
polymerise into amyloid-like fibrils in vitro (Adda et al., 2004). 
The function of the protein appears to be essential since several attempts to disrupt the msp2 
gene have failed (Cowman et al., 2000; Paul Sanders, personal communication). Allelic 
exchange experiments showed that an FC27-type gene could replace an endogenous 3D7-type 
gene. This indicated that an allele from one family can fully complement the function of an 
allele belonging to the other family (Wickham 2003). 
 
MSP2-specific antibodies are abundant in sera of protected individuals from malaria endemic 
areas (Al-Yaman et al., 1994). The reactivity of the MSP2-specific antibody response has 
been investigated and it was found that most of it is directed against the central dimorphic and 
repetitive parts and only to a minor extent to the conserved terminal regions (Al-Yaman et al., 
1994; Lawrence et al., 2000). It was proposed that the conformation of the protein on the 
surface allows the exposure of the central variable part only. Furthermore it was suggested 
that the function of the polymorphic repeat region, which is highly antigenic, is merely to 
mislead the host’s immune system to produce large amounts of non-protective antibodies 
(Anders, 1986). The high degree of length and sequence polymorphism within the repeat 
region indicates that it is unlikely to play an important functional role like in protein 
interaction. 
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 Despite the fact that the functional and immunological importance of the different domains of 
MSP2 remain to be established, MSP2 is considered a vaccine candidate and underwent first 
testing in a field trial in PNG (Genton et al., 2002). We therefore undertook a study on the 
functional role of the central polymorphic domain of MSP2. We hypothesised that the repeat 
region is not required for in vitro growth of the parasite. To answer this question we 
constructed mutant parasites expressing MSP2 with the repeat region deleted. By successively 
extending this deletion we wanted to test whether the semi-conserved dimorphic domain or 
parts of it are also dispensable for parasite survival in culture. With this approach we aimed at 
elucidating  the functional importance of the central domains of MSP2. The new msp2 genes 
generated by the internal deletions are shown schematically in figure 1.  
 
The functional complementation of a 3D7-type msp2 gene by an FC27 allele has been 
successfully performed (Wickham, 2002). The approach for this replacement had been a 
single cross-over strategy involving a plasmid vector with a human dihydrofolate reductase 
(hdhfr) selection cassette, a transgene cassette designed for expression of the msp2 gene from 
the FC27 strain, and a single target sequence consisting of a truncated 3D7 msp2 gene with 
mutated start codon and lacking the signal for GPI-anchor addition. Upon integration via a 
single crossover between the endogenous msp2 of the 3D7 line and the target sequence, one 
or more copies of the plasmid were integrated into the msp2 locus, leading to gene disruption 
by insertion-duplication that yields two unfunctional copies of the 3D7 msp2 gene while the 
FC27 msp2 transgene is expressed. Initially, we had chosen a similar approach to produce a 
mutant expressing 3D7 MSP2 lacking the central repeat region on a 3D7 background but 
could not achieve integration into the msp2 locus (data not shown). 
 
Here we based our replacement constructs on plasmid pHTK (Duraisingh et al., 2002). This 
parental plasmid (Fig. 2A) also contains a human dhfr cassette to select for transfectants. In 
addition, it carries a Herpes simplex thymidine kinase (tk) gene cassette that can be used to  
select against the plasmid backbone. This allows for active selection of double cross-over 
recombination events. 
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 Material and Methods 
 
Construction of Plasmodium falciparum transfection vectors 
We generated three different transfection plasmids designed for integration in the msp2 locus 
of the 3D7 parasite line. All constructs were based on the transfection vector pHTK 
(Duraisingh et al., 2002). 
 
Plasmid pHTK (Fig. 2A) was cut with restriction enzymes SacII and SpeI (New England 
Biolabs) to be ligated to a PCR product amplified from pBS-M2 (a derivative of pM2F 
(Wickham et al., 2003)) consisting of the whole msp5-msp2 intergenic region, a multiple 
cloning site and the P. berghei dhfr-ts 3’UTR with primers 5’flank-F 
AGTCCCGCGGGAAaTCTTATTCTT GCCATCC and 5'flank-R 
AGTCACTAGTCTACCCTGAAGAAGAAAAGTC (sequences in bold mark restriction 
sites) to yield plasmid pTK-M2-5’flank. The msp5-msp2 intergenic region served as 5’target 
sequence for integration of the constructs in the P. falciparum 3D7 msp2 locus. The NheI site 
located in the introduced multiple cloning site was used for a further cloning step involving 
insertion of different msp2 coding regions. 
 
The 3’ target sequence consisting of the conserved C-terminal part of msp2 and the msp2 
3’UTR from the 3D7 line was PCR amplified from 3D7 genomic DNA using primers 3’flank-
F AGTCACGCGTCACCAGAGAATAAAGGTACAG and 3’flank-R GACACTGCAAGTT 
GGGCAC with insertion of an AflIII site (ACATGT) at the 5’ end. The PCR product was cut 
with AflIII (an endogenous AflIII site is located near the end of the 3’UTR) and ligated into 
pTK-M2-5’ digested with NcoI making use of compatible overhangs to yield pTK-M2. 
 
Msp2 coding regions with internal deletions were generated by separate amplification of  the 
corresponding 5’ and 3’ parts of the gene from D10 genomic DNA. Primer M2F-Avr 
CAAACCTAGGCAAAATGAAGGTAATTAAAACATTGTC and M2R-Avr ATCC 
CCTAGGAAGAGAATTATATGAATATGGC include the msp2 start and stop codon, 
respectively (underlined) and were used for all amplifications of coding sequences. The 5’ 
conserved region and the 5’-conserved plus 5’-FC27 (D10) family-specific part was amplified 
using primer M2F-Avr and Cons-N-term-R-Xba GATCTCTAGATGCCATACTTCTCCTT 
ATACTCAT or FC27-5’fsp-R-Xba GATCTCTAGAATTTGGAGCATTTGCACCTAC, 
respectively. The corresponding 3’-conserved and the 3’-FC27 family-specific parts were 
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 amplified separately using primers Cons-C-term-F-Nhe 
GATCGCTAGCGCTGCACCAGAGAATAAAGGTAC or FC27-3’fsp-F-Nhe 
GATCGCTAGCGAAAGTTCAAGTTCTGGCAATG, respectively. The corresponding 5’ 
and 3’ PCR products were then digested with either XbaI or NheI, ligated, and redigested with 
XbaI and NheI, leaving only correctly ligated fragments.  These ligated products were used as 
PCR templates for an amplification with the outer primers only (primer M2F-Avr and primer 
M2R-Avr ) to yield FC27 (D10) msp2 coding regions lacking the repeat or the complete 
variable domain. Similarly, the D10 full-length coding region was amplified from genomic 
DNA.  
 
These PCR products, after digestion with AvrII, were finally ligated into the NheI site of pTK-
M2 making use of the compatible overhangs. The ligations were transformed into E.coli PMC 
103 (ATCC) by electroporation and plated on LB-agar containing ampicillin at 100 µg/ml. 
The integrity of the plasmids was checked by restriction digests, the correctness of coding 
regions and 500bp of the upstream region were checked by sequencing (micromon 
sequencing facility, Monash University, Clayton, Victoria, Australia). The newly constructed 
Plasmodium falciparum transfection vectors were named pTK-M2-FC27-full-length, pTK-
M2-FC27-delta-rep, and pTK-M2-N-C-cons. 
 
Parasite cultures and transfection 
The 3D7 cloned line of P. falciparum was used for all transfections. Parasites were grown in 
human O+ red blood cells (erythrocyte concentrate from blood bank at Royal Melbourne 
Hospital) at 4% hematocrit in RPMI 1640 supplemented with Albumax (GibcoBRL) to a final 
concentration of 0.5% and gassed with 5% CO2 and 0.5% O2 in N2 at 37 °C as described 
previously (Trager and Jensen, 1976). Cultures to be transfected were synchronised by 
treatment with 5% sorbitol 48 hours before transfections. 5ml of a ring-stage culture with at 
least 5% parasitaemia was used per transfection. 80 to 100  µg of maxi prep DNA (QIAGEN, 
Valencia, CA, USA) was transfected by electroporation with a single pulse of high 
capacitance (950 µF) and low voltage (310V) as described (Wu et al., 1995; Fidock and 
Wellems, 1997). The antifolate drug WR99210 (kindly provided by Jacobs Pharmaceuticals 
Co. Inc.) was added to the cultures 6 hours post transfection at a concentration of 5nM to 
select for parasites expressing human dihydrofolate reductase (hdhfr) from episomes. Culture 
medium was changed daily for the first week and every second day thereafter. Fresh red blood 
cells were added weekly to maintain 4% hematocrit until a population of WR99210-resistant 
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 parasites was established. WR99210 was withdrawn and re-applied 3 weeks after (cycle 1). 
Without drug selection parasites lose episomal plasmids. Thus, after re-application of 
WR99210  transfectants having integrated the plasmids in the chromosome are enriched. This 
drug cycling was repeated (cycle 2) and negative selection applied after the second cycle. The 
pro-drug ganciclovir (Cytovene®, provided by Roche, Basel, Switzerland) selecting against 
the presence of the Herpes simplex thymidine kinase (tk) gene on episomes and integrated 
plasmid copies was added at a concentration of 20 µM after re-establishment of WR99210-
resistant cultures and the parasites were cultivated under both selections to select for double 
cross-over integration events. After establisment of double drug resistant parasite populations 
ganciclovir selection was omitted. 
 
Isolation of genomic DNA  from P. falciparum  
Genomic DNA was extracted from the 3D7 parental strain, WR99210-resistant transfectant 
cultures after drug cycling, and ganciclovir-selected parasite cultures. 10ml parasite cultures 
with at least 5% late stages (late trophozoites/schizonts) were subjected to saponin lysis 
(0.05% Saponin in PBS incubated on ice for 5 minutes) and washed with PBS. Parasite pellets 
were resuspended in 400 µl resuspension buffer A (500 mM Na Acetate pH 5.2, 100mM 
NaCl, 1mM EDTA), ½ volume 10% Sodium-dodecyl-sulfate (SDS) was added and mixed. 
The DNA was extracted twice with 1 volume of a phenol / chloroform mixture (1:1) followed 
by a chloroform extraction. The DNA was precipitated with 2 volumes of 100% ethanol, 
washed, dissolved in TE and stored at 4°C. 
 
Southern blotting 
Genomic DNA from different transfected parasite cultures and maxiprep plasmid DNA was 
completely digested with XmnI (New England Biolabs) overnight and separated on a 0.6% 
agarose gel. The gel was soaked in 0.25M HCl for 10 minutes for depurination of the DNA 
and subsequently DNA was denatured by soaking the gel in 0.4M NaOH for 15 minutes. A 
capillary blot setup was used to transfer the DNA to a Hybond XL Nylon membrane 
(Amersham, Uppsala, Sweden). Subsequently the DNA was crosslinked to the membrane 
using an Amersham UV crosslinker (700 energy units). The membrane was prehybridized in 
hybridization solution (6x SSC, 5% Denhardt’s, 0.5% SDS) for 1 hour at 62°C. Hybridization 
solution was discarded and replaced by 15 ml of hybridization solution containing denatured 
herring sperm DNA at a concentration of 200 µg/ml and prehybridized for at least 2 h at 
62°C. Radioactive probes were made using the random prime labelling kit Decaprime II 
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 (Ambion, Austin, TE, USA) according to the manufacturer’s protocol. In brief, 2.5  µl 
decamers were mixed with 10 ng purified PCR product (msp2 5’UTR) or linearized plasmid 
(pGEM-T easy, Promega, Madison, WI, USA) in 11.5 µl H20 and denatured for 5 minutes at 
100°C, then put on ice. 5 µl 5x reaction buffer – dATP, 1 µl Klenow and 5 µl 32P α-dATP 
were added and incubated for 30 to 60 minutes at 37°C. A prepacked sephadex G50 spin 
column was spun at 0.8 g for 1 minute. 50  µl TE (with 2x EDTA) was added to the labelling 
reaction and the reaction loaded on the spin column to remove unincorporated nucleotides. 
Labelling of the probe was checked with a Geiger counter, the probe denatured for 2 minutes 
at 100°C, and added to the hybridisation solution. Hybridisation was carried out overnight at 
62°C. Washing was performed twice in 2x SSC for 10 minutes and once in 0.2 x SSC/0.05% 
SDS. The membrane was removed from the hybritube, wrapped in saran wrap and exposed to 
an X-ray film in a cassette with two enhancer screens at -70°C for 2 to 15 hours, depending 
on signal intensity. 
 
Western blot analysis 
Late stage P. falciparum cultures were lysed with saponin, parasite pellets washed twice with 
PBS before resuspension in 2x Laemmli buffer containing β-mercaptoethanol. Equivalents of 
200 µl of a culture with 5% parasitaemia were boiled for 2 minutes and separated on a 12% 
SDS-polyacrylamide gel. The proteins were transferred to nitrocellulose membranes by tank 
blotting (Biorad) in Tris-Glycine buffer containing 20% methanol. The membranes were 
blocked in phosphate-buffered saline (PBS) containing 5% non-fat milk powder. Antibody 
reactions were carried out in PBS/0.1% Tween 20 (PBS-T) with 1% non-fat milk powder. 
Primary antibodies were used at the following dilutions: Rabbit anti-FVO-MSP2 affinity-
purified on recombinant full-length FVO-MSP2 (3D7-type) at a dilution of 1:80 (Wickham, 
2002); second bleed rabbit sera R633 and R634 raised against recombinant 3D7-family-
specific domain of MSP2 (Irion, 2001) as well as R630 and R631 raised against recombinant 
FC27-family-specific domain D61/9 (Irion, 2001) were used at a 1:200 dilution. Primary 
antibodies were reacted for 2 hours at room temperature. Washing was performed in PBS-T 
with 0.5% milk 3 times for 10 minutes. The blots were then incubated with horse raddish 
peroxidase-labelled goat anti-rabbit IgG (Southern Biotech, Birmingham, AL, USA) for 1 
hour and washed as above. Binding was visualized with enhanced chemiluminescence (ECL) 
(Amersham, Uppsala, Sweden). 
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 Results 
 
Our aim was the expression of internally deleted msp2 variants from the msp2 locus instead of 
the endogenous msp2 gene. The resulting mutants can be expected to be potentially 
deleterious. Using WR99210 drug cycling to enrich for recombinants is a rather weak 
selection and may not yield the desired mutants. A recently established negative selectable 
marker makes it possible to actively select against the plasmid backbone and for double cross-
over recombination (Duraisingh et al., 2002). This strategy was used for gene disruptions 
(Duraisingh et al., 2003; Wiek et al., 2004; Triglia et al., 2005) but never for gene 
replacements. The msp2 replacement constructs presented here are based on the pHTK vector 
of Duraisingh et al. (2002). 
 
Figure 2B shows the basic structure of the plasmids designed for msp2 replacements. They 
contain a human dihydrofolate reductase gene (hdhfr) cassette for positive selection with 
WR99210 flanked by an msp2 transgene expression cassette and the 3’conserved part of the 
msp2 gene plus the msp2 3’untranslated region (UTR). The 1100 bp long msp5-msp2 
intergenic region contains the msp2 promoter that drives expression of the msp2 transgenes 
and also serves as 5’target sequence for homologous recombination. The 800 bp fragment 
encompassing the 3’ conserved part of the msp2 gene and its 3’UTR serves as 3’ target 
sequence for recombination. The plasmid also contains a Herpes simplex thymidine kinase 
(tk) gene cassette that can be selected against with ganciclovir. This allows for selection of 
double cross-over recombination events in the msp2 locus leading to replacement of the 
endogenous msp2 gene by a full-length or partially deleted msp2 transgene. 
 
Figure 3 shows the three possible recombination events that can be in principle expected after 
targeting of the msp2 locus with the replacement constructs. Figure 3A depicts the desired 
double cross-over event. The plasmid with its target sequences, the wild-type msp2 locus, and 
the situation at the msp2 locus after a double cross-over recombination event are shown. Such 
a recombination leads to disruption of the endogenous msp2 gene. Single cross-over 
recombination within either the 3’ or the 5’ target sequence leads to insertion of the entire 
plasmid as shown in figure 3B and 3C. These integrations do not disrupt the endogenous 
msp2 gene and are thus not desirable. 
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 Southern blot Analysis of transfected P. falciparum cultures 
The three plasmid constructs were transfected into P. falciparum strain 3D7 and the cultures 
selected for expression of human dihydrofolate reductase with WR99210 (WR). Drug 
resistant populations were subjected to drug cycling (off/on WR) and negative selection 
against the presence of thymidine kinase with ganciclovir. Genomic DNA from the three 
different WR-cycled and ganciclovir-treated cultures was subjected to Southern blot analysis 
to check for integration in the msp2 locus. 
 
For the control construct pTK-M2-FC27-full-length (Fig. 4A) Southern blot analysis showed 
no evidence for integration in the msp2 locus after one WR drug cycle. Sequences of plasmid 
origin were still present. However, the plasmid was no more in its original form. Two major 
fragments of 9 kb and 6 kb were detected by Southern blot probably representing re-arranged 
plasmid integrated into a locus other than msp2. The faint band of around 8 kb could represent 
episomes of the same re-arranged plasmid. After the second WR cycle and negative selection 
with ganciclovir none of the three expected recombination events depicted in Figure 3 had 
taken place in this culture. Plasmid sequences were still present as detected with a pGEM-
specific probe. A single band of around 5.5kb was detected with the msp2 5’UTR probe while 
the band corresponding to the wild-type msp2 locus was absent, indicating that a re-arranged 
plasmid had integrated into the msp2 locus. Parasites survived well the addition of 
ganciclovir. This points towards mutations in the thymidine kinase gene rendering it 
unfunctional or to a further recombination event that had led to loss of the TK gene. 
 
For the culture transfected with the plasmid carrying the FC27-type msp2 gene with the 
internal repeat deletion (pTK-M2-FC27 delta-Rep) no integration was detected when the 
parasites were hit with ganciclovir without previous WR cycling (Fig. 4B). The plasmid was 
present in its original form, which showed that direct selection with ganciclovir was not 
efficient. However, after two cycles off/on WR but without ganciclovir (Fig. 4B, lane 3), the 
whole population had integrated several copies of the plasmid in the msp2 locus via a cross-
over with the 3’target sequence. This result corresponds to the expected integration depicted 
in  Fig. 3B. Integration of multiple plasmid copies has been reported previously and is due to 
episomal plasmids being present as concatamers (Crabb et al., 1997; O’Donnell et al., 2001). 
Therefore it is possible that all tandemly repeated plasmid integrations in this culture 
originated from a single recombination event. Our plasmids were designed in a way that a 
single cross-over integration does not lead to disruption of the endogenous msp2 gene. 
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 Negative selection with ganciclovir after two WR cycles (Fig. 4B, lane 4) led to excision and 
loss of all integrated plasmids resulting in parasites that had converted the msp2 locus back to 
wild-type. In this case the negative selection had worked well. However, the parasites must 
have developed a resistance to WR in the course of double selection because they maintain 
resistance despite excision of integrated plasmids from the msp2 locus. A WR resistance in P. 
falciparum has not been reported to date. Another more likely explanation is that the human 
dhfr gene has integrated at another locus, i.e. calmodulin or hrp2. This is possible because 
regulatory sequences in the selection cassette originated from these loci. Such recombination 
events were not detectable with our probes.  
 
For the culture transfected with pTK-M2-N-C-cons, Southern blot also revealed other than 
the desired integration event. Direct treatment with ganciclovir selected for parasites carrying 
a mutated form of the plasmid (Fig. 4C). A single band was detected with the pGEM probe 
that is around 3 kb smaller than the originally transfected plasmid and does not correspond to 
one of the expected integration events. This recombined plasmid is likely to lack the 
thymidine kinase gene since parasites carrying it were not eliminated by ganciclovir 
treatment. The msp2 5’UTR probe only detected the wild-type msp2 locus confirming that no 
integration had occurred. However, the majority of the parasites in this culture lost all 
episomes after two drug cycles and integrated several plasmid copies in the msp2 locus via a 
cross-over with the 3’ target sequence (Fig. 4C, lane cycle 2). Subjecting these cycled 
parasites to ganciclovir selected for parasites carrying the mutated, ganciclovir-resistant 
episome. But parasites with 3’ cross-over integrations of the full plasmid were eliminated by 
ganciclovir. 
 
The expected band for a double cross-over recombination was around 10 kb. A band of that 
size was detected in WR-cycled cultures transfected with pTK-M2-FC27-delta-Rep and pTK-
M2-N-C-cons (Fig. 4B and 4C) before ganciclovir treatment. The Southern blot analysis 
however shows clearly that this band originates from several integrated plasmid copies and 
hence a single cross-over recombination, since the ratios of band intensities are similar for the 
msp2 5’UTR- and pGEM-specific probes. 
 
Summarizing the results of both deletion constructs we have shown that only single cross-
over recombination events were selected by WR. Selection resulted in the insertion of 
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 multiple full length copies of the plasmid constructs. No double cross-over integrants were 
obtained and allelic replacement was thus not achieved. 
 
Analysis of transgene expression 
Since the transfected plasmids contain a complete transgene cassette with a full-length 
promoter that has been shown to drive expression of similar transgenes from episomes 
(Wickham et al., 2003) it was reasonable to assume that our FC27-type msp2 transgenes 
would be co-expressed with the endogenous 3D7-type msp2. We conducted western blot 
analyses on total parasite protein extracts using antibodies specific for either of the two allelic 
MSP2 families. The rabbit sera used were raised against recombinant proteins corresponding 
to the non-repetitive family-specific parts of MSP2 (D46/1 and D61/9 for 3D7 or FC27 
family, respectively) (Irion, 2001). The antibodies have proven to be highly specific for MSP2 
of the corresponding family. While the chromosomal MSP2 was well detected, we could not 
detect any protein of episomal origin (Fig. 5) in the transfectant cultures 3D7-TK-M2-FC27-
full-length and 3D7-TK-M2-FC27-delta-rep. The culture transfected with plasmid pTK-M2-
N-C-cons does not contain any FC27-type-specific sequences and therefore constitutes a 
perfect negative control. The lack of episomal expression could be due to a deleterious 
promoter. The promoter of the transgene cassette on the plasmids could have contained 
mutations that completely abolish episomal expression. Such mutations or deletions could 
arise in the course of cloning and even after parasite transfection. This remains to be shown 
by sequencing. Despite of the lack of an intact promoter the transgene could still be expressed 
upon integration via a 5’ single cross-over or a double cross-over. But neither of these events 
were selected in our transfectant cultures. 
 
 
Discussion 
 
An allelic replacement of the 3D7 msp2 with a full-length msp2 gene from the heterologous 
allelic family has been achieved previously (Wickham et al., 2003). This experiment showed 
the functional equivalence of members of the two families in vitro. This successful allelic 
replacement led us further to expect that also other, modified and deleted msp2 alleles could 
replace a wild-type gene – provided the introduced construct does not compromise the 
essential function of MSP2. MSP2 appears to be essential since efforts to knock out msp2 
failed so far. We hypothezised that the central polymorphic regions may well be of great 
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 immunological importance but have no essential function for parasite survival in vitro. This 
was to be tested by allelic replacement with an msp2 construct carrying an internal repeat 
deletion. Furthermore we were interested whether the semi-conserved family-specific part is 
essential. We addressed this question of the functional importance of the dimorphic domains 
of the molecule by a replacement with a fusion of the conserved terminal regions completely 
devoid of any family-specific sequences. We transfected parasites with three plasmid 
constructs that would disrupt the endogenous msp2 gene in strain 3D7 upon double cross-over 
recombination within the msp2 locus and instead express a transgenic msp2 gene of the FC27 
family (control construct) or genes with internal deletions. 
 
Southern blot analysis of our transfectants clearly showed that the plasmid episomes had re-
arranged during culturing. This was most evident in the case of the positive control (the 3D7 – 
FC27 exchange) where parasites with plasmids survived ganciclovir selection well. It is 
probable that the re-arrangement of the plasmid had led to loss of the thymidine kinase gene. 
Plasmid sequences are still detected after ganciclovir selection, but do not seem to be 
associated with the msp2 locus. The plasmid probably had integrated into the calmodulin or 
hrp2 locus since regulatory sequences from these genes were also present in the human dhfr 
selection cassette. It is unlikely that the plasmid was still present episomally, since two WR 
cycles should have sufficiently selected against them (O’Donnell et al., 2002). Though, stably 
replicating forms consisting of large concatamers have been reported that are not lost when 
WR selection was omitted (O’Donnell et al., 2001). As an alternative explanation to insertion 
of plasmid in another locus, concatamerization could have led to persistence of the plasmid 
despite WR cycling. 
 
Southern blot analysis of maxi-prep plasmid DNA revealed a band at 7.5 kb although XmnI 
digestion should linearize the plasmids (~11 kb). Such a band was detected in all three 
plasmid maxi-preps but was by far most prominent in the control plasmid. It had not been 
seen on ethidium bormide-stained gels and was first thought to have resulted from star 
activity due to the high enzyme concentration in the overnight digestion. Alternatively, a 
subpopulation of re-arranged plasmid carrying one or more deletions could have been present 
before transfection. This is a likely explanation considering that the plasmid copy numbers for 
these constructs were very low, a sign for plasmid instability in bacteria. Smaller, re-arranged 
plasmids could have been taken up preferentially during parasite transfection or been selected 
for during the long culture period. 
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 In summary, the results gained from Southern blot analysis of the full-length control 
transfectants can explain why no FC27-msp2 transgene was expressed at any time. The failure 
to generate a positive control parasite line was due to recombination in the 3D7-FC27 allelic 
exchange construct and makes it difficult to identify reasons for the failure to achieve double 
cross-overs with the two internal deletion constructs.  
 
Transfection with deletion constructs and subsequent WR drug cycling led to selection of 3’ 
single cross-over events with insertion of multiple plasmid copies that do not disrupt the 
endogenous msp2 gene. Multiple insertion of plasmids is a known phenomenon (Maier et al., 
2003). Negative selection with ganciclovir against the plasmid backbone led to reversion to 
the wild-type msp2 locus showing that the integrated plasmids contained a functional 
thymidine kinase gene. However, ganciclovir selection did not lead to the desired double 
cross-over recombinations. It remains open whether this is due to all domains of MSP2 being 
essential for survival or whether this is an artifact of unstable plasmid constructs. No plasmid 
sequences were detected after ganciclovir selection in the culture transfected with the 
construct with internal repeat deletion. It is likely that the parasites surviving ganciclovir 
treatment had the dhfr gene integrated in a locus other than msp2 (i.e. calmodulin or hrp2). In 
the culture transfected with the construct with the deletion of the entire dimorphic part, 
ganciclovir treatment selected for parasites carrying the re-arranged plasmid of 7.5 kb that 
was present at time of transfection. This shows that it is crucial that the transfected plasmid 
population is uniform and does not contain traces of any recombined molecules. 
 
In none of the three transfectant cultures we could detect the expected double cross-over 
integration leading to msp2 gene disruption and expression of the introduced msp2 transgene, 
although the negative selection with ganciclovir was principally effective in eliminating 
plasmid backbone sequences in one case (3D7-pTK-M2-FC27-delta-rep). All single cross-
over recombinants selected for with drug cycling arose from recombinations with the 3’target 
sequence on the plasmids, consisting of the conserved 3’part of the msp2 gene plus its 3’UTR. 
No cross-overs within the 5’target sequence were found. The 5’target sequence largely 
consisted of non-coding sequence with a high A/T content and only ~ 120 bp coding region. It 
was found previously that A/T-rich intergenic sequences do not promote plasmid integration 
(Alan Cowman, personal communication). However, although desirable, it was not possible 
to use large stretches of coding region for a target sequence because the entire N-terminal 
conserved region spans only 40 amino acids. The 5’target sequences also included the entire 
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 promoter, which could therefore drive expression of the msp2 transgene. But we did not find 
expression from episomes. It is likely that parts of the promoter were lost. This is also 
suggested by the findiing that the construct for FC27-msp2-full-length expression was clearly 
re-arranged before ganciclovir selection and no plasmid-associated msp2 5’UTR was detected 
(Fig. 4A). For the other two constructs, the plasmids appear to be slightly smaller in the 
transfectants than the corresponding maxi-prep plasmids indicating that short sequence 
stretches may have been deleted. Such a deletion occurring within the 5’target sequence could 
likewise affect expression from the episome and recombination efficiency. Still, integration 
involving a cross-over in the promoter or 5’UTR would inevitably provide the transgene with 
a full-length promoter and it would be expressed at the expense of the endogenous msp2 gene. 
The fact that this event was never found in the cultures transfected with plasmids with the 
partially deleted msp2 genes suggests that the repeat region is not dispensable for in vitro 
growth. However, the full-length control is crucial to corroborate this assumption. It is also 
possible that not the repeat sequence itself is essential but that a spacer is needed between the 
semi-conserved dimorphic parts. However, our attempts to replace the repeat region with 
multiple epitope tags (3x c-myc) was not successful. 
 
We generated family-specific anti-MSP2 rabbit sera that could be used for detection of the 
full-length FC27-type MSP2 and the FC27-type MSP2 with deleted repeat region. In contrast 
to what was found by Wickham and co-workers, our msp2 transgenes were not expressed 
from the episome (Fig. 5). Reasons for this could be mutations or deletions in the promoter 
region as discussed above. 
 
Thymidine kinase as negative selectable marker has basically worked in selecting aginst the 
plasmid backbone but did not lead to selection of double cross-overs. It has become clear that 
this selection can only work if i) the transfected plasmid population is unifom and ii) the 
plasmids are stable in the transfected parasites. Both preconditions were not met in our 
experiments. A further technical weakness became apparent after Southern blot analysis of 
transfected cultures. Ganciclovir selection without WR drug cycling did not lead to plasmid 
loss, confirming that this negative selection is not 100 % effective as seen by others (Tony 
Triglia, personal communication) and that previous WR drug cycling is advisable. To date, no 
double cross-over gene replacement was achieved in Plasmodium falciparum by use of the 
TK vector. Several publications show the successful use of the system for the generation of 
gene knock-outs by double cross-over recombination since the proof of principle in 2002 
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 (Duraisingh et al., 2003a; Duraisingh et al., 2003b; Gilberger et al., 2003; Wieks et al., 2004; 
Triglia et al., 2005). Yet the value of TK as a negative selectable marker for gene 
replacements remains to be established. Our results do not support its further use. 
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 Figures 
 
Fig. 1. Schematic representation of MSP2 constructs. The basic structure of MSP2 is 
shown of representatives for the two allelic families (3D7 and FC27). FC27delta-Rep and N-
C-cons display the internal deletion constructs to be expressed from the msp2 locus. They 
lack the FC27 repeat or the complete central domains, respectively. For amino acid sequences 
of the constructs see supplementary figure S5 (appendix) 
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 Fig. 2. Plasmodium falciparum msp2 gene replacement constructs. 
(A) Parental plasmid pHTK is shown. It contains a human dihydrofolate reductase (dhfr) 
cassette for positive selection with WR99210 and a Herpes simplex thymidine kinase (tk) 
cassette for negative selection with ganciclovir. The P. falciparum calmodulin (cam) 
promoter and 5’ untranslated region (UTR) drive expression of human dhfr while P. 
falciparum heat shock protein 86 (hsp86) promoter/5’UTR drives expression of the tk gene. 
The transcriptional terminators used in the selection cassettes are the 3’UTRs from P. 
falciparum histidine rich protein 2 (hrp2) gene (dhfr cassette) and P. berghei dihydrofolate 
reductase-thymidine synthase (dhfr-ts) gene (tk cassette), respectively. Two multiple cloning 
sites (MCS) flanking the dhfr cassette facilitate the insertion of target sequences for 
homologous recombination. Restriciton sites relevant for cloning are underlined. 
(B) Schematic representation of the transfection constructs designed for double cross-over 
integration into the msp2 locus on chromosome 2. The constructs derive from the plasmid 
described in (A). A complete msp2 transgene expression cassette was inserted into MCS 1. It  
contains 1.1kb of target sequence for homologous recombination within the msp2 upstream 
region followed by a full-length or partially deleted msp2 gene. The transcriptional terminator 
used is the P. berghei dhfr-ts 3’UTR. A second target sequence for homologous 
recombination consisting of the 3’conserved part of the msp2 gene and its 3’UTR was 
inserted into MCS 2. 
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 Fig. 3. Integration of replacement constructs into msp2 locus. 
Expected recombination events at the msp2 locus are displayed schematically. The 5’ and 3’ 
target sequences for homologous recombination are represented by black or gray boxes, 
respectively. The selection cassettes and the msp2 transgene are represented by open boxes. 
The endogenous msp2 coding region is marked with asterisks. The XmnI restriciton sites 
relevant for Southern blotting are indicated (X) and fragment sizes for the control construct 
given in kilobases. Sizes in brackets are for the cultures transfected with the two partial msp2 
deletion constructs. Regions used as hybridization probes for Southern blotting are indicated 
by black (msp2 5’UTR) and open (pGEM) bars, respectively. (A) double cross-over 
recombination and the resulting msp2 locus with a disrupted msp2 gene. (B) single cross-over 
recombination in the 5’ target sequence. (C) single cross-over recombination in the 3’ target 
sequence. 
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 Fig. 4. Southern blot analysis of transfected Plasmodium falciparum cultures. 
Genomic DNA of the parental 3D7 strain and different transfectant cultures as well as 
purified plasmid DNA digested with XmnI was subjected to Southern blotting. The membrane 
was probed for the msp2 5’UTR, stripped, and re-hybridized to a pGEM plasmid probe. The 
size standard is in kilobases. (A) 3D7 parental line and 3D7-pTK-M2-FC27-full-length 
(control). (B) 3D7-pTK-M2-FC27-delta-rep transfectant cultures. (C) 3D7-pTK-M2-N-C-
cons transfectant cultures. 
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 Fig. 5. Analysis of MSP2 expression in cultures transfected with msp2 replacement 
constructs. 
Total lysates from late stage cultures of 3D7 and D10 wild-type parasites as well as non-
cycled transfectants 3D7-pTK-M2 FC27-full-length, 3D7-pTK-M2 FC27-delta-rep, and 3D7-
pTK-M2-N-C-cons were subjected to Western blotting and reacted with anti-MSP2 rabbit 
sera. (A) Reacted with rabbit sera specific for the 3D7 family-specific part. (B) Reacted with 
rabbit sera specific for FC27-type MSP2. Relevant size standards are indicated. 
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Abstract 
 
Attachment of a glycosylphosphatidylinositol (GPI) moiety is one of several mechanisms for 
membrane anchhoring of proteins. In protozoa, GPI-anchored proteins often constitute the 
most abundant cell-surface proteins and have important roles in defence against the host 
immune system. In Plasmodium falciparum all membrane-associated merozoite surface 
proteins (MSPs) are GPI-anchored. It is not known by which mechanisms and pathways GPI-
anchored proteins are transported from the endoplasmatic reticulum (ER) to the cell surface. 
The GPI anchor is necessary for surface targeting. We investigated whether further essential 
transport signals are present on the protein moiety of a mature GPI-anchored merozoite 
surface protein. In order to identify such signals, we generated a series of transgenic P. 
falciparum parasites expressing Yellow Fluorescent Protein (YFP) flanked by different 
portions of the conserved terminal regions of the merozoite surface protein 2 (MSP2). A 
fluorescent reporter flanked by conserved N- and C-terminal MSP2 sequences was correctly 
trafficked to the plasma membrane in schizonts and merozoites. In contrast, a fluorescent 
reporter only flanked by the MSP2 signal peptide and the GPI anchor signal remained in the 
ER. This suggested the presence of crucial transport signals within the conserved regions of 
MSP2. We further investigated whether the transmembrane domain from apical membrane 
antigen (AMA-1) can mimick a GPI anchor signal when placed at the very C-terminus of a 
fluorescent reporter. Our results do not show whether this reporter was porvided with a GPI 
anchor, however, it was not targeted to the plasma membrane. A further YFP reporter fused 
N-terminally to the AMA-1 transmembrane domain and cytoplasmic tail was correctly 
trafficked to the micronemes, suggesting that the C-terminus of this protein contains 
important transport signals. However, trafficking of this reporter was not efficient. 
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 Introduction 
 
The merozoite is the invasive stage in the erythrocytic cycle of the malaria parasite 
Plasmodium falciparum. A number of merozoite surface proteins (MSPs) have been identified 
and all MSPs directly associated with the parasite plasma membrane are attached by a 
glycosyl-phosphatidyl-inositol (GPI)-anchor. These are MSP1, MSP2, MSP4, MSP5, and 
MSP-10. Functional redundancy among these proteins is unlikely since attempts to disrupt 
these genes were not successful (Cowman et al., 2000). Proteins provided with a GPI anchor 
display an N-terminal signal peptide for entering the secretory pathway and a predicted C-
terminal signal for addition of the lipid anchor. The latter signal consists of a hydrophobic C-
terminus preceded by a short hydrophilic spacer and the actual site of cleavage, the ω-site, 
which is the first of three amino acids with small side chains (Furukawa et al., 1997; 
Kodukula et al., 1993). Cleavage and lipid anchor addition is catalyzed by the GPI-
transamidase complex and takes place at the lumenal side of the endoplasmatic reticulum 
(ER) membrane (Amthauer et al., 1993). 
 
The structure of P. falciparum GPIs is known. The parasite GPIs differ from those of the host 
in that they contain palmitic and myristic acids at C-2 of inositol, and do not contain 
additional phosphoethanolamine substitution in their core glycan structures. The components 
of the GPI biosynthetic pathway have been identified and offer potential drug targets 
(Delorenzi et al., 2002). The purified parasite GPIs can induce tumor necrosis factor  release 
from macrophages (Naik et al. 2000) and several studies have shown that GPI functions as the 
dominant parasite toxin in a malaria infection (Schofield et al., 1993; Schofield et al.,  2002).  
 
In yeast GPI-anchored proteins are transported from the ER to the Golgi apparatus in vesicles 
distinct from those containing non-GPI-anchored proteins (Muniz et al., 2001). This finding 
demonstrated that protein sorting can occur upon exit from the ER. However, it is not known 
how this sorting and the trafficking to the plasma membrane is achieved. Therefore, we aimed 
at identifying putative transport signals present on a mature GPI-anchored merozoite surface 
protein. For our analysis we chose the polymorphic merozoite surface protein 2 (MSP2) that 
is transcribed in late blood stages and localizes to the surface of schizonts and merozoites. 
We hypothesized putative transport signals to be present in the conserved N- or C-terminal 
domains of MSP2. After cleavage of the N-terminal signal peptide and the C-terminal GPI 
anchor signal, 20 amino acids of the N-terminal and 47 amino acids of the C-terminal 
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 conserved domain remain on the mature protein. Due to their sequence conservation it is more 
likely that putative transport signals are located within these terminal regions than in 
polymorphic central domains. To examine this, we made a panel of transgenic parasites 
expressing reporter constructs. These involve enhanced yellow fluorescent protein (eYFP) 
flanked by various portions of the MSP2 conserved terminal domains. 
 
Transmembrane domains resemble GPI anchor signals in that they show a similar 
hydrophobicity. They are usually followed by a hydrophilic tail. We wanted to test whether a 
transmembrane domain of another merozoite-associated protein, apical membrane antigen 1 
(AMA-1), can function as GPI-anchor addition signal when placed at the very C-terminus of a 
reporter construct. To localize our YFP reporter constructs we used live fluorescent 
microscopy and indirect immunofluorescence assays. 
 
 
Material and Methods 
 
Construction of Plasmodium falciparum transfection vectors using Multisite GatewayTM 
recombinational cloning technology. 
Construction of P. falciparum transfection vectors has been difficult since plasmids 
containing large stretches of P. falciparum DNA appear to be unstable in E.coli, presumably 
due to the high A/T content of P. falciparum DNA. We have used Multisite GatewayTM 
cloning for the construction of transfection vectors carrying MSP2-reporter constructs to be 
expressed episomally in Plasmodium falciparum parasites. The MultiSite GatewayTM cloning 
system (Invitrogen, Carlsbad, CA, USA) is generally used when a larger number of similar 
reporter constructs are to be cloned. It allows three different DNA fragments to be combined 
in a single reaction to yield the final expression clone by using mixtures of the λ Integrase 
(Int), Excisionase (Xis), and E.coli Integration Host Factor (IHF) to insure efficient 
homologous recombinations between DNA molecules (PCR products and supercoiled 
plasmids). In addition, it utilizes a negative selection that greatly enhances cloning efficiency. 
 
Construction of entry clones 
A panel of entry clones, depicted in figure 1A, were constructed by recombination of PCR-
products carrying specific att sites for recombination with the appropriate pDONR vectors in 
BP clonase reactions according to the manufacturer’s protocol to generate 5’ entry clones 4/1 
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 (attL4/R1), central entry clones 1/2 (attL1/L2), and 3’ entry clones 2/3 (attR2/L3). The 
primers used for PCR are listed in table 1. Att sites for site-specific recombination with 
DONR vectors are underlined. Msp2-specific sequences to generate 4/1, 1/2, and 2/3 entry 
clones were amplified from the allelic exchange vector pM2F (Wickham, 2003) or from 3D7 
genomic DNA (for the 4/1 entry clone msp2 prom+N-cons*, which carries a full-length msp5 
to msp2 intergenic region and the N-terminal conserved part of msp2 ). Apical membrane 
antigen 1 (ama1)-specific sequences were amplified from 3D7 genomic DNA. The gene for 
enhanced yellow fluorescent protein (eYFP) was amplified from a plasmid carrying the gene 
(Marti et al, 2004). The triple hemagglutinin tag (3xHA) was amplified with primers 
containing attL1 and attL2 sequences from a 3’ entry clone containing the same tag (kindly 
provided by Kylie Mullin, Melbourne University). The 1/2 entry clones FC27central and 
eYFPcentral were generated by directional TOPO cloning into pENTR™/D-TOPO that 
already contains attL1 and attL2 sites. 
 
The generated entry clones are depicted in figure 1A. All 5’ entry clones contain a msp2 
promoter and N-terminal parts of the msp2 gene, consisting of either the msp2 signal peptide 
or the complete conserved 5’ region of the gene. Central entry clones carry the reporters (the 
family-specific part of FC27-type msp2, the enhanced yellow fluorescent protein (eYFP) gene 
without initiating methionine, or a triple hemagglutinin epitope tag). 3’ entry clones again 
carry parts of the gene of interest, (the msp2 3’ conserved region including the GPI-anchor 
addition signal, the msp2 GPI-anchor addition signal only, the ama-1 transmembrane domain 
plus cytoplasmic tail, the ama-1 transmembrane domain only), or a reporter (triple 
hemagglutinin tag). 
 
The BP recombination reactions were transformed into E.coli PMC 103 (ATCC) and plated 
on LB agar containing kanamycin at a concentration of 50 µg/ml. Positive clones were 
identified by restriction digests of mini prep plasmid DNA (QIAGEN, Valencia, CA, USA). 
The correctness of the inserted fragments was checked by sequencing (micromon sequencing 
facility, Monash University, Clayton, Australia). Compared to the sequence in the P. 
falciparum genome data base (www.plasmoDB.org) a 80 bp deletion was found in entry 
clones carrying the msp2 promoter, msp2 prom+N-cons and msp2 prom+SP, around 700 bp 
upstream from the msp2 start codon marked with a Δ in figure 1. According to Wickham and 
co-workers (2003) this region contains a positive regulatory element. A 5’ truncation deleting 
this element led to a drop-off in promoter activity of 45% compared to a truncation retaining 
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 this region. This deletion must have occured during propagation of plasmid pM2F in E.coli. 
Despite an expected drop in promoter activity we continued to work with constructs I to VII 
(including the deletion) since our reporter constructs could be toxic, making it desirable not to 
have full promoter activity. The same constructs carrying the 3D7 full-length msp2 promoter 
and no deletion were also generated (constructs VIII to XIII) (Fig.1C). 
 
Generation of P. falciparum transfection vectors by MultiSite Gateway LR reactions 
The generated entry clones were used in MultiSite Gateway LR reactions together with the P. 
falciparum destination vector pHH-VP-att4/1 (Marti et al. 2004) displayed in figure 1B to 
create expression clones according to the manufacturer’s protocol (Invitrogen). pHH-VP-
att4/1 is a derivative of pHH, containing a human dihydrofolate reductase (hdhfr) selection 
cassette to confer resistance to the antifolate WR99210. The destination vector also contains a 
cassette with a chloramphenicol resistance gene (CamR) and a ccdB killer gene for negative 
selection against non-recombined plasmids in E.coli. The ccdB gene product is a potent 
poison of gyrase. The CamR/ccdB gene cassette is flanked by attR4 and attR1 sites that 
facilitate site-specific recombination with attL4 and attL1 sites present in entry clones. 
Adjacent to the CamR/ccdB cassette, the plasmid contains the P.berghei dhfr-ts 3’untranslated 
region (UTR) that is fused to the reporter construct upon recombination, completing the 
transgene expression cassette. The cassette is separated from the hdhfr selection cassette by 
0.5 kb of telomeric Rep20 repeat for better plasmid segregation (O’Donnell et al., 2002). The 
destination vector carries an ampicillin resistence gene (AmpR) while all entry clones carry a 
kanamycin resistence (KanR). Three entry clones (1x attL4/attR1, 1x attL1/attL2, and 1x 
attR2/attL3) and the destination vector (attR4/attR1) were combined in LR recombination 
reactions according to manufacturer’s protocol. The reactions were extracted with a 
phenol/chloroform mixture, precipitated, and transformed into electrocompetent E.coli 
PMC103 and plated on LB agar plates containing ampicillin at a concentration of 100 µg/ml. 
Positive clones were identified by PCR screening. Plasmid mini preps (QIAGEN, Valencia, 
CA, USA) were analysed by restriciton digests. Plasmid maxi preps (QIAGEN) were made of 
correct clones. The P. falciparum expression plasmids obtained from LR recombination 
reactions are listed in figure 1C. 
 
Parasite culture and transfection 
The cloned line 3D7 of P. falciparum was used for all transfections. Parasites were grown in 
human O+ red blood cells (erythrocyte concentrate from blood bank at Royal Melbourne 
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 Hospital) at 4% hematocrit in RPMI 1640 supplemented with Albumax (GibcoBRL) to a final 
concentration of 0.5% and gassed with 5% CO2 and 0.5% O2 in N2 at 37 °C as described 
previously (Trager and Jensen, 1976). Cultures to be transfected were synchronised by 
treatment with 5% sorbitol 48 hours before transfection. 5ml of a ring-stage culture with at 
least 5% parasitaemia was used per transfection. 80 to 100 µg of maxi prep DNA (QIAGEN) 
was transfected by electroporation with a single pulse of high capacitance (950 µF) and low 
voltage (310V) as described (Wu et al., 1995; Fidock and Wellems, 1997). The antifolate drug 
WR99210 (kindly provided by Jacobs Pharmaceuticals Co. Inc.) was added to the cultures 6 
hours post transfection at a concentration of 5nM to select for parasites expressing human 
dihydrofolate reductase (hdhfr) from episomes. Culture medium was changed daily for the 
first week and every second day thereafter. Fresh red blood cells were added weekly to 
maintain 4% hematocrit until a population of WR99210-resistant parasites was established. 
 
Fluorescence microscopy 
Transfected P. falciparum cultures containing at least 5% schizonts or magnet-purified late 
stages were mounted wet on microscope slides, covered with glass cover-slips and imaged at 
room temperature using a Zeiss Axioscop 2 microscoppe equipped with a PCO SensiCam 
(12-bit) camera and Axiovision 3 software. Captured images were processed using Adobe 
Photoshop (version 7). Prior to microscopy live cells were incubated for 20 minutes at 37°C 
with either DAPI (4',6-diamidino-2-phenylindole) DNA stain to a final concentration of 5 
µg/ml to visualize nuclei, or with ER-TrackerTM Blue-white (molecular probes) to a final 
concentration of 0.25µM to stain the parasite endoplasmatic reticulum. 
 
Indirect immunofluorescence assays were performed on p-formaldehyde/glutaraldehyde-fixed 
infected erythrocytes using a batch protocol as described previously (Tonkin et al., 2004) on 
Methanol/Acetone-fixed blood smears. Antibody reactions were carried out in PBS 
containing 3% BSA for 1 hour at room temperature. As primary antibodies an affinity-
purified rabbit serum against FVO (3D7-type) MSP2 (Wickham et al, 2003) and mouse 
monoclonal antibody 8G10/48 (Epping et al., 1988) specific for FC27-type MSP2 were used 
at a dilution of 1:20 or 1:32, respectively. A mouse monoclonal antibody against GFP (Roche 
diagnostics) was used at a dilution of 1:50. Secondary antibodies used were Alexa Fluor 568-
conjugated anti-rabbit IgG and Alexa Fluor 488-conjugated anti-mouse IgG (Molecular 
probes) diluted 1:500. The cells were mounted on glass slides with Vectashield mounting 
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 medium H-1000 (Vector Laboratories, Burlingame, CA, USA) containing DAPI at a 
concentration of 1 µg/ml. 
 
Purification of late stage parasites using MACS columns 
50ml of P. falciparum cultures containing at least 5% late trophozoites and schizonts were 
centrifuged at 1200g for 5 minutes and the cell pellet was resuspended in 10ml wash buffer 
(Hepes-buffered RPMI 1640 with 0.2% NaHCO3). The suspension was loaded on a MACS 
CS column equilibrated with 20ml wash buffer attached to a varioMACS magnet (Miltenyi 
Biotech, Germany). The column was washed with 20ml wash buffer followed by 10ml of 
culture medium. The column was then removed from the magnet and bound infected 
erythrocytes eluted with 12ml culture medium. 
 
FACS sorting of YFP-expressing Plasmodium falciparum parasites 
MACS-purified late stages were resuspended to 4x107 cells per ml in culture medium and 
sorted according to presence or absence of green fluorescence (YFP) using a Moflo 
fluorescence-activated cell sorter (FACS) at a speed of 16’000 cells per second. Populations 
of fluorescence positive and negative cells were collected in culture medium. Fluorescence 
positive cells were put back to culture in a 2 ml dish containing fresh red blood cells (4% 
hematocrit) and sorting repeated upon establishment of the culture. Alternatively, sorted cells 
were spun down and resuspended in 2x Laemmli buffer for SDS-PAGE and western blotting. 
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 Results 
 
We used Gateway™ recombinational cloning to generate the P. falciparum transfection 
constructs I to XIII shown in figure 1C (The amino acid sequences of the reporter proteins are 
shown in supplementary figure S6 A to D). These constructs are designed to be maintained 
episomally in the parasite nuclei and to express fluorescent or other reporter genes. All 
reporters are driven by the msp2 promoter to insure correctly timed expression at the schizont 
stage. A schizont-specific promoter is important since inappropriate timing of expression can 
interfere with correct trafficking (Rug et al., 2004). Expression of reporter genes in the first 
set of plasmid constructs (I to VII) was driven by a msp2 promoter with an 80 bp deletion  
~700 bp upstream of the start codon. The deleted region was shown to contain a positive 
promoter element (Wickham et al., 2003) and transgene expression in these transfectants was 
generally infrequent. This prompted us to re-clone some of the constructs with a full-length 
msp2 promoter. 
 
All constructs (I to XIII) contain the hydrophobic N-terminal signal peptide of MSP2 for 
entry to the endoplasmatic reticulum (von Heijne, G. 1990). In P. falciparum bloodstages, a 
classical signal sequence in the absence of other transport signals directs transport of a 
fluorescent reporter to the parasitophorous vacuole (Waller et al., 2000; Wickham et al., 2001; 
Adisa et al., 2003). We aimed at identifying putative signals on GPI-linked merozoite surface 
protein 2 (MSP2) necessary for transport to the merozoite surface. For this we looked at the 
localisation of reporter constructs flanked by different proportions of the MSP2 conserved 
terminal domains. 
 
Double immuno-fluorescence reveals transgenic FC27-type MSP2 expressed at the 
merozoite surface. As control for the design of our reporter constructs we transfected 3D7 
parasites with plasmid construct (I) that expresses a reconstituted full-length FC27-type 
MSP2 (clone D10). Thus, transgenic parasites were expected to express both, a 3D7 
endogenous and a FC27 transgenic MSP2 at the merozoite surface. This vector was 
constructed with the MultiSite Gateway recombination system, using the same 5’ and 3’ entry 
clones as for other reporter constructs. The resulting recombinant FC27-type protein differs 
from its parental, the MSP2 of clone D10, in some additional amino acids introduced by att 
sites used for homologous recombination. Fifteen foreign amino acids were introduced before 
and after the FC27 family-specific domain (supplementary figure S6A). 
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 Indirect immuno-fluorescence microscopy on the 3D7 parental strain was carried out with an 
antibody against 3D7 MSP2 to show parasite surface localization in schizonts and free 
merozoites (Fig. 2A). Double immuno-fluorescence on transfectant parasites (construct I) 
with MSP2 family-specific antibodies revealed that the introduced FC27-type MSP2 co-
localizes with the endogenous 3D7 MSP2 at the merozoite surface (Fig. 2B). 
 
YFP fused to MSP2 conserved terminal domains localizes to the merozoite surface. We 
conducted live fluorescence microscopy of parasites transfected with YFP reporter constructs. 
Constructs II and IX were designed to yield a GPI-anchored YFP flanked on each side by the 
conserved terminal domains of MSP2 (Fig. 1C). The only difference between these two 
constructs lay in the msp2 promoter driving expression of the transgene. Construct IX carried 
a full-length promoter while construct II had a deletion of 80 basepairs  ~700 bases upstream 
from the start codon. The protein expressed by construct II and IX was expected to localize to 
the merozoite surface since it contains all the conserved MSP2 sequences that are most likely 
to contain transport signals. We did live fluorescence microscopy on transfectant cultures II 
and IX. Late trophozoites, schizonts, and merozoites from transfectant IX are shown in figure 
3. YFP fluorescencee appeared in unsegmented parasites with multiple nuclei (Fig. 3A) and 
localized to the confines of the parasites, indicative of the parasite plasma membrane. In later 
stages, where the formation of merozoites has started or been completed (Fig. 3B to E), the 
fluorescence pattern matched that of a merozoite surface staining by MSP2-specific 
antibodies (see Fig. 2B). In ruptured schizonts the fluorescence remains associated with 
individual merozoites, ruling out the parasitophorous vaculole as a possible localization for 
the YFP reporter construct. We also conducted fluorescence microscopy on transfectant 
parasites labelled with ER-tracker to show that the reporter protein is not retained in the ER 
(Fig. 3 F and G). Construct (XI) that consists of a triple haemagglutinin (HA) tag flanked by 
both conserved terminal MSP2 regions was also expressed at the merozoite surface (data not 
shown). 
 
‘Naked’ GPI-anchored YFP is not transported to the merozoite surface. Expression of 
the reporter constructs (III) and (IV) was too low and infrequent to allow a reliable 
localisation for the fluorescence signal. Construct (V) was expressed at slightly higher rates 
(>0.1%) and three consecutive FACS sortings for green fluorescence enriched for parasites 
expressing the YFP reporter by  ~50 fold. YFP reporter in construct (V) is only flanked by 
MSP2 sequences that constitute known signals, but both signals are absent from the mature 
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 protein. These are the N-terminal signal peptide for entry to the endoplasmatic reticulum (ER) 
and the C-terminal signal for addition of the GPI-anchor. Thus, no MSP2-specific sequences 
were present in the mature reporter protein. We found that in mature segmenters and free 
merozoites the fluorescence was not associated with the merozoite surface (Fig. 4). The 
location was perinuclear (Fig. 4A), indicative of ER localization (Leann Tilley, personal 
communication). Van Dooren and co-workers followed ER morphology over the erythrocytic 
cycle and described a pattern similar to the bottom pannel of figure 4B for segmenters (van 
Dooren et al., 2005). Labelling of parasites with ER tracker showed a partial colocalization of 
the YFP fluorescence with ER (Fig. 4C). Therefore we assume that the ER tracker we used 
stained other membranes in addition to the ER. 
 
Enrichment of fluorescent parasites using fluorescence-activated cell sorting allowed 
colocalization studies with MSP2 as a merozoite surface marker. Figure 4D shows schizonts 
labelled with anti-GFP and anti-3D7-type MSP2 antibodies. We found that YFP fluorescence 
did not colocalize with MSP2. The schizonts depicted are not fully segmented and the YFP 
fluorescence is surrounded by the MSP2 fluorescence.  
 
These data indicate that GPI-anchored YFP is not expressed at the merozoite surface nor is it 
secreted into the parasitophorous vacuole. It is probably retained at some point along the 
secretory pathway. This suggests that crucial transport signals are absent from the reporter 
and that GPI-addition alone is not sufficient for surface targeting. 
 
The AMA-1 transmembrane domain and cytoplasmic tail are sufficient for reporter 
transport to the micronemes. Transmembrane domains and GPI-anchor addition signals are 
similar in that they basically consist of a hydrophobic stretch of amino acids. GPI-signals are 
located at the extreme C-terminus while transmembrane domains are usually followed by a 
hydrophilic cytoplasmic tail. 
 
The apical membrane antigen 1 (AMA-1) is a micronemal protein (Bannister et al., 2003) that 
is secreted and distributed over the merozoite surface from the apical tip in mature merozoites 
and during invasion. It has been shown before for EBA-175, another micronemal 
transmembrane portein, that the cytoplasmic domain is not essential for correct trafficking 
(Gilberger et al., 2003). Our reporter construct (VI) has an N-terminal conserved part of 
MSP2 including the signal peptide followed by YFP and the AMA-1 C-terminal part 
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 including the transmembrane domain (TM) and the cytoplasmic tail. Live fluorescence 
microscopy of schizonts showed a pattern of bright spots that appeared to be associated with 
the apical end of merozoites (Fig. 5A). This suggested that the AMA-1 C-terminus directed 
the YFP reporter to the micronemes. A weak fluorescence underlied the bright spots in figure 
5A, This pattern was similar to that observed in parasites transfected with construct (V). The 
weak background fluorescence probably represents a pool of immature or not properly 
trafficked reporter in the ER. 
 
We were interested, whether truncation of the C-terminus of a transmembrane protein 
downstream of the transmembrane domain would result in GPI-anchor addition. If this 
addition was achieved, the transmembrane domain would act as GPI anchor addition signal. 
Construct (VII) consists of the MSP2 signal peptide followed by YFP and the AMA-1 
transmembrane domain. Fluorescence microscopy of schizonts (Fig. 5B) showed a picture 
similar to that seen for the YFP-GPI construct (V). Micronemal targeting was abolished and 
fluorescence was associated with the ER. Whether the reporter constructs with the TM were 
linked to a GPI-anchor remains to be examined. The Big-PI GPI anchor signal prediction 
software does not predict a potential ω-site for anchor addition in this reporter construct 
(Eisenhaber et al., 1999; http://mendel.imp.univie.ac.at/sat/gpi/gpi_server.html). 
 
Low and infrequent transgene expression. We found that our reporter genes were generally 
expressed at very low frequencies (~0.1%). Our first set of transfection constructs (I to VII) 
had a deletion in the msp2 promoter driving expression of the reporter constructs that may 
have been responsible for the infrequent expression. Alternatively,  toxicity of the YFP 
reporter proteins may also have impaired growth. We also observed infrequent expression of 
construct I, which is a reconstitution of an FC27-type MSP2. This contrasted the findings of 
Wickham and co-workers who created a transgenic parasite line co-expressing MSP2 of both 
allelic families at comparable levels (Wickham et al., 2003). That led us to suppose that 
episomal expression of our transgenes might be abolished due to the 80 bp promoter deletion 
and that the occasional parasites expressing the reporter gene could have integrated the 
plasmid into the chromosomal msp2 locus. 
 
Aiming at enriching for parasites expressing the transgene and at analysing endogenous 
MSP2 expression in these parasites, we sorted cultures transfected with constructs (II) and (V) 
for YFP fluorescence in a fluorescence-activated cell-sorter. The first sort yielded 30’000 
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 YFP-positive schizonts for culture (II) and 70’000 for culture (V). The frequency of 
fluorescent parasites were 0.1% and 0.17%, respectively. 30’000 parasites each were put back 
in a culture dish with fresh red blood cells. A culture with 1% parasitaemia was established 
after two weeks for the transfectants carrying the construct with the YFP-GPI reporter (V). 
These parasites showed normal growth rates thereafter and were subjected to a second round 
of sorting. The YFP-positive parasites represented 2.3% of the population at the time of the 
second sorting and 9% one week after the a third sorting. From the sorted parasites transfected 
with the YFP construct (II) no culture could be re-established after two months of culturing 
although the size of the inoculum was the same as for (V). 
 
For transfectant (V) MSP2 expression was analysed by western blot directly after FACS 
sorting. No reduction in endogenous MSP2 expression was found (data not shown). This 
indicates that the chromosomal msp2 locus was not targeted by the reporter plasmid. 
 
To further investigate whether the 80 bp promoter deletion in our first set of constructs led to 
infrequent expression of the reporter genes, we re-cloned some of the constructs with a full-
length MSP2 promoter (constructs VIII, IX, X) (Fig. 1C). In addition, we made new 
constructs with a triple heamagglutinin (3xHA) tag as a reporter instead of YFP (constructs 
XI and XII). A control construct with both reporters (YFP followed by 3xHA) without C-
terminal signal was also constructed. But from these six new transfectants only transfectants 
(IX) and (XI) expressed the transgene at detectable levels.  
We conclude that the promoter deletion in the first set of constructs was not the only reason 
for the infrequent transgene expression since the use of the full-length msp2 promoter does 
not guarantee expression of similar reporter genes. The finding that drug resistant cultures 
were established but did barely or not express the transgenes can be explained by plasmid 
instability due to AT-rich P. falciparum DNA stretches. At the time of transfection, a small 
and undetectable proportion of the plasmid preparation may already have contained deletions 
due to instability of our large constructs in E. coli. If a parasite is transformed with such a 
plasmid that does not allow reporter gene expression, it has an overwhelming advantage over 
those forced to express an unfavourable gene. 
 
The triple haemagglutinin (HA) tag flanked by both conserved terminal MSP2 regions (XI) 
was expressed at the merozoite surface (data not shown). 
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 Discussion 
 
Localization of YFP reporter constructs 
We made a series of P. falciparum mutants designed to express different YFP-reporter 
constructs in order to identify putative transport signals on a mature GPI-anchored merozoite 
surface protein. The YFP reporter was flanked by different portions of the MSP2 N- and C-
terminal regions including sequences that represent known signals for entry into the secretory 
pathway and for GPI-anchor attachment. In addition, we included sequences of the conserved 
parts of MSP2 that were most likely to contain trafficking signals because these domains are 
strictly conserved in all alleles of the polymorphic MSP2.  
 
The YFP reporter flanked by the conserved N- and C-terminal regions of MSP2 (constructs II 
and IX) was expressed at the merozoite surface as judged by the fluorescence pattern in 
schizonts. To our knowledge this is the first report on a GPI-linked surface-expressed 
fluorescent reporter in apicomplexan parasites. Our data show that a GPI-linked fluorescent 
reporter can be correctly trafficked to the merozoite surface. YFP trafficking to the surface 
was uncertain since it was shown repeatedly that a fluorescent reporter can interfere with 
trafficking of the fusion protein in P. falciparum (Adisa et al., 2003; Knuepfer et al., 2005).  
 
In contrast, a YFP reporter flanked only by the two MSP2 signal sequences that are cleaved in 
the ER (V), was clearly not trafficked to the merozoite surface. The perinuclear fluorescence 
pattern in merozoites indicated that the fluorescent protein remained in the ER. This 
suggested that transport signals essential for targeting to the surface were missing. Such 
signals might be provided by the MSP2 conserved regions in construct IX, that enabled 
transport of the fusion protein to the plasma membrane. The difference between the two 
constructs (V and IX) consists of 23 amino acids from the conserved N-terminal domain of 
MSP2 and 45 amino acids from the conserved C-terminal domain of MSP2. In order to search 
for a signal in these MSP2 regions, we performed sequence alignments with other GPI-
anchored merozoite surface proteins (MSP1, MSP4, MSP5, MSP10) but they did not reveal a 
conserved motif. This is not surprising since the GPI-anchor addition signal among these 
proteins is also not conserved on amino acid sequence level. The lack of a common targeting 
signal in our alignment may also indicate that different merozoite surface proteins use 
different transport mechanisms. One possibility is the use of specific escorter proteins. Our 
data do not allow to assign the putative transport signal to either of the conserved MSP2 
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 domains since localisation of reporter constructs (III) and (IV) was not achieved (Fig. 1 C) 
due to infrequent reporter expression. However, the need of a transport signal in addition to 
the GPI-anchor signal in MSP2 contradicts what is known from mammalian proteins. 
Experiments involving a C-terminal fusion of a GPI-anchor signal to an otherwise secreted 
protein led to its insertion into the plasma membrane (Caras et al., 1989). Furthermore, a null 
mutant for the major GPI-anchored surface glycoproteins of procyclic forms of African 
trypanosomes was found to express high levels of free GPI anchors at the surface (Vassella et 
al., 2003). This also suggests that the GPI anchor lead to its association with transport vesicles 
that are destined to the plasma membrane. 
 
If it holds true as a general rule that the GPI anchor is sufficient as a signal for plasma 
membrane targeting, the question arises whether our reporter construct (V), consisting of YFP 
flanked by both signals but not targeted to the surface, was provided with a GPI anchor. The 
MSP2 GPI-anchor signal in construct (V) included three amino acids N-terminal to the only 
predicted GPI anchor addition site (Big-PI predictor, Eisenhaber et al., 1999). The proximity 
of the YFP to the cleavage site may influence the efficiency of anchor addition. Transport of 
proteins with an uncleaved GPI anchor signal was found to be blocked between the ER-Golgi 
intermediate compartment and the Golgi stacks (Field et al., 1994). However, it has not been 
reported that cleavage and GPI anchor addition were inhibited by the amino acid composition 
of sequences N-terminal to the cleavage site. Furthermore, in our reporter constructs the YFP 
is separated from the C-terminal portion of MSP2 by a spacer of 15 amino acids that was 
introduced by GATEWAY cloning. Therefore it is unlikely that construct (V) is not GPI-
linked. 
 
In agreement with our results, a green fluorescent protein (GFP) fusion with the 
corresponding MSP1 signals (signal peptide and GPI anchor signal) and a spacer of 10 
alanine residues between GFP and the GPI anchor signal was also trapped in the ER 
(Meissner et al., 2005; Paul Gilson, personal communication). In conclusion, to prove that 
transport signals were missing from our construct (V) it remains to be shown that the reporter 
protein was provided with a GPI anchor and that this was not sufficient for plasma membrane 
targeting. 
 
The finding that the AMA-1 C-terminal part (transmembrane domain plus cytoplasmic tail) 
appears to be sufficient to target a YFP reporter to the micronemes was surprising. Gilberger 
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 and co-workers found that a truncation of the cytoplasmic tail of EBA-175, another 
micronemal type 1 transmembrane protein, was trafficked correctly. This suggested that 
sorting signals lie in the domain facing the microneme lumen or in the transmembrane domain 
(Gilberger et al., 2003). We didn’t incorporate any sequences upstream of the transmembrane 
domain and still got correct trafficking (construct VI). This suggests that the signal for 
micronemal targeting lies within the transmembrane domain. However, our results obtained 
with construct (VII) did not support this suggestion. When we placed the AMA-1 
transmembrane domain at the very C-terminus trafficking to the micronemes was abolished. 
The fluorescence pattern seen in parasites transfected with construct (VII) is typical for ER. 
This could mean that the YFP in this case interferes with correct trafficking or that the AMA1 
cytoplasmic domain is not dispensable in contrast to the situation in EBA-175. 
 
We also investigated whether the AMA-1 transmembrane domain can trigger GPI anchor 
addition. The big-PI predictor software (Eisenhaber et al., 1999) did not find an appropriate 
GPI-addition site in this construct. Our results indicated that the reporter remained in the ER. 
This would be expected if no anchor were added. Proteins with an uncleaved GPI anchor 
signal (i.e. a hydrophobic C-terminus) were shown not to be secreted (Field et al., 1994). To 
confirm that a C-terminal transmembrane domain does not act as a GPI anchor signal, it needs 
to be shown in our transfectant, that the reporter found in the ER found in the ER indeed has 
no GPI anchor attached. 
 
Lack of efficient expression of reporter constructs 
All reporters from the first set of transfection constructs were expressed at low frequencies 
(~0.1%). The question arose whether the low frequencies are due to the 80 bp deletion in the 
msp2 promoter of this first set of constructs. This would be a likely explanation since a 
positive promoter element was mapped to the deleted region (Wickham et al., 2003). A 5’ 
truncation to 770 base pairs upstream of the ATG led to 60% of full-length promoter activity. 
Truncation of another 200 base pairs led to a further drop of activity to 15% (Wickham et al., 
2003). Our deletion may have removed a positive regulatory element, thus leading to down 
regulation. However, it was not expected that promoter activity was abolished completely. 
The promoter element deleted in our constructs represents a conserved tandem repeat with an 
underlying 11 nucleotide repeat unit (TAAATATAATA)7. 
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 The occasional parasites that were able to express the reporter gene probably differed 
genetically from the bulk of non-expressing ones. They could have integrated the plasmid into 
the msp2 locus. Recombination within the msp2 promoter, the only matching target sequence 
on our plasmid constructs, can lead to a promoter swap providing the YFP reporter with the 
endogenous promoter that allows expression. In exchange, the endogenous msp2 gene will 
aquire the promoter with the deletion and might not be expressed to detectable levels. 
Analysis of FACS sorted transfectant (V) did not support this hypothesis since the levels of 
endogenous MSP2 was unchanged. It would have been surprising to find an MSP2 knock-
down since MSP2 is an abundant component of the merozoite surface and is probably 
essential (Cowman et al., 2000). 
 
Expression of the reporter constructs with the full-length msp2 promoter showed that the 
deletion in the promoter was not responsible for infrequent expression. As a general rule 
expression frequencies were not higher for reporter genes driven by the full-length promoter. 
We also designed and transfected some new constructs using a heamagglutinin (HA) epitope 
tag instead of the fluorescent reporter (Figure 1C). Drug resistant populations were readily 
established for five of the six transfectants (VIII, X, XI, XII, and XIII). However, only 
transfectant (XI) (N-cons-3xHA-C-cons) expressed its transgene at detectable levels. This 
also indicated that the promoter deletion in the first set of constructs was not the sole reason 
for the infrequent expression. 
 
High level expression of GPI-anchored YFP at the merozoite surface is toxic. At first, no 
drug resistant population was established for the culture transfected with construct (IX), 
which is a repetition of construct (II) with the full-length promoter. Occasionally, some 
parasites could be detected in Giemsa-stained blood smears but the parasitaemia did not 
increase over several weeks. When we omitted the drug pressure, the culture reached 1% 
parasitemia within two weeks, indicating that the parasites had been forced under selection to 
express a YFP-reporter that was toxic to them. Without drug pressure, the plasmid copy 
number may have decreased, thus also reducing the level of transgene expression. It is 
unlikely that the plasmid was lost completely during this short removal of drug since it 
contains a Rep20 telomeric repeat sequence that was shown to improve plasmid segregation 
(O’Donnell et al., 2002). When the drug was re-applied, no parasite dying was observed, 
supporting the idea that most parasites still contained plasmid. However, it was surprising to 
find that ~10% of the parasites expressed the fluorescent reporter to a level detectable with 
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 fluorescence microscopy. The parasites now grew at normal growth rates at a drug 
concentration they had not grown at initially. It is therefore probable that short-term removal 
of the drug led to reduction of plasmid copy number and thus selected for parasites that 
express the reporter at lower levels, no more reaching toxic concentrations. 
 
Our attempts to enrich transfectant culture (II) (expressing the same reporter gene as IX) for 
YFP fluorescence by FACS sorting had also indicated toxicity of the reporter. No culture was 
established from the sorted culture in contrast to transfectant (V). This supports the idea that 
expression of this particular reporter construct at high levels may be toxic. 
 
In conclusion, we have shown that a YFP reporter flanked by the conserved terminal domains 
of MSP2 is expressed at the surface of merozoites. Its transport to the plasma membrane is 
mediated by MSP2 sequences present on the mature protein since a reporter lacking these 
sequences and only containing the N-terminal signal peptide and the GPI anchor signal does 
not show surface localisation. This implies that surface transport of endogenous MSP2 also 
depends on sequences present on the mature protein and that addition of the GPI anchor is not 
sufficient for correct targeting. The sequence motif necessary for surface targeting remains to 
be identified. Furthermore it remains to be shown if trafficking of other GPI-anchored 
merozoite surface proteins also relies on sequence motifs present on the processed molecule. 
This could lead to identification of a conserved motif. 
 
In this work a we have established a transgenic parasite that expresses a GPI-anchored YFP 
reporter flanked by the conserved terminal domains of MSP2 at the merozoite surface. This 
parasite may be a valuable tool for analysing the function of MSP2. 
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 Figures 
 
Fig. 1. Schematic representation of P. falciparum Gateway™ transfection plasmids. 
Figure 1A shows all generated entry clones. The plasmids contain a kanamycin resistance 
gene and att sites for site-specific recombination. Att L4 from 5’ entry clones recombines with 
att R4 on the destination vector shown in 1B, att R1 recombines with att L1 from a central 
entry clone, att L2 of central entry clones recombines with att R2 of a 3’ entry clone and att 
L3 again with the destination vector in an LR reaction. Figure 1C shows the P. falciparum 
expression constructs gained from Gateway recombinational cloning. The red Δ marks the 80 
base pair deletion in the msp2 promoter. 
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 Fig. 2. Immunofluorescence microscopy of MSP2 in 3D7 wild-type and transfected 
parasites. (A) 3D7 parasites were labelled with a 3D7-type-specific anti-MSP2 rabbit serum 
followed by Alexa 568-conjugated anti-rabbit IgG to show parasite surface staining in 
schizonts (upper panel) and free merozoites (lower panel). (B) Double staining of a schizont 
from a culture transfected with construct (I) with 3D7-type-specific anti-MSP2 rabbit serum 
and an FC27-type-specific anti-MSP2 mouse monoclonal antibody followed by Alexa 488-
conjugated anti-rabbit IgG and Alexa 568-conjugated anti-mouse IgG. The left panels show 
nuclear staining with DAPI. Merge 1 in (A) is an overlay of blue and red fluorescence 
channels, merge 1 in (B) is an overlay of green and red fluorescence channels. 
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 Fig. 3. Live fluorescence microscopy of transfectant IX. 3D7 parasites transfected with 
construct IX expressing YFP reporter flanked by the conserved terminal domains of MSP2 
are shown. (A) late trophozoite. (B to D) Schizonts of increasing maturity. (E) ruptured 
schizont with free merozoites. (F) late trophozoite. (G) Schizont. YFP fluorescence is shown 
in green (first column). Live cultures were stained with DAPI to visualize nuclei (A to E, 
blue), or ER-tracker (F and G, red) (second column). Merge 1 is an overlay of the green and 
blue fluorescence channel (A to E) or the green and red fluorescence channel (F and G). 
Merge 2 schows an overlay of the bright field image and the green fluorescence channel. 
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 Fig. 4. Fluorescence microscopy of parasites transfected with construct V. (A to C) Live 
fluorescence microscopy of late stages. (A) cultures were treated with DAPI to visualize 
nuclei (blue): segmenter with ruptured parasitophorous vaculolar membrane, upper panel, and 
free merozoites (lower panel). (B) YFP fluorescence in two segmenters. (C) Cultures were 
treated with ER tracker. YFP fluorescence is shown in green and ER tracker staining in red. 
(D) Indirect immunofluorescence double labelling on methanol-fixed schizonts using a mouse 
monoclonal antibody against GFP followed by an Alexa 488-conjugated anti-mouse IgG 
antibody (green) and anti-MSP2 rabbit serum followed by a Alexa 568-conjugated anti-rabbit 
IgG antibody (red). 
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 Fig. 5. Live fluorescence microscopy of parasites expressing YFP reporters with AMA-1 
C-terminal domains. YFP fluorescence is shown in a segmenter of transfectant VI (A). 
White arrowheads indicate apical organelles that appear dark in the bright field image. (B) 
YFP fluorescence in a segmenter of transfectant VII. YFP autofluorescence is shown. 
Corresponding reporter constructs are represented schematically. 
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 7. General Discussion and Conclusions 
 
Malaria is still one of the top ranking causes of morbidity and death in tropical countries. Per 
year, 500 million people become infected and 1 to 2 millions die, the majority of deaths 
occurring in children under the age of 5 and caused by Plasmodium falciparum. A vaccine 
would be one of the most cost-effective interventions, but is still not available. The reasons 
for this are mainly the complex life cycle of the parasite, its antigenic diversity and variation, 
the incomplete knowledge of the immune responses it induces, and of factors determining the 
outcome of an infection. However, there are reasons to believe that development of an 
effective vaccine is feasible. 1) Transient sterile immunity was demonstrated by repeated 
vaccination with attenuated sporozoites (Clyde et al., 1973). 2) Continuous natural exposure 
leads to development of a clinical immunity associated with high antibody titers against major 
surface molecules of the merozoite stage, however, immunity is never sterile. 3) It is well 
established that anti-parasite antibodies are important in controlling blood stage parasite 
growth. Passive transfer of immunoglobulin fractions from immune donors can protect naïve 
individuals from clinical malaria (Cohen et al., 1961; McGregor et al., 1963; Cohen and 
Butcher, 1970). Furthermore, antibodies specific to antigens of the merozoite stage can inhibit 
parasite growth in vitro by directly blocking important invasion molecules (Epping et al., 
1988; Ahlborg et al., 1993; O’Donnell et al., 2001; Moreno et al., 2001; Müller et al., 2003) 
or by interaction with blood monocytes via FC-gammaII receptors inducing killing of intra-
erythrocytic parasites (Khusmith and Druilhe, 1983; Bouharoun-Tayoun et al., 1990; 
Bouharoun-Tayoun et al., 1995; Oeuvray et al., 1994; Singh et al., 2004; Theisen et al., 2000) 
In addition to antibody responses and the required T-cell help, cell-mediated immunity is 
probably also important in controlling blood stage parasites, however, its regulation is poorly 
understood. It is known from animal models that CD4+ T-cells can limit parasite growth in 
the absence of B-cells (van der Heyde HC et al., 1994). Gamma delta T-cells were shown to 
target extracellular merozoites (Elloso et al., 1994). High parasite densities can lead to 
apoptosis of effector and helper CD4+ T cells as well as antibody-producing B cells. These 
regulatory mechanisms may limit harmful effects on host tissues but also result in ineffective 
antiparasite immunity (reviewed in Good et al., 2005)  
 
Although irradiated sporozoites proved to be an effective vaccine, such a whole organism 
approach is not practical, hindered by technical difficulties to produce large amounts of 
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 antigen. Thus, research has been focussed mainly on the development of recombinant subunit 
vaccines during the last three decades. 
 
Three stages of the parasite, pre-erythrocytic, blood stages, and sexual stages of the parasite 
can be targeted by subunit vaccines. An anti-sporozoite and anti-hepatocytic stage vaccine 
would ideally lead to sterile immunity. The disadvantage of such a vaccine is that 
development of natural immunity would be prevented (Reeder, 2001). Sexual stage vaccines 
aim at blocking the transmission to the mosquito. The benefit of such a vaccine is for the 
community, not for the vaccinated individual. The aim of vaccines against the blood stages is 
primarily to reduce the parasite load and hence clinical symptoms and complications. It is 
hoped that such vaccines also accelerate the acquisition of natural immunity. 
 
The only pure blood stage vaccine tested in the field to date was Combination B. Combination 
B is a three component vaccine consisting of an N-terminal fragment of merozoite surface 
protein 1 (MSP1), the full-length MSP2 from strain 3D7, and the ring-infected erythrocyte 
surface antigen (RESA). Combination B showed an efficacy of 62% in reduction of parasite 
density in Papua New Guinean children aged 5 to 9 years. Since a selecting effect on 
breakthrough parasites was observed, favouring genotypes carrying an MSP2 of the alternate 
allelic family, it was suggested that the MSP2 component of the vaccine had some protective 
effect against parasites carrying a 3D7-type MSP2 allele (Genton et al., 2002). Humoral and 
cellular responses to the individual vaccine components were analysed. Antibody titres were 
increased to all three antigens, while only the MSP1 component elicited a significant T-cell 
response (Genton et al., 2002; Genton et al., 2003).  
 
We have addressed the question, which domains of the 3D7-MSP2 vaccine molecule in 
Combination B were effective in reducing parasite density. We therefore analysed the 
Combination B-induced antibody response to conserved, repetitive, and dimorphic domains of 
MSP2 (chapter 2). The antibody titres against individual MSP2 domains of the vaccine 
molecule were determined in vaccinees and placebo recipients, thus providing a measure of 
immunogenicity of each domain. The key finding was that the elicited response was 
exclusively directed against strain- and family-specific domains. The vaccine increased 
antibody titres to the Gly-Gly-Ser-Ala (GGSA) repeat by 3-fold and those against the non-
repetitive family-specific part by almost 5-fold. The identified targets of the response to the 
3D7-MSP2 vaccine molecule highlights the problems when using polymorphic antigens as 
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 vaccines. The elicited response was strain-specific. However, an ideal malaria vaccine would 
confer strain-transcending protection. To reach this, the vaccine molecule must either consist 
of conserved epitopes or several variants of the antigen must be combined. The conserved 
parts of MSP2 were shown not to be immunogenic in the Combination B trial. This result is 
consistent with low antibody titres found in naturally exposed individuals (Lawrence et al., 
2000; Metzger et al., 2003; Weisman et al., 2001). However, inclusion of these domains in 
future MSP2-based vaccines should be considered since they were shown to contain T-cell 
epitopes in mice (Rzepczyk et al., 1992). Also, minor changes in the amino acid sequence 
might improve immunogenicity without changing the antigenic properties. This has been 
demonstrated for peptides from conserved MSP1-19 sequences (Torres et al., 2003; Espejo et 
al., 2004). 
 
The vaccine effect of Combination B was imperfect. Vaccination did not entirely protect 
against breakthrough infections with parasites carrying a 3D7-type MSP2. Genotyping of all 
blood samples of the Combination B trial had shown reduced prevalence of 3D7-type 
parasites in vaccinees. We have aimed at characterizing the selective effect on sequence level 
(chapter 3). We sequenced all 3D7-type msp2 alleles detected in the trial. Alleles occurring in 
vaccine recipients were no different from those in placebo recipients. A phylogenetic analysis 
showed no clustering of alleles from breakthrough infections in vaccinees. This argues against 
a strain-specific protective response but in favour of family-specific protection. This indicates 
that conserved stretches within the family-specific part were most likely to have contributed 
to protection. 
 
Repetitive domains in Plasmodium antigens are generally immunodominant and were 
proposed to function as smoke screens in that they elicit a massive, non-protective antibody 
response distracting the immune system from mounting a response to adjacent protective 
epitopes (Anders, 1986; Schofield, 1991). These anti-repeat responses may result from T-cell-
independent B-cell activation by crosslinking of surface immunoglobulin and would therefore 
be short-lived and of low affinity. Parasites carrying MSP2 alleles containing the 3D7 repeat 
sequence GGSA were present in five children vaccinated with Combination B. These children 
had consistently low titre antibodies to the (GGSA)5 repeat of the vaccine molecule and 
vaccination did not considerably increase these titres. It remains open whether they would 
have been protected against these particular genotypes if a high titre anti-repeat response had 
been induced. However, it became evident that the anti-repeat responses to Combination B 
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 varied considerably in their magnitude between individual vaccinees. This indicates that anti-
repeat responses may be restricted in some individuals. 
 
Apart from choosing appropriate antigens to confer a strain-transcending protection, a very 
important feature of an effective malaria vaccine is the induction of a persistent protection. It 
is known that anti-parasite antibody levels in naturally exposed indiviuals drop rapidly in the 
absence of natural challenge (Cavanagh et al., 1998; Giha et al., 1999; Genton et al., 2000). 
The drop of antibody levels varies considerably depending on the antigen. MSP2 antibody 
titres were found to be high but also to drop rapidly without exposure. This can be due to the 
fact, that MSP2-specific antibodies are predominantly of the short-lived IgG3 subclass. This 
indicates a defect in IgG subclass switching to the more durable IgG1 but also a defect in 
generating specific memory B-cells as it has been proposed for some malarial antigens 
(Dorfman et al., 2005). It remains open whether the unusual subclass distribution of MSP2-
specific antibodies is beneficial or detrimental to the host. IgG3 has been implicated in 
antibody-dependent cellular inhibition, a proposed effector mechanism of antibodies targeted 
to merozoites (Bouharoun-Tayoun et al., 1992; Tebo et al., 2001). However, since heavy-
chain switching and the generation of memory cells are largely dependent on the antigen, it 
will be difficult to produce an MSP2-based malaria vaccine giving long term protection.  
Nevertheless, in infants and young children, even a vaccine inducing short-term, partial 
protection may be a valuable measure to reduce parasite densities and concomitantly severe 
disease. 
 
It was shown that MSP2 forms amyloid-like fibrils in vitro and it was proposed that these 
fibrils are also formed on the surface of merozoites (Adda et al., 2004). Through fibril 
formation, individual MSP2 molecules would probably be placed in very close proximity to 
eachother and display a parallel and thus repetitive structure. It is known that densely packed 
repetitive and highly ordered viral epitopes are potent inducers of T-cell-independent B-cell 
responses (Bachmann et al., 1995; Jegerlehner et al., 2002). Similarly, antigen organization on 
the surface of Plasmodium merozoites could influence induction of T-cell-independent B-cell 
responses. Assuming that MSP2 is organized as a polymer at the merozoite surface, that could 
mean that antibodies to non-repetitive epitopes of the MSP2 molecule are also produced in a 
T-cell-independent manner. T-cell-independent antibody responses may be potent in 
neutralizing viruses but are probably disadvantageous in the context of a malaria infection 
(Schofield, 1991). However, presenting MSP2 as a monomer in a vaccine would, with 
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 appropriate T-cell help provided, give rise to high affinity antibodies that exceed the quality 
of naturally acquired antibodies. Circular dichroism spectra suggest that random coil is the 
dominant conformation in both, monomeric and polymeric 3D7-type MSP2 (Adda et al., 
2004). This indicates that most antibodies raised against the monomer will also react with the 
polymer. 
 
The result of the Combination B trial suggested to include both family-specific domains in an 
optimized MSP2-based vaccine. If the family-specific non-repetitive part of the alternative 
family (FC27) proves to be as effective in inducing a protective antibody response against 
most members of the own family, then a combination of the two molecules in one vaccine 
could result in a strain-transcending protection. Nevertheless, it is advisable to also include 
other antigens since it is unlikely that antibodies to a single target will give maximal 
protection. 
  
We evaluated two long synthetic MSP2 peptides as vaccine candidates (chapter 4). They each 
represent either of the two allelic MSP2 families (3D7 and FC27). They contain the non-
repetitive dimorphic domain starting downstream of the repeat region plus the C-terminal 
conserved domain. The peptides proved to be recognized by immune sera at high prevalences 
and were immunogenic in mice. Monoclonal antibodies raised from mice immunized with the 
3D7-MSP2 peptide as well as antibodies purified from human immune sera on both peptides 
reacted with parasite-derived MSP2. The peptide-purified antibodies were mainly directed 
against the family-specific part. Preliminary experiments also showed that the antibody 
purified on the 3D7-MSP2 peptide inhibits parasite growth in cooperation with monocytes. 
Taken together, these data suggest that the peptides are recognized by antibodies relevant to 
an anti-parasite response and that they have the potential to elicit a protective response. 
 
To date most malaria vaccine candidates have been produced as recombinant proteins. As an 
example, the 3D7 molecule that was part of Combination B and the FC27 variant are 
currently being developed for large scale manufacture in Escherichia coli for clinical trials in 
humans (Robin Anders, Latrobe University, Bundoora, Australia and GroPep Ltd, Adelaide, 
Australia). The large scale production of recombinant proteins is a time-consuming process. 
The advantage of producing an antigen synthetically is that any sequence can be synthesised 
within weeks and purification from E. coli protein contamination is obsolete. The peptide 
synthesis approach has great implication in view of a genome-wide approach to screening and 
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 development of new vaccine candidates. With our work we could demonstrate that synthetic 
peptides can replace recombinantly produced antigens in some cases.  
 
Another aim of this thesis was to address the question of the functional importance of the 
different domains of MSP2. We hypothesised that the polymorphic repeat region of MSP2 
was dispensable for in vitro growth. This is based on the smoke screen hypothesis, only 
attributing an immunological relevance but no essential function to this domain. However, 
two monoclonal antibodies directed to epitopes in the repeat region were shown to inhibit 
parasite growth in vitro (Epping et al., 1988; Ramasamy, 1990). This would argue for an 
important functional role of the repetitive domain. This view contrasts with the 
immunological smoke screen hypothesis that suggests that these repeats are primarily a means 
to diverge the immune response from other important antigenic determinants. It is also 
conceivable that low-affinity anti-repeat antibodies elicited during natural infections actually 
help to protect the function of the repeats by impeding binding of rare high-affinity 
antibodies.  
 
To investigate the importance of the repeat domain, we targeted the msp2 locus of 3D7 
parasites with a plasmid construct designed to replace the endogenous msp2 gene with an 
FC27 msp2 gene lacking the repeat region (chapter 5). The plasmid integrated into the msp2 
locus via a single cross-over. A double cross-over, which would have led to gene 
replacement, was not achieved. Replacement with the full-length control construct was also 
not achieved, because this plasmid had recombined, rendering it resistant to negative selection 
with ganciclovir. It remains open whether gene replacement with the internally deleted msp2 
gene was not achieved due to the importance of the missing repeat region or for technical 
reasons. The major problem of our approach consisted in recombination events either during 
propagation in E. coli or in the course of drug selection of transfected P. falciparum cultures. 
For designing alternative approaches to clarify the functional role of repeats, the choice of 
deletion constructs needs to be reconsidered. 
 
An ancestral MSP2 molecule might have carried just one copy of the repeat unit. This is 
suggested by some wild-type FC27 alleles carrying only a single copy or a deletion of one 
repeat, while presence of two repeat units is the rule in FC27-type alleles. Therefore, the 
repetitive nature of the domain as such may not be essential. Our approach of deleting all 
repeats might have been too radical. In a more conservative approach, a gene replacement 
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 could be attempted with a minimized msp2 gene containing only one copy of a repeat unit. 
Problems could also arise here when spacing is important. However, this is unlikely 
considering the great length polymorphism observed among different msp2 alleles, although, 
there may be a minimal allowed length. 
 
We also investigated the putative function of the conserved terminal domains (chapter 6). 
MSP2 is a GPI-anchored protein and therefore the mechanism of its transport to the cell 
surface is uncertain. It could be that the addition of the anchor is sufficient as a signal for 
plasma membrane targeting. In addition, a specific sequence on the processed protein could 
be necessary. Our data obtained from localisation studies on YFP-fusion proteins suggest that 
the conserved terminal domains do contain sequences acting as transport signal. To 
conclusively prove the involvment of the conserved domains in transport processes, it needs 
to be determined whether the fusion construct lacking the two conserved MSP2 domains, that 
was not transported to the surface, was provided with a GPI-anchor. After confirming the role 
of conserved MSP2 domains, the putative transport signals need to be assigned to either the 
N- or C-terminal domain, followed by identification of the actual sequence involved. 
 
In conclusion, we have addressed several aspects of the functional and immunological role of 
the different domains of MSP2, a major surface antigen of the invasive stage of P. 
falciparum. A detailed molecular and serological analysis of a vaccine field trial proved 
highly informative for our goal to identify the MSP2 domains most relevant for inclusion in a 
subunit vaccine. Both, msp2 sequence analysis and anti-MSP2 antibody responses highlighted 
a non-repetitive region that is totally conserved within the allelic family and could be 
considered as a potential vaccine subunit. Following this line of evidence, we were able to 
evaluate two synthetic peptides in a formalized pathway, that showed promising results. Our 
parallel approach to assess the function of the repetitive and conserved domains was based on 
technically challenging transfection experiments and produced several successfully 
transfected parasite lines. These experiments suggested a new role for the conserved MSP2 
domains in transport to the merozoite surface, yet this awaits definitive experimental 
verification. 
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 8. Appendix 
 
Supplementary figures 
 
Supplementary figure to chapter 5 
 
 
Fig. S5 Deduced amino acid sequences of msp2 transgenes to replace the endogenous msp2 
gene in strain 3D7. Note: A serine and an arginine residue were introduced by restriction sites 
(bold). 
 
FC27 full-length (265 amino acids) 
 
MKVIKTLSIINFFIFVTFNIKNESKYSNTFINNAYNMSIRRSMANEGSNTNSVGANAPN
ADTIASGSQRSTNSASTSTTNNGESQTTTPTAADTIASGSQRSTNSASTSTTNNGESQT
TTPTAADTPTATESISPSPPITTTESSSSGNAPNKTDGKGEESEKQNELNESTEEGPKAP
QEPQTAENENPAAPENKGTGQHGHMHGSRNNHPQNTSDSQKECTDGNKENCGAAT
SLLSNSSNIASINKFVVLISATLVLSFAIFI 
 
 
FC27 delta rep (184 amino acids) 
 
MKVIKTLSIINFFIFVTFNIKNESKYSNTFINNAYNMSIRRSMANEGSNTNSVGANAPN
SRESSSSGNAPNKTDGKGEESEKQNELNESTEEGPKAPQEPQTAENENPAAPENKGT
GQHGHMHGSRNNHPQNTSDSQKECTDGNKENCGAATSLLSNSSNIASINKFVVLISA
TLVLSFAIFI 
 
 
N-C-cons (122 amino acids) 
 
MKVIKTLSIINFFIFVTFNIKNESKYSNTFINNAYNMSIRRSMASRAAPENKGTGQHGH
MHGSRNNHPQNTSDSQKECTDGNKENCGAATSLLSNSSNIASINKFVVLISATLVLSF
AIFI 
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 Supplem
entary figures to chapter 6 
           1            15 16           30 31           45 46           60 61           75 76           90  
    FC27 MKVIKTLSIINFFIF VTFNIKNESKYSNTF INNAYNMSIRRSMA- --------------N EGSNTNSVGANAPNA DTIASGSQRSTNSAS     75 
    I    MKVIKTLSIINFFIF VTFNIKNESKYSNTF INNAYNMSIRRSMAS LYKKAGSAAAPFTAN EGSNTNSVGANAPNA DTIASGSQRSTNSAS     90 
          91          105 106         120 121         135 136         150 151         165 166         180  
    FC27 TSTTNNGESQTTTPT AADTIASGSQRSTNS ASTSTTNNGESQTTT PTAADTPTATESISP SPPITTTESSSSGNA PNKTDGKGEESEKQN    165 
    I    TSTTNNGESQTTTPT AADTIASGSQRSTNS ASTSTTNNGESQTTT PTAADTPTATESISP SPPITTTESSSSGNA PNKTDGKGEESEKQN    180 
          181         195 196         210 211         225 226         240 241         255 256         270  
    FC27 ELNESTEEGPKAPQE PQTAENENP-------- ------AAPENKG TGQHGHMHGSRNNHP QNTSDSQKECTDGNK ENCGAATSLLSNSSN    241 
    I    ELNESTEEGPKAPQE PQTAENENPAKGGRA DPAFLYKVAAPENKG TGQHGHMHGSRNNHP QNTSDSQKECTDGNK ENCGAATSLLNNSSN    270 
          271         285 286 
    FC27 IASINKFVVLISATL VLSFAIFI    264 
    I    IASINKFVVLISATL VLSFAIFI    293    
  Fig. S6A
. D
educed am
ino acid sequences of w
ild-type FC
27 M
SP2 and M
ultisite G
atew
ay-constructed reconstitution of the gene (construct 
I). C
onserved M
SP2 sequences are m
arked gray, am
ino acids introduced by G
atew
ay cloning are in bold. 
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          1            15 16           30 31           45 46           60 61           75 76           90  
    VI  MKVIKTLSIINFFIF VTFNIKNESKYSNTF INNAYNMSIRRSMAS LYKKAGSAAAPFTVS KGEELFTGVVPILVE LDGDVNGHKFSVSGE     90 
    VII MKVIKTLSIINFFIF VTFNIKN-------- -------------AS LYKKAGSAAAPFTVS KGEELFTGVVPILVE LDGDVNGHKFSVSGE     69 
         91          105 106         120 121         135 136         150 151         165 166         180  
    VI  GEGDATYGKLTLKFI CTTGKLPVPWPTLVT TFGYGLQCFARYPDH MKQHDFFKSAMPEGY VQERTIFFKDDGNYK TRAEVKFEGDTLVNR    180 
    VII GEGDATYGKLTLKFI CTTGKLPVPWPTLVT TFGYGLQCFARYPDH MKQHDFFKSAMPEGY VQERTIFFKDDGNYK TRAEVKFEGDTLVNR    159 
         181         195 196         210 211         225 226         240 241         255 256         270  
    VI  IELKGIDFKEDGNIL GHKLEYNYNSHNVYI MADKQKNGIKVNFKI RHNIEDGSVQLADHY QQNTPIGDGPVLLPD NHYLSYQSALSKDPN    270 
    VII IELKGIDFKEDGNIL GHKLEYNYNSHNVYI MADKQKNGIKVNFKI RHNIEDGSVQLADHY QQNTPIGDGPVLLPD NHYLSYQSALSKDPN    249 
         271         285 286         300 301         315 316         330 331         345 346         360  
    VI  EKRDHMVLLEFVTAA GITLGMDELYKKGGR ADPAFLYKVDKPTYD KMKIIIASSAAVAVL ATILMVYLYKRKGNA EKYDKMDEPQDYGKS    360 
    VII EKRDHMVLLEFVTAA GITLGMDELYKKGGR ADPAFLYKVDKPTYD KMKIIIASSAAVAVL ATILMVYLYKRKGNA ---------------    324 
          361         375 376         390 391 
    VI  NSRNDEMLDPEASFW GEEKRASHTTPVLME KPYY    394 
    VII --------------- --------------- ----    324 
  Fig. S6C
. M
SP2-Y
FP-A
M
A
1 fusions. C
onserved M
SP2 sequences are shaded dark gray, Y
FP light gray, and A
M
A
-1 C
-term
inal sequences black. 
A
m
ino acids introduced by G
atew
ay cloning are bold. 
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